n-(3-chloro-7-indolyl)-1,4-benzenedisulphonamide profile

N-(3-chloro-7-indolyl)-1,4-benzenedisulphonamide: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

indisulam : A chloroindole that is 3-chloro-1H-indole substituted by a [(4-sulfamoylphenyl)sulfonyl]nitrilo group at position 7. It is a carbonic anhydrase inhibitor and a potential anti-cancer agent currently in clinical development. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	216468
CHEMBL ID	77517
CHEBI ID	145431
SCHEMBL ID	91389
MeSH ID	M0405811

Synonym
er-35744
e-7070
indisulam
n-(3-chloro-1h-indol-7-yl)-1,4-benzenedisulfonamide
n-(3-chloro-1h-indol-7-yl)benzene-1,4disulfonamide
e 7070
1,4-benzenedisulfonamide, n-(3-chloro-1h-indol-7-yl)-
indisulam (usan/inn)
D04522
165668-41-7
1-n-(3-chloro-1h-indol-7-yl)benzene-1,4-disulfonamide
e7070
chembl77517 ,
indisulam (ind)
bdbm10890
n-(3-chloro-1h-indol-7-yl)benzene-1,4-disulfonamide
n-(3-chloro-7-indolyl)-1,4-benzenedisulphonamide
n(1)-(3-chloro-1h-indol-7-yl)benzene-1,4-disulfonamide
indisulamum
CHEBI:145431
n-(3-chloro-1h-indol-7-yl)-4-sulfamoylbenzenesulfonamide
4-n-(3-chloro-1h-indol-7-yl)benzene-1,4-disulfonamide
S9742
wj98j3nm90 ,
indisulam [usan:inn:ban]
unii-wj98j3nm90
gtpl7046
indisulam [usan]
1,4-benzenedisulfonamide, n-(3-chloro-1h-indol-7-yl)
indisulam [who-dd]
indisulam [mi]
indisulam [inn]
n1-(3-chloro-1h-indol-7-yl)benzene-1,4-disulfonamide
SCHEMBL91389
AKOS022181456
DTXSID50168008
n1-(3-chloro-1h-indol-7-yl)-1,4-benzenedisulfonamide
indisulam (e7070)
AS-69532
indisulam, >=98% (hplc)
FT-0740093
BCP06110
DB06370
Q27078056
SB16544
n~1~-(3-chloro-1h-indol-7-yl)benzene-1,4-disulfonamide
ef6 ,
1,4-benzenedisulfonamide, n1-(3-chloro-1h-indol-7-yl)-
HY-13650
CS-0007710
C73201
A904802
AC-36646
EN300-7378250
Z2724205552

Excerpt	Reference	Relevance
" The pharmacokinetic profile of E7070 at this schedule is non-linear with increasing dose."	( Phase I and pharmacokinetic study of E7070, a novel sulfonamide, given at a daily times five schedule in patients with solid tumors. A study by the EORTC-early clinical studies group (ECSG). Campone, M; Faber, MN; Fumoleau, P; Punt, CJ; Ravic, M; van de Walle, B, 2001)	0.31
" Pharmacokinetic analyses of all studies revealed E7070 to have nonlinear pharmacokinetics."	( Population pharmacokinetics of the novel anticancer agent E7070 during four phase I studies: model building and validation. Armand, JP; Beijnen, JH; Dittrich, Ch; Droz, JP; Dumez, H; Fumoleau, P; Mathôt, RA; Punt, C; Ravic, M; Raymond, E; Roché, H; Schellens, JH; Van Kesteren, Ch; Wanders, J, 2002)	0.31
"Plasma concentration-time data of all patients (n = 143) were fitted to several pharmacokinetic models using NONMEM."	( Population pharmacokinetics of the novel anticancer agent E7070 during four phase I studies: model building and validation. Armand, JP; Beijnen, JH; Dittrich, Ch; Droz, JP; Dumez, H; Fumoleau, P; Mathôt, RA; Punt, C; Ravic, M; Raymond, E; Roché, H; Schellens, JH; Van Kesteren, Ch; Wanders, J, 2002)	0.31
" The fits of 500 bootstrap replicates of the data set demonstrated the robustness of the developed population pharmacokinetic model."	( Population pharmacokinetics of the novel anticancer agent E7070 during four phase I studies: model building and validation. Armand, JP; Beijnen, JH; Dittrich, Ch; Droz, JP; Dumez, H; Fumoleau, P; Mathôt, RA; Punt, C; Ravic, M; Raymond, E; Roché, H; Schellens, JH; Van Kesteren, Ch; Wanders, J, 2002)	0.31
"A population pharmacokinetic model has been designed and validated that accurately describes the data of four phase I studies with E7070."	( Population pharmacokinetics of the novel anticancer agent E7070 during four phase I studies: model building and validation. Armand, JP; Beijnen, JH; Dittrich, Ch; Droz, JP; Dumez, H; Fumoleau, P; Mathôt, RA; Punt, C; Ravic, M; Raymond, E; Roché, H; Schellens, JH; Van Kesteren, Ch; Wanders, J, 2002)	0.31
" The pharmacokinetic profile of E7070 was also determined."	( Phase I clinical and pharmacokinetic study of E7070, a novel sulfonamide given as a 5-day continuous infusion repeated every 3 weeks in patients with solid tumours. A study by the EORTC Early Clinical Study Group (ECSG). Droz, JP; Faber, MN; Ravic, M; Roché, H; Schellens, JH; Terret, C; Wanders, J; Zanetta, S, 2003)	0.32
" The pharmacokinetic profile of E7070 was determined."	( Phase I and pharmacokinetic study of E7070, a chloroindolyl-sulfonamide anticancer agent, administered on a weekly schedule to patients with solid tumors. Calvert, H; Dittrich, C; Dumez, H; Faber, M; Fumoleau, P; Hanauske, A; Ravic, M; Wanders, J; Yule, M, 2003)	0.32
" Pharmacokinetic parameters of acenocoumarol were calculated by noncompartmental analysis and revealed that in both patients the area under the concentration-time curve up to 24 h after the acenocoumarol administration was higher following E7070 (2."	( Pharmacokinetic drug-drug interaction of the novel anticancer agent E7070 and acenocoumarol. Beijnen, JH; Critchley, DJ; Schellens, JH; Sparidans, RW; van den Bongard, HJ, 2004)	0.32
" The objectives of this phase I study of E7070 were to estimate the maximal tolerated dose (MTD), to determine the recommended dose for phase II, and to clarify the pharmacokinetic profile of E7070 and its relation to polymorphisms of CYP2C9 (2, 3) and CYP2C19 (2, 3) in Japanese patients."	( Phase I pharmacokinetic and pharmacogenomic study of E7070 administered once every 21 days. Fujisaka, Y; Horiike, A; Nishioka, Y; Sakamoto, T; Shimoyama, T; Takayama, K; Tamura, T; Yamada, Y; Yamamoto, N; Yasuda, S, 2005)	0.33
"The pharmacokinetic profile of the anti-cancer agent indisulam is non-linear."	( A semi-physiological population pharmacokinetic model describing the non-linear disposition of indisulam. Beijnen, JH; Copalu, W; Huitema, AD; Schellens, JH; Zandvliet, AS, 2006)	0.33
" The secondary aims were to determine progression-free survival, to assess the safety and tolerability of indisulam, and to study its pharmacokinetic and pharmacodynamic profile."	( A randomized phase II pharmacokinetic and pharmacodynamic study of indisulam as second-line therapy in patients with advanced non-small cell lung cancer. Bosquee, L; Cattell, E; Ellis, P; Huitema, AD; Johnston, C; Norbury, CJ; Reck, M; Talbot, DC; von Pawel, J; Yule, SM; Zandvliet, AS, 2007)	0.34
" The pharmacokinetics of indisulam in each treatment schedule were adequately described using a previously developed population pharmacokinetic model and were mostly consistent with the results of the phase I program."	( A randomized phase II pharmacokinetic and pharmacodynamic study of indisulam as second-line therapy in patients with advanced non-small cell lung cancer. Bosquee, L; Cattell, E; Ellis, P; Huitema, AD; Johnston, C; Norbury, CJ; Reck, M; Talbot, DC; von Pawel, J; Yule, SM; Zandvliet, AS, 2007)	0.34
" Pharmacokinetic data were analysed with nonlinear mixed effects modelling."	( Population pharmacokinetic and pharmacodynamic analysis to support treatment optimization of combination chemotherapy with indisulam and carboplatin. Beijnen, JH; Dittrich, C; Huitema, AD; Schellens, JH; Wanders, J; Zandvliet, AS, 2008)	0.35

Excerpt	Reference	Relevance
" These results indicate that E7070 may primarily interact with acenocoumarol by reducing its systemic clearance."	( Pharmacokinetic drug-drug interaction of the novel anticancer agent E7070 and acenocoumarol. Beijnen, JH; Critchley, DJ; Schellens, JH; Sparidans, RW; van den Bongard, HJ, 2004)	0.32
" A significant reduction in glutathione synthetase and glutathione reductase transcripts by indisulam provided a molecular basis for its combination with platinum agents."	( A phase I and pharmacokinetic study of indisulam in combination with carboplatin. Dittrich, C; Gneist, M; Huitema, AD; King, AA; Wanders, J; Zandvliet, AS, 2007)	0.34
"This dose escalation study was designed to determine the recommended dose of the multi-targeted cell cycle inhibitor indisulam in combination with capecitabine in patients with solid tumours and to evaluate the pharmacokinetics of the combination."	( A dose-escalation study of indisulam in combination with capecitabine (Xeloda) in patients with solid tumours. Beijnen, JH; Diéras, V; Girre, V; Huitema, AD; King, A; Milano, G; Richmond, E; Schellens, JH; Siegel-Lakhai, WS; Tibben, MM; Wanders, J; Zandvliet, AS, 2008)	0.35
" We investigated the antitumor effect and mechanism of synergism when indisulam was administered in combination with CPT-11."	( Therapeutic potential and molecular mechanism of a novel sulfonamide anticancer drug, indisulam (E7070) in combination with CPT-11 for cancer treatment. Asada, M; Kusano, K; Owa, T; Ozawa, Y; Yokoi, A; Yoshimatsu, K, 2012)	0.38

Excerpt	Relevance	Reference
" Furthermore, it has been demonstrated that BSA-guided dosing for E7070 is important."	( Population pharmacokinetics of the novel anticancer agent E7070 during four phase I studies: model building and validation. Armand, JP; Beijnen, JH; Dittrich, Ch; Droz, JP; Dumez, H; Fumoleau, P; Mathôt, RA; Punt, C; Ravic, M; Raymond, E; Roché, H; Schellens, JH; Van Kesteren, Ch; Wanders, J, 2002)	0.31
" The aims of this study were (i) to develop a pharmacokinetic-pharmacodynamic (PK-PD) model to describe the myelosuppressive effect of the combination, and (ii) to use this model to select a dosing regimen for Phase II evaluation."	( Population pharmacokinetic and pharmacodynamic analysis to support treatment optimization of combination chemotherapy with indisulam and carboplatin. Beijnen, JH; Dittrich, C; Huitema, AD; Schellens, JH; Wanders, J; Zandvliet, AS, 2008)	0.35
" This study aimed to evaluate the influence of patient-related covariates on pharmacokinetics and pharmacodynamics, to identify patients at risk for severe myelosuppression and to develop a dosing algorithm for treatment optimization."	( Covariate-based dose individualization of the cytotoxic drug indisulam to reduce the risk of severe myelosuppression. Beijnen, JH; Copalu, W; Huitema, AD; Schellens, JH; Zandvliet, AS, 2009)	0.35
" A dosing strategy was developed to optimize treatment for patient subgroups."	( Covariate-based dose individualization of the cytotoxic drug indisulam to reduce the risk of severe myelosuppression. Beijnen, JH; Copalu, W; Huitema, AD; Schellens, JH; Zandvliet, AS, 2009)	0.35

Role	Description
EC 4.2.1.1 (carbonic anhydrase) inhibitor	An EC 4.2.1.* (hydro-lyases) inhibitor that interferes with the action of carbonic anhydrase (EC 4.2.1.1). Such compounds reduce the secretion of H(+) ions by the proximal kidney tubule.
antineoplastic agent	A substance that inhibits or prevents the proliferation of neoplasms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
chloroindole	A compound based on an indole skeleton, containing one or more chlorine atoms
sulfonamide	An amide of a sulfonic acid RS(=O)2NR'2.
organochlorine compound	An organochlorine compound is a compound containing at least one carbon-chlorine bond.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Carbonic anhydrase	Astrosclera willeyana	Ki	0.4230	0.0320	1.5172	9.6000	AID644379
Carbonic anhydrase	Sulfurihydrogenibium sp. YO3AOP1	Ki	0.0841	0.0045	0.1624	0.8760	AID1268964
Carbonic anhydrase	Stylophora pistillata	Ki	0.1630	0.0000	0.6867	10.0000	AID436565; AID552130
Carbonic anhydrase	Stylophora pistillata	Ki	0.3940	0.0000	0.5071	5.7100	AID552131
Carbonic anhydrase	Helicobacter pylori 26695	Ki	0.4235	0.0200	0.5486	4.3600	AID261581; AID263638
Carbonic anhydrase 12	Homo sapiens (human)	Ki	0.0069	0.0002	1.1043	9.9000	AID1062684; AID1067227; AID1154448; AID1204091; AID1593068; AID1799734; AID238467; AID271040; AID486935; AID512004; AID614108; AID770582
Glycogen phosphorylase, muscle form	Oryctolagus cuniculus (rabbit)	Ki	0.1040	0.0250	4.8903	9.0000	AID614109
Tyrosine-protein kinase ABL1	Homo sapiens (human)	IC50 (µMol)	0.0070	0.0001	0.7128	10.0000	AID1799511
Carbonic anhydrase 1	Homo sapiens (human)	IC50 (µMol)	0.0310	0.0058	2.1410	7.9000	AID50344
Carbonic anhydrase 1	Homo sapiens (human)	Ki	0.0358	0.0000	1.3726	10.0000	AID1062687; AID1067230; AID1142833; AID1154445; AID1188134; AID1190063; AID1194024; AID1195369; AID1262263; AID1268962; AID1275563; AID1275913; AID1287517; AID1434427; AID1453412; AID1628036; AID1796552; AID1796595; AID1796855; AID1797276; AID1797360; AID1798769; AID1799734; AID238085; AID238208; AID238211; AID238409; AID238620; AID238753; AID238760; AID238770; AID254240; AID261579; AID263636; AID271037; AID271172; AID271710; AID275807; AID281082; AID287698; AID331498; AID349605; AID367820; AID369271; AID371705; AID414955; AID427125; AID436563; AID484213; AID486932; AID50352; AID50375; AID50377; AID512001; AID552127; AID577526; AID612725; AID614105; AID644380; AID725955; AID743515; AID764719; AID770586
Carbonic anhydrase 2	Homo sapiens (human)	IC50 (µMol)	0.0110	0.0002	1.1060	8.3000	AID1799511; AID47748
Carbonic anhydrase 2	Homo sapiens (human)	Ki	0.1096	0.0000	0.7236	9.9200	AID1061069; AID1062686; AID1067229; AID1142834; AID1154446; AID1188135; AID1190064; AID1194025; AID1195370; AID1240217; AID1262264; AID1268963; AID1275564; AID1275912; AID1278409; AID1287518; AID1434428; AID1453413; AID1593066; AID1628037; AID1796552; AID1796582; AID1796595; AID1796771; AID1796855; AID1797276; AID1797360; AID1798769; AID1799734; AID238084; AID238220; AID238223; AID238437; AID238635; AID238768; AID238772; AID238787; AID254241; AID254247; AID256963; AID261580; AID263637; AID271038; AID271173; AID271711; AID275808; AID281083; AID287699; AID331499; AID349606; AID367821; AID369272; AID371706; AID414956; AID427124; AID436564; AID437749; AID47900; AID47940; AID48088; AID484214; AID486933; AID512002; AID552128; AID577527; AID612726; AID614106; AID644381; AID669115; AID725956; AID743514; AID764718; AID770585
Carbonic anhydrase 3	Homo sapiens (human)	Ki	10.4000	0.0002	2.0102	10.0000	AID301578
Cytochrome P450 3A4	Homo sapiens (human)	Ki	0.0137	0.0001	1.4162	9.9000	AID1154447; AID1154448
Dihydrofolate reductase	Escherichia coli K-12	IC50 (µMol)	0.0070	0.0015	0.5512	6.8000	AID1799511
Cytochrome P450 2C9	Homo sapiens (human)	Ki	0.0240	0.0003	1.6842	10.0000	AID1154447
Carbonic anhydrase 6	Homo sapiens (human)	Ki	0.0520	0.0001	1.4710	9.9200	AID1798769; AID275806; AID369273; AID552129
Cyclin-dependent kinase 2	Homo sapiens (human)	IC50 (µMol)	0.0070	0.0004	1.0444	10.0000	AID1799511
Delta-type opioid receptor	Mus musculus (house mouse)	Ki	0.0230	0.0000	0.5393	9.4000	AID1188134; AID1188135
Cytochrome P450 2C19	Homo sapiens (human)	Ki	0.0034	0.0001	0.8300	10.0000	AID1154448
Delta-type opioid receptor	Rattus norvegicus (Norway rat)	Ki	0.0150	0.0000	0.6068	9.2330	AID1188135
Mu-type opioid receptor	Rattus norvegicus (Norway rat)	Ki	0.0310	0.0000	0.3845	8.6000	AID1188134
Carbonic anhydrase 5A, mitochondrial	Homo sapiens (human)	Ki	0.0490	0.0000	1.2725	9.9000	AID1796582; AID256964
Carbonic anhydrase 7	Homo sapiens (human)	Ki	0.1220	0.0002	1.3737	9.9000	AID764717; AID770584
Carbonic anhydrase	Saccharomyces cerevisiae S288C	Ki	0.1330	0.0820	0.5609	8.7000	AID367822
Carbonic anhydrase	Mycobacterium tuberculosis H37Rv	Ki	0.0150	0.0120	2.7238	9.1200	AID371703
Mu-type opioid receptor	Cavia porcellus (domestic guinea pig)	Ki	0.0150	0.0000	0.2786	9.0000	AID1188135
Beta-carbonic anhydrase 1	Mycobacterium tuberculosis H37Rv	Ki	0.0750	0.0048	3.3841	9.8400	AID1798985; AID349607; AID371704
Carbonic anhydrase 2	Mycobacterium tuberculosis H37Rv	Ki	0.7170	0.0090	2.2096	9.8400	AID437750
Carbonic anhydrase 9	Homo sapiens (human)	Ki	0.0248	0.0001	0.7874	9.9000	AID1062685; AID1067228; AID1154447; AID1593067; AID1758423; AID1796595; AID1796771; AID1796855; AID1797276; AID1797360; AID1798769; AID1799734; AID238083; AID238224; AID238227; AID238438; AID238769; AID238774; AID238788; AID239048; AID254246; AID254248; AID271039; AID271174; AID271712; AID275809; AID281084; AID287700; AID317578; AID331500; AID369274; AID48295; AID48301; AID48302; AID484215; AID486934; AID512003; AID614107; AID770583
Carbonic anhydrase, alpha family	Hydrogenovibrio crunogenus XCL-2	Ki	0.2730	0.0025	0.3234	1.1000	AID1268965
Carbonic anhydrase	Cryptococcus neoformans var. grubii	Ki	0.9630	0.0100	0.7364	8.3470	AID669116
Carbonic anhydrase	Candida albicans SC5314	Ki	1.0583	0.0105	1.4444	8.3470	AID1799266; AID427122; AID669117
Carbonic anhydrase	Anopheles gambiae (African malaria mosquito)	Ki	0.2260	0.0098	0.5117	4.3600	AID1195371
Delta carbonic anhydrase	Conticribra weissflogii	Ki	0.3750	0.0496	0.9978	9.2000	AID1061066
Tubulin beta-2B chain	Bos taurus (cattle)	IC50 (µMol)	100.0000	0.2500	1.8838	8.7000	AID214028
Carbonic anhydrase	Nakaseomyces glabratus CBS 138	Ki	0.0940	0.0070	1.2174	9.1700	AID744415
Similar to alpha-tubulin isoform 1	Bos taurus (cattle)	IC50 (µMol)	100.0000	0.2500	1.8779	8.7000	AID214028
Similar to alpha-tubulin isoform 1	Bos taurus (cattle)	IC50 (µMol)	100.0000	0.2500	1.8656	8.7000	AID214028
Carbonic anhydrase 4	Bos taurus (cattle)	IC50 (µMol)	0.0650	0.0210	0.2060	0.6200	AID48112
Carbonic anhydrase 4	Bos taurus (cattle)	Ki	0.0533	0.0030	0.5934	9.6500	AID1797276; AID48287; AID48292
Carbonic anhydrase 15	Mus musculus (house mouse)	Ki	0.0637	0.0009	1.8846	10.0000	AID1798769; AID369275
Carbonic anhydrase 14	Homo sapiens (human)	Ki	0.1040	0.0002	1.5099	9.9000	AID486936; AID614109
Carbonic anhydrase 5B, mitochondrial	Homo sapiens (human)	Ki	0.0350	0.0000	1.3412	9.9700	AID1796582; AID256965
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Carbonic anhydrase	Brucella suis 1330	Kinact	0.0500	0.0170	0.8628	5.8700	AID459696
Carbonic anhydrase 12	Homo sapiens (human)	Kinact	0.0034	0.0030	0.6674	9.6000	AID1183268; AID386502; AID408472
Carbonic anhydrase 1	Homo sapiens (human)	Kinact	0.0310	0.0100	0.9387	8.6000	AID1183265; AID293811; AID299242; AID386500; AID408469
Carbonic anhydrase 2	Homo sapiens (human)	Kinact	0.0150	0.0030	0.7946	10.0000	AID1183266; AID293812; AID299243; AID386499; AID408470
Dipeptidyl peptidase 4	Homo sapiens (human)	Kinact	0.0150	0.0080	0.0174	0.0380	AID386499
Carbonic anhydrase 9	Homo sapiens (human)	Kinact	0.0240	0.0050	0.3197	6.6700	AID1183267; AID293813; AID386501; AID408471
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
estrous cycle	Carbonic anhydrase 12	Homo sapiens (human)
chloride ion homeostasis	Carbonic anhydrase 12	Homo sapiens (human)
one-carbon metabolic process	Carbonic anhydrase 12	Homo sapiens (human)
response to oxidative stress	Tyrosine-protein kinase ABL1	Homo sapiens (human)
positive regulation of cytosolic calcium ion concentration	Tyrosine-protein kinase ABL1	Homo sapiens (human)
negative regulation of ubiquitin-protein transferase activity	Tyrosine-protein kinase ABL1	Homo sapiens (human)
negative regulation of phospholipase C activity	Tyrosine-protein kinase ABL1	Homo sapiens (human)
mitotic cell cycle	Tyrosine-protein kinase ABL1	Homo sapiens (human)
neural tube closure	Tyrosine-protein kinase ABL1	Homo sapiens (human)
B-1 B cell homeostasis	Tyrosine-protein kinase ABL1	Homo sapiens (human)
positive regulation of protein phosphorylation	Tyrosine-protein kinase ABL1	Homo sapiens (human)
B cell proliferation involved in immune response	Tyrosine-protein kinase ABL1	Homo sapiens (human)
transitional one stage B cell differentiation	Tyrosine-protein kinase ABL1	Homo sapiens (human)
mismatch repair	Tyrosine-protein kinase ABL1	Homo sapiens (human)
regulation of DNA-templated transcription	Tyrosine-protein kinase ABL1	Homo sapiens (human)
autophagy	Tyrosine-protein kinase ABL1	Homo sapiens (human)
DNA damage response	Tyrosine-protein kinase ABL1	Homo sapiens (human)
integrin-mediated signaling pathway	Tyrosine-protein kinase ABL1	Homo sapiens (human)
canonical NF-kappaB signal transduction	Tyrosine-protein kinase ABL1	Homo sapiens (human)
associative learning	Tyrosine-protein kinase ABL1	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage	Tyrosine-protein kinase ABL1	Homo sapiens (human)
response to xenobiotic stimulus	Tyrosine-protein kinase ABL1	Homo sapiens (human)
post-embryonic development	Tyrosine-protein kinase ABL1	Homo sapiens (human)
regulation of autophagy	Tyrosine-protein kinase ABL1	Homo sapiens (human)
positive regulation of endothelial cell migration	Tyrosine-protein kinase ABL1	Homo sapiens (human)
peptidyl-tyrosine phosphorylation	Tyrosine-protein kinase ABL1	Homo sapiens (human)
cerebellum morphogenesis	Tyrosine-protein kinase ABL1	Homo sapiens (human)
negative regulation of cell-cell adhesion	Tyrosine-protein kinase ABL1	Homo sapiens (human)
microspike assembly	Tyrosine-protein kinase ABL1	Homo sapiens (human)
actin cytoskeleton organization	Tyrosine-protein kinase ABL1	Homo sapiens (human)
actin filament polymerization	Tyrosine-protein kinase ABL1	Homo sapiens (human)
regulation of endocytosis	Tyrosine-protein kinase ABL1	Homo sapiens (human)
regulation of cell adhesion	Tyrosine-protein kinase ABL1	Homo sapiens (human)
neuron differentiation	Tyrosine-protein kinase ABL1	Homo sapiens (human)
BMP signaling pathway	Tyrosine-protein kinase ABL1	Homo sapiens (human)
negative regulation of BMP signaling pathway	Tyrosine-protein kinase ABL1	Homo sapiens (human)
regulation of axon extension	Tyrosine-protein kinase ABL1	Homo sapiens (human)
regulation of microtubule polymerization	Tyrosine-protein kinase ABL1	Homo sapiens (human)
regulation of Cdc42 protein signal transduction	Tyrosine-protein kinase ABL1	Homo sapiens (human)
positive regulation of type II interferon production	Tyrosine-protein kinase ABL1	Homo sapiens (human)
positive regulation of interleukin-2 production	Tyrosine-protein kinase ABL1	Homo sapiens (human)
regulation of actin cytoskeleton organization	Tyrosine-protein kinase ABL1	Homo sapiens (human)
positive regulation of osteoblast proliferation	Tyrosine-protein kinase ABL1	Homo sapiens (human)
substrate adhesion-dependent cell spreading	Tyrosine-protein kinase ABL1	Homo sapiens (human)
cellular response to oxidative stress	Tyrosine-protein kinase ABL1	Homo sapiens (human)
response to endoplasmic reticulum stress	Tyrosine-protein kinase ABL1	Homo sapiens (human)
platelet-derived growth factor receptor-beta signaling pathway	Tyrosine-protein kinase ABL1	Homo sapiens (human)
protein modification process	Tyrosine-protein kinase ABL1	Homo sapiens (human)
peptidyl-tyrosine autophosphorylation	Tyrosine-protein kinase ABL1	Homo sapiens (human)
Fc-gamma receptor signaling pathway involved in phagocytosis	Tyrosine-protein kinase ABL1	Homo sapiens (human)
neuropilin signaling pathway	Tyrosine-protein kinase ABL1	Homo sapiens (human)
signal transduction in response to DNA damage	Tyrosine-protein kinase ABL1	Homo sapiens (human)
positive regulation of apoptotic process	Tyrosine-protein kinase ABL1	Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transduction	Tyrosine-protein kinase ABL1	Homo sapiens (human)
positive regulation of neuron apoptotic process	Tyrosine-protein kinase ABL1	Homo sapiens (human)
endothelial cell migration	Tyrosine-protein kinase ABL1	Homo sapiens (human)
regulation of T cell differentiation	Tyrosine-protein kinase ABL1	Homo sapiens (human)
positive regulation of vasoconstriction	Tyrosine-protein kinase ABL1	Homo sapiens (human)
negative regulation of mitotic cell cycle	Tyrosine-protein kinase ABL1	Homo sapiens (human)
positive regulation of mitotic cell cycle	Tyrosine-protein kinase ABL1	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Tyrosine-protein kinase ABL1	Homo sapiens (human)
alpha-beta T cell differentiation	Tyrosine-protein kinase ABL1	Homo sapiens (human)
protein autophosphorylation	Tyrosine-protein kinase ABL1	Homo sapiens (human)
positive regulation of fibroblast proliferation	Tyrosine-protein kinase ABL1	Homo sapiens (human)
spleen development	Tyrosine-protein kinase ABL1	Homo sapiens (human)
thymus development	Tyrosine-protein kinase ABL1	Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylation	Tyrosine-protein kinase ABL1	Homo sapiens (human)
activated T cell proliferation	Tyrosine-protein kinase ABL1	Homo sapiens (human)
T cell receptor signaling pathway	Tyrosine-protein kinase ABL1	Homo sapiens (human)
B cell receptor signaling pathway	Tyrosine-protein kinase ABL1	Homo sapiens (human)
neuromuscular process controlling balance	Tyrosine-protein kinase ABL1	Homo sapiens (human)
positive regulation of release of sequestered calcium ion into cytosol	Tyrosine-protein kinase ABL1	Homo sapiens (human)
positive regulation of oxidoreductase activity	Tyrosine-protein kinase ABL1	Homo sapiens (human)
neuron apoptotic process	Tyrosine-protein kinase ABL1	Homo sapiens (human)
negative regulation of ubiquitin-protein transferase activity	Tyrosine-protein kinase ABL1	Homo sapiens (human)
myoblast proliferation	Tyrosine-protein kinase ABL1	Homo sapiens (human)
positive regulation of stress fiber assembly	Tyrosine-protein kinase ABL1	Homo sapiens (human)
establishment of localization in cell	Tyrosine-protein kinase ABL1	Homo sapiens (human)
regulation of cell cycle	Tyrosine-protein kinase ABL1	Homo sapiens (human)
mitochondrial depolarization	Tyrosine-protein kinase ABL1	Homo sapiens (human)
positive regulation of focal adhesion assembly	Tyrosine-protein kinase ABL1	Homo sapiens (human)
Bergmann glial cell differentiation	Tyrosine-protein kinase ABL1	Homo sapiens (human)
cardiac muscle cell proliferation	Tyrosine-protein kinase ABL1	Homo sapiens (human)
neuroepithelial cell differentiation	Tyrosine-protein kinase ABL1	Homo sapiens (human)
cellular response to hydrogen peroxide	Tyrosine-protein kinase ABL1	Homo sapiens (human)
ERK1 and ERK2 cascade	Tyrosine-protein kinase ABL1	Homo sapiens (human)
negative regulation of ERK1 and ERK2 cascade	Tyrosine-protein kinase ABL1	Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascade	Tyrosine-protein kinase ABL1	Homo sapiens (human)
DNA conformation change	Tyrosine-protein kinase ABL1	Homo sapiens (human)
cellular response to lipopolysaccharide	Tyrosine-protein kinase ABL1	Homo sapiens (human)
cellular response to transforming growth factor beta stimulus	Tyrosine-protein kinase ABL1	Homo sapiens (human)
response to epinephrine	Tyrosine-protein kinase ABL1	Homo sapiens (human)
negative regulation of protein serine/threonine kinase activity	Tyrosine-protein kinase ABL1	Homo sapiens (human)
positive regulation of cell migration involved in sprouting angiogenesis	Tyrosine-protein kinase ABL1	Homo sapiens (human)
cellular senescence	Tyrosine-protein kinase ABL1	Homo sapiens (human)
cell-cell adhesion	Tyrosine-protein kinase ABL1	Homo sapiens (human)
positive regulation of dendrite development	Tyrosine-protein kinase ABL1	Homo sapiens (human)
positive regulation of substrate adhesion-dependent cell spreading	Tyrosine-protein kinase ABL1	Homo sapiens (human)
negative regulation of long-term synaptic potentiation	Tyrosine-protein kinase ABL1	Homo sapiens (human)
regulation of hematopoietic stem cell differentiation	Tyrosine-protein kinase ABL1	Homo sapiens (human)
positive regulation of extracellular matrix organization	Tyrosine-protein kinase ABL1	Homo sapiens (human)
podocyte apoptotic process	Tyrosine-protein kinase ABL1	Homo sapiens (human)
cellular response to dopamine	Tyrosine-protein kinase ABL1	Homo sapiens (human)
positive regulation of establishment of T cell polarity	Tyrosine-protein kinase ABL1	Homo sapiens (human)
DN4 thymocyte differentiation	Tyrosine-protein kinase ABL1	Homo sapiens (human)
protein localization to cytoplasmic microtubule plus-end	Tyrosine-protein kinase ABL1	Homo sapiens (human)
positive regulation of microtubule binding	Tyrosine-protein kinase ABL1	Homo sapiens (human)
positive regulation of actin filament binding	Tyrosine-protein kinase ABL1	Homo sapiens (human)
regulation of modification of synaptic structure	Tyrosine-protein kinase ABL1	Homo sapiens (human)
positive regulation of blood vessel branching	Tyrosine-protein kinase ABL1	Homo sapiens (human)
activation of protein kinase C activity	Tyrosine-protein kinase ABL1	Homo sapiens (human)
negative regulation of double-strand break repair via homologous recombination	Tyrosine-protein kinase ABL1	Homo sapiens (human)
positive regulation of Wnt signaling pathway, planar cell polarity pathway	Tyrosine-protein kinase ABL1	Homo sapiens (human)
regulation of cell motility	Tyrosine-protein kinase ABL1	Homo sapiens (human)
negative regulation of endothelial cell apoptotic process	Tyrosine-protein kinase ABL1	Homo sapiens (human)
positive regulation of T cell migration	Tyrosine-protein kinase ABL1	Homo sapiens (human)
negative regulation of cellular senescence	Tyrosine-protein kinase ABL1	Homo sapiens (human)
epidermal growth factor receptor signaling pathway	Tyrosine-protein kinase ABL1	Homo sapiens (human)
protein phosphorylation	Tyrosine-protein kinase ABL1	Homo sapiens (human)
one-carbon metabolic process	Carbonic anhydrase 1	Homo sapiens (human)
morphogenesis of an epithelium	Carbonic anhydrase 2	Homo sapiens (human)
positive regulation of synaptic transmission, GABAergic	Carbonic anhydrase 2	Homo sapiens (human)
positive regulation of cellular pH reduction	Carbonic anhydrase 2	Homo sapiens (human)
angiotensin-activated signaling pathway	Carbonic anhydrase 2	Homo sapiens (human)
regulation of monoatomic anion transport	Carbonic anhydrase 2	Homo sapiens (human)
secretion	Carbonic anhydrase 2	Homo sapiens (human)
regulation of intracellular pH	Carbonic anhydrase 2	Homo sapiens (human)
neuron cellular homeostasis	Carbonic anhydrase 2	Homo sapiens (human)
positive regulation of dipeptide transmembrane transport	Carbonic anhydrase 2	Homo sapiens (human)
regulation of chloride transport	Carbonic anhydrase 2	Homo sapiens (human)
carbon dioxide transport	Carbonic anhydrase 2	Homo sapiens (human)
one-carbon metabolic process	Carbonic anhydrase 2	Homo sapiens (human)
response to bacterium	Carbonic anhydrase 3	Homo sapiens (human)
one-carbon metabolic process	Carbonic anhydrase 3	Homo sapiens (human)
lipid hydroxylation	Cytochrome P450 3A4	Homo sapiens (human)
lipid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
steroid catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
cholesterol metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
androgen metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
estrogen metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
alkaloid catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
monoterpenoid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
calcitriol biosynthetic process from calciol	Cytochrome P450 3A4	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
retinol metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
retinoic acid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
long-chain fatty acid biosynthetic process	Cytochrome P450 3A4	Homo sapiens (human)
aflatoxin metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
oxidative demethylation	Cytochrome P450 3A4	Homo sapiens (human)
10-formyltetrahydrofolate biosynthetic process	Dihydrofolate reductase	Escherichia coli K-12
response to xenobiotic stimulus	Dihydrofolate reductase	Escherichia coli K-12
folic acid biosynthetic process	Dihydrofolate reductase	Escherichia coli K-12
one-carbon metabolic process	Dihydrofolate reductase	Escherichia coli K-12
response to methotrexate	Dihydrofolate reductase	Escherichia coli K-12
tetrahydrofolate biosynthetic process	Dihydrofolate reductase	Escherichia coli K-12
response to antibiotic	Dihydrofolate reductase	Escherichia coli K-12
dihydrofolate metabolic process	Dihydrofolate reductase	Escherichia coli K-12
folic acid metabolic process	Dihydrofolate reductase	Escherichia coli K-12
xenobiotic metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
cholesterol metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
estrogen metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
monoterpenoid metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
epoxygenase P450 pathway	Cytochrome P450 2C9	Homo sapiens (human)
urea metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
monocarboxylic acid metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 2C9	Homo sapiens (human)
long-chain fatty acid biosynthetic process	Cytochrome P450 2C9	Homo sapiens (human)
amide metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
icosanoid biosynthetic process	Cytochrome P450 2C9	Homo sapiens (human)
oxidative demethylation	Cytochrome P450 2C9	Homo sapiens (human)
omega-hydroxylase P450 pathway	Cytochrome P450 2C9	Homo sapiens (human)
detection of chemical stimulus involved in sensory perception of bitter taste	Carbonic anhydrase 6	Homo sapiens (human)
one-carbon metabolic process	Carbonic anhydrase 6	Homo sapiens (human)
G1/S transition of mitotic cell cycle	Cyclin-dependent kinase 2	Homo sapiens (human)
G2/M transition of mitotic cell cycle	Cyclin-dependent kinase 2	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Cyclin-dependent kinase 2	Homo sapiens (human)
DNA replication	Cyclin-dependent kinase 2	Homo sapiens (human)
DNA repair	Cyclin-dependent kinase 2	Homo sapiens (human)
chromatin remodeling	Cyclin-dependent kinase 2	Homo sapiens (human)
DNA-templated transcription	Cyclin-dependent kinase 2	Homo sapiens (human)
protein phosphorylation	Cyclin-dependent kinase 2	Homo sapiens (human)
potassium ion transport	Cyclin-dependent kinase 2	Homo sapiens (human)
centriole replication	Cyclin-dependent kinase 2	Homo sapiens (human)
Ras protein signal transduction	Cyclin-dependent kinase 2	Homo sapiens (human)
regulation of mitotic cell cycle	Cyclin-dependent kinase 2	Homo sapiens (human)
positive regulation of cell population proliferation	Cyclin-dependent kinase 2	Homo sapiens (human)
peptidyl-serine phosphorylation	Cyclin-dependent kinase 2	Homo sapiens (human)
positive regulation of heterochromatin formation	Cyclin-dependent kinase 2	Homo sapiens (human)
mitotic G1 DNA damage checkpoint signaling	Cyclin-dependent kinase 2	Homo sapiens (human)
positive regulation of DNA-templated DNA replication initiation	Cyclin-dependent kinase 2	Homo sapiens (human)
telomere maintenance in response to DNA damage	Cyclin-dependent kinase 2	Homo sapiens (human)
post-translational protein modification	Cyclin-dependent kinase 2	Homo sapiens (human)
positive regulation of DNA replication	Cyclin-dependent kinase 2	Homo sapiens (human)
positive regulation of DNA-templated transcription	Cyclin-dependent kinase 2	Homo sapiens (human)
centrosome duplication	Cyclin-dependent kinase 2	Homo sapiens (human)
cell division	Cyclin-dependent kinase 2	Homo sapiens (human)
meiotic cell cycle	Cyclin-dependent kinase 2	Homo sapiens (human)
cellular response to nitric oxide	Cyclin-dependent kinase 2	Homo sapiens (human)
cellular senescence	Cyclin-dependent kinase 2	Homo sapiens (human)
regulation of anaphase-promoting complex-dependent catabolic process	Cyclin-dependent kinase 2	Homo sapiens (human)
regulation of G2/M transition of mitotic cell cycle	Cyclin-dependent kinase 2	Homo sapiens (human)
signal transduction	Cyclin-dependent kinase 2	Homo sapiens (human)
regulation of gene expression	Cyclin-dependent kinase 2	Homo sapiens (human)
response to organic substance	Cyclin-dependent kinase 2	Homo sapiens (human)
behavioral fear response	Dipeptidyl peptidase 4	Homo sapiens (human)
response to hypoxia	Dipeptidyl peptidase 4	Homo sapiens (human)
proteolysis	Dipeptidyl peptidase 4	Homo sapiens (human)
cell adhesion	Dipeptidyl peptidase 4	Homo sapiens (human)
positive regulation of cell population proliferation	Dipeptidyl peptidase 4	Homo sapiens (human)
negative regulation of extracellular matrix disassembly	Dipeptidyl peptidase 4	Homo sapiens (human)
peptide hormone processing	Dipeptidyl peptidase 4	Homo sapiens (human)
receptor-mediated endocytosis of virus by host cell	Dipeptidyl peptidase 4	Homo sapiens (human)
T cell costimulation	Dipeptidyl peptidase 4	Homo sapiens (human)
regulation of cell-cell adhesion mediated by integrin	Dipeptidyl peptidase 4	Homo sapiens (human)
locomotory exploration behavior	Dipeptidyl peptidase 4	Homo sapiens (human)
psychomotor behavior	Dipeptidyl peptidase 4	Homo sapiens (human)
T cell activation	Dipeptidyl peptidase 4	Homo sapiens (human)
endothelial cell migration	Dipeptidyl peptidase 4	Homo sapiens (human)
symbiont entry into host cell	Dipeptidyl peptidase 4	Homo sapiens (human)
receptor-mediated virion attachment to host cell	Dipeptidyl peptidase 4	Homo sapiens (human)
negative chemotaxis	Dipeptidyl peptidase 4	Homo sapiens (human)
membrane fusion	Dipeptidyl peptidase 4	Homo sapiens (human)
negative regulation of neutrophil chemotaxis	Dipeptidyl peptidase 4	Homo sapiens (human)
glucagon processing	Dipeptidyl peptidase 4	Homo sapiens (human)
long-chain fatty acid metabolic process	Cytochrome P450 2C19	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 2C19	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 2C19	Homo sapiens (human)
monoterpenoid metabolic process	Cytochrome P450 2C19	Homo sapiens (human)
epoxygenase P450 pathway	Cytochrome P450 2C19	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 2C19	Homo sapiens (human)
omega-hydroxylase P450 pathway	Cytochrome P450 2C19	Homo sapiens (human)
one-carbon metabolic process	Carbonic anhydrase 5A, mitochondrial	Homo sapiens (human)
positive regulation of synaptic transmission, GABAergic	Carbonic anhydrase 7	Homo sapiens (human)
positive regulation of cellular pH reduction	Carbonic anhydrase 7	Homo sapiens (human)
neuron cellular homeostasis	Carbonic anhydrase 7	Homo sapiens (human)
regulation of chloride transport	Carbonic anhydrase 7	Homo sapiens (human)
regulation of intracellular pH	Carbonic anhydrase 7	Homo sapiens (human)
one-carbon metabolic process	Carbonic anhydrase 7	Homo sapiens (human)
response to hypoxia	Carbonic anhydrase 9	Homo sapiens (human)
morphogenesis of an epithelium	Carbonic anhydrase 9	Homo sapiens (human)
response to xenobiotic stimulus	Carbonic anhydrase 9	Homo sapiens (human)
response to testosterone	Carbonic anhydrase 9	Homo sapiens (human)
secretion	Carbonic anhydrase 9	Homo sapiens (human)
one-carbon metabolic process	Carbonic anhydrase 9	Homo sapiens (human)
microtubule-based process	Tubulin beta-2B chain	Bos taurus (cattle)
nervous system development	Tubulin beta-2B chain	Bos taurus (cattle)
positive regulation of axon guidance	Tubulin beta-2B chain	Bos taurus (cattle)
one-carbon metabolic process	Carbonic anhydrase 14	Homo sapiens (human)
response to bacterium	Carbonic anhydrase 5B, mitochondrial	Homo sapiens (human)
one-carbon metabolic process	Carbonic anhydrase 5B, mitochondrial	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
zinc ion binding	Carbonic anhydrase 12	Homo sapiens (human)
carbonate dehydratase activity	Carbonic anhydrase 12	Homo sapiens (human)
supercoiled DNA binding	Tyrosine-protein kinase ABL1	Homo sapiens (human)
magnesium ion binding	Tyrosine-protein kinase ABL1	Homo sapiens (human)
four-way junction DNA binding	Tyrosine-protein kinase ABL1	Homo sapiens (human)
bubble DNA binding	Tyrosine-protein kinase ABL1	Homo sapiens (human)
phosphotyrosine residue binding	Tyrosine-protein kinase ABL1	Homo sapiens (human)
DNA binding	Tyrosine-protein kinase ABL1	Homo sapiens (human)
transcription coactivator activity	Tyrosine-protein kinase ABL1	Homo sapiens (human)
actin monomer binding	Tyrosine-protein kinase ABL1	Homo sapiens (human)
nicotinate-nucleotide adenylyltransferase activity	Tyrosine-protein kinase ABL1	Homo sapiens (human)
protein kinase activity	Tyrosine-protein kinase ABL1	Homo sapiens (human)
protein tyrosine kinase activity	Tyrosine-protein kinase ABL1	Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activity	Tyrosine-protein kinase ABL1	Homo sapiens (human)
protein kinase C binding	Tyrosine-protein kinase ABL1	Homo sapiens (human)
protein binding	Tyrosine-protein kinase ABL1	Homo sapiens (human)
ATP binding	Tyrosine-protein kinase ABL1	Homo sapiens (human)
kinase activity	Tyrosine-protein kinase ABL1	Homo sapiens (human)
SH3 domain binding	Tyrosine-protein kinase ABL1	Homo sapiens (human)
syntaxin binding	Tyrosine-protein kinase ABL1	Homo sapiens (human)
manganese ion binding	Tyrosine-protein kinase ABL1	Homo sapiens (human)
neuropilin binding	Tyrosine-protein kinase ABL1	Homo sapiens (human)
SH2 domain binding	Tyrosine-protein kinase ABL1	Homo sapiens (human)
ephrin receptor binding	Tyrosine-protein kinase ABL1	Homo sapiens (human)
actin filament binding	Tyrosine-protein kinase ABL1	Homo sapiens (human)
mitogen-activated protein kinase binding	Tyrosine-protein kinase ABL1	Homo sapiens (human)
proline-rich region binding	Tyrosine-protein kinase ABL1	Homo sapiens (human)
delta-catenin binding	Tyrosine-protein kinase ABL1	Homo sapiens (human)
sequence-specific double-stranded DNA binding	Tyrosine-protein kinase ABL1	Homo sapiens (human)
arylesterase activity	Carbonic anhydrase 1	Homo sapiens (human)
carbonate dehydratase activity	Carbonic anhydrase 1	Homo sapiens (human)
protein binding	Carbonic anhydrase 1	Homo sapiens (human)
zinc ion binding	Carbonic anhydrase 1	Homo sapiens (human)
hydro-lyase activity	Carbonic anhydrase 1	Homo sapiens (human)
cyanamide hydratase activity	Carbonic anhydrase 1	Homo sapiens (human)
arylesterase activity	Carbonic anhydrase 2	Homo sapiens (human)
carbonate dehydratase activity	Carbonic anhydrase 2	Homo sapiens (human)
protein binding	Carbonic anhydrase 2	Homo sapiens (human)
zinc ion binding	Carbonic anhydrase 2	Homo sapiens (human)
cyanamide hydratase activity	Carbonic anhydrase 2	Homo sapiens (human)
carbonate dehydratase activity	Carbonic anhydrase 3	Homo sapiens (human)
protein binding	Carbonic anhydrase 3	Homo sapiens (human)
zinc ion binding	Carbonic anhydrase 3	Homo sapiens (human)
nickel cation binding	Carbonic anhydrase 3	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 3A4	Homo sapiens (human)
steroid binding	Cytochrome P450 3A4	Homo sapiens (human)
iron ion binding	Cytochrome P450 3A4	Homo sapiens (human)
protein binding	Cytochrome P450 3A4	Homo sapiens (human)
steroid hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
retinoic acid 4-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 3A4	Homo sapiens (human)
oxygen binding	Cytochrome P450 3A4	Homo sapiens (human)
enzyme binding	Cytochrome P450 3A4	Homo sapiens (human)
heme binding	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D3 25-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
caffeine oxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
quinine 3-monooxygenase activity	Cytochrome P450 3A4	Homo sapiens (human)
testosterone 6-beta-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
anandamide 8,9 epoxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
anandamide 11,12 epoxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
anandamide 14,15 epoxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
aromatase activity	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D 24-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
estrogen 16-alpha-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
estrogen 2-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
1,8-cineole 2-exo-monooxygenase activity	Cytochrome P450 3A4	Homo sapiens (human)
dihydrofolate reductase activity	Dihydrofolate reductase	Escherichia coli K-12
protein binding	Dihydrofolate reductase	Escherichia coli K-12
folic acid binding	Dihydrofolate reductase	Escherichia coli K-12
oxidoreductase activity	Dihydrofolate reductase	Escherichia coli K-12
NADP binding	Dihydrofolate reductase	Escherichia coli K-12
methotrexate binding	Dihydrofolate reductase	Escherichia coli K-12
dihydrofolic acid binding	Dihydrofolate reductase	Escherichia coli K-12
NADP+ binding	Dihydrofolate reductase	Escherichia coli K-12
NADPH binding	Dihydrofolate reductase	Escherichia coli K-12
monooxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
iron ion binding	Cytochrome P450 2C9	Homo sapiens (human)
arachidonic acid epoxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
steroid hydroxylase activity	Cytochrome P450 2C9	Homo sapiens (human)
arachidonic acid 14,15-epoxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
arachidonic acid 11,12-epoxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 2C9	Homo sapiens (human)
(S)-limonene 6-monooxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
(S)-limonene 7-monooxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
caffeine oxidase activity	Cytochrome P450 2C9	Homo sapiens (human)
(R)-limonene 6-monooxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
aromatase activity	Cytochrome P450 2C9	Homo sapiens (human)
heme binding	Cytochrome P450 2C9	Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	Cytochrome P450 2C9	Homo sapiens (human)
zinc ion binding	Carbonic anhydrase 6	Homo sapiens (human)
carbonate dehydratase activity	Carbonic anhydrase 6	Homo sapiens (human)
histone kinase activity	Cyclin-dependent kinase 2	Homo sapiens (human)
magnesium ion binding	Cyclin-dependent kinase 2	Homo sapiens (human)
protein serine/threonine kinase activity	Cyclin-dependent kinase 2	Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase activity	Cyclin-dependent kinase 2	Homo sapiens (human)
protein binding	Cyclin-dependent kinase 2	Homo sapiens (human)
ATP binding	Cyclin-dependent kinase 2	Homo sapiens (human)
protein domain specific binding	Cyclin-dependent kinase 2	Homo sapiens (human)
cyclin binding	Cyclin-dependent kinase 2	Homo sapiens (human)
cyclin-dependent protein kinase activity	Cyclin-dependent kinase 2	Homo sapiens (human)
protein serine kinase activity	Cyclin-dependent kinase 2	Homo sapiens (human)
virus receptor activity	Dipeptidyl peptidase 4	Homo sapiens (human)
protease binding	Dipeptidyl peptidase 4	Homo sapiens (human)
aminopeptidase activity	Dipeptidyl peptidase 4	Homo sapiens (human)
serine-type endopeptidase activity	Dipeptidyl peptidase 4	Homo sapiens (human)
signaling receptor binding	Dipeptidyl peptidase 4	Homo sapiens (human)
protein binding	Dipeptidyl peptidase 4	Homo sapiens (human)
serine-type peptidase activity	Dipeptidyl peptidase 4	Homo sapiens (human)
dipeptidyl-peptidase activity	Dipeptidyl peptidase 4	Homo sapiens (human)
identical protein binding	Dipeptidyl peptidase 4	Homo sapiens (human)
protein homodimerization activity	Dipeptidyl peptidase 4	Homo sapiens (human)
chemorepellent activity	Dipeptidyl peptidase 4	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 2C19	Homo sapiens (human)
iron ion binding	Cytochrome P450 2C19	Homo sapiens (human)
steroid hydroxylase activity	Cytochrome P450 2C19	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 2C19	Homo sapiens (human)
(S)-limonene 6-monooxygenase activity	Cytochrome P450 2C19	Homo sapiens (human)
(S)-limonene 7-monooxygenase activity	Cytochrome P450 2C19	Homo sapiens (human)
oxygen binding	Cytochrome P450 2C19	Homo sapiens (human)
enzyme binding	Cytochrome P450 2C19	Homo sapiens (human)
heme binding	Cytochrome P450 2C19	Homo sapiens (human)
(R)-limonene 6-monooxygenase activity	Cytochrome P450 2C19	Homo sapiens (human)
aromatase activity	Cytochrome P450 2C19	Homo sapiens (human)
long-chain fatty acid omega-1 hydroxylase activity	Cytochrome P450 2C19	Homo sapiens (human)
arachidonic acid epoxygenase activity	Cytochrome P450 2C19	Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	Cytochrome P450 2C19	Homo sapiens (human)
carbonate dehydratase activity	Carbonic anhydrase 5A, mitochondrial	Homo sapiens (human)
zinc ion binding	Carbonic anhydrase 5A, mitochondrial	Homo sapiens (human)
zinc ion binding	Carbonic anhydrase 7	Homo sapiens (human)
carbonate dehydratase activity	Carbonic anhydrase 7	Homo sapiens (human)
carbonate dehydratase activity	Carbonic anhydrase 9	Homo sapiens (human)
protein binding	Carbonic anhydrase 9	Homo sapiens (human)
zinc ion binding	Carbonic anhydrase 9	Homo sapiens (human)
molecular function activator activity	Carbonic anhydrase 9	Homo sapiens (human)
GTPase activity	Tubulin beta-2B chain	Bos taurus (cattle)
metal ion binding	Tubulin beta-2B chain	Bos taurus (cattle)
protein heterodimerization activity	Tubulin beta-2B chain	Bos taurus (cattle)
zinc ion binding	Carbonic anhydrase 4	Bos taurus (cattle)
zinc ion binding	Carbonic anhydrase 14	Homo sapiens (human)
carbonate dehydratase activity	Carbonic anhydrase 14	Homo sapiens (human)
carbonate dehydratase activity	Carbonic anhydrase 5B, mitochondrial	Homo sapiens (human)
zinc ion binding	Carbonic anhydrase 5B, mitochondrial	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
plasma membrane	Carbonic anhydrase 12	Homo sapiens (human)
membrane	Carbonic anhydrase 12	Homo sapiens (human)
basolateral plasma membrane	Carbonic anhydrase 12	Homo sapiens (human)
apical plasma membrane	Carbonic anhydrase 12	Homo sapiens (human)
plasma membrane	Carbonic anhydrase 12	Homo sapiens (human)
ruffle	Tyrosine-protein kinase ABL1	Homo sapiens (human)
nucleus	Tyrosine-protein kinase ABL1	Homo sapiens (human)
nucleoplasm	Tyrosine-protein kinase ABL1	Homo sapiens (human)
nucleolus	Tyrosine-protein kinase ABL1	Homo sapiens (human)
cytoplasm	Tyrosine-protein kinase ABL1	Homo sapiens (human)
mitochondrion	Tyrosine-protein kinase ABL1	Homo sapiens (human)
cytosol	Tyrosine-protein kinase ABL1	Homo sapiens (human)
actin cytoskeleton	Tyrosine-protein kinase ABL1	Homo sapiens (human)
nuclear body	Tyrosine-protein kinase ABL1	Homo sapiens (human)
dendrite	Tyrosine-protein kinase ABL1	Homo sapiens (human)
growth cone	Tyrosine-protein kinase ABL1	Homo sapiens (human)
nuclear membrane	Tyrosine-protein kinase ABL1	Homo sapiens (human)
neuronal cell body	Tyrosine-protein kinase ABL1	Homo sapiens (human)
perinuclear region of cytoplasm	Tyrosine-protein kinase ABL1	Homo sapiens (human)
postsynapse	Tyrosine-protein kinase ABL1	Homo sapiens (human)
protein-containing complex	Tyrosine-protein kinase ABL1	Homo sapiens (human)
plasma membrane	Tyrosine-protein kinase ABL1	Homo sapiens (human)
cytosol	Carbonic anhydrase 1	Homo sapiens (human)
extracellular exosome	Carbonic anhydrase 1	Homo sapiens (human)
cytoplasm	Carbonic anhydrase 2	Homo sapiens (human)
cytosol	Carbonic anhydrase 2	Homo sapiens (human)
plasma membrane	Carbonic anhydrase 2	Homo sapiens (human)
myelin sheath	Carbonic anhydrase 2	Homo sapiens (human)
apical part of cell	Carbonic anhydrase 2	Homo sapiens (human)
extracellular exosome	Carbonic anhydrase 2	Homo sapiens (human)
cytoplasm	Carbonic anhydrase 2	Homo sapiens (human)
plasma membrane	Carbonic anhydrase 2	Homo sapiens (human)
apical part of cell	Carbonic anhydrase 2	Homo sapiens (human)
cytosol	Carbonic anhydrase 3	Homo sapiens (human)
cytosol	Carbonic anhydrase 3	Homo sapiens (human)
cytoplasm	Carbonic anhydrase 3	Homo sapiens (human)
cytoplasm	Cytochrome P450 3A4	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 3A4	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 3A4	Homo sapiens (human)
cytosol	Dihydrofolate reductase	Escherichia coli K-12
cytosol	Dihydrofolate reductase	Escherichia coli K-12
endoplasmic reticulum membrane	Cytochrome P450 2C9	Homo sapiens (human)
plasma membrane	Cytochrome P450 2C9	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2C9	Homo sapiens (human)
cytoplasm	Cytochrome P450 2C9	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2C9	Homo sapiens (human)
extracellular region	Carbonic anhydrase 6	Homo sapiens (human)
extracellular space	Carbonic anhydrase 6	Homo sapiens (human)
cytosol	Carbonic anhydrase 6	Homo sapiens (human)
extracellular exosome	Carbonic anhydrase 6	Homo sapiens (human)
extracellular space	Carbonic anhydrase 6	Homo sapiens (human)
chromosome, telomeric region	Cyclin-dependent kinase 2	Homo sapiens (human)
condensed chromosome	Cyclin-dependent kinase 2	Homo sapiens (human)
X chromosome	Cyclin-dependent kinase 2	Homo sapiens (human)
Y chromosome	Cyclin-dependent kinase 2	Homo sapiens (human)
male germ cell nucleus	Cyclin-dependent kinase 2	Homo sapiens (human)
nucleus	Cyclin-dependent kinase 2	Homo sapiens (human)
nuclear envelope	Cyclin-dependent kinase 2	Homo sapiens (human)
nucleoplasm	Cyclin-dependent kinase 2	Homo sapiens (human)
cytoplasm	Cyclin-dependent kinase 2	Homo sapiens (human)
endosome	Cyclin-dependent kinase 2	Homo sapiens (human)
centrosome	Cyclin-dependent kinase 2	Homo sapiens (human)
cytosol	Cyclin-dependent kinase 2	Homo sapiens (human)
Cajal body	Cyclin-dependent kinase 2	Homo sapiens (human)
cyclin A1-CDK2 complex	Cyclin-dependent kinase 2	Homo sapiens (human)
cyclin A2-CDK2 complex	Cyclin-dependent kinase 2	Homo sapiens (human)
cyclin E1-CDK2 complex	Cyclin-dependent kinase 2	Homo sapiens (human)
cyclin E2-CDK2 complex	Cyclin-dependent kinase 2	Homo sapiens (human)
cyclin-dependent protein kinase holoenzyme complex	Cyclin-dependent kinase 2	Homo sapiens (human)
transcription regulator complex	Cyclin-dependent kinase 2	Homo sapiens (human)
cytoplasm	Cyclin-dependent kinase 2	Homo sapiens (human)
nucleus	Cyclin-dependent kinase 2	Homo sapiens (human)
extracellular region	Dipeptidyl peptidase 4	Homo sapiens (human)
lysosomal membrane	Dipeptidyl peptidase 4	Homo sapiens (human)
plasma membrane	Dipeptidyl peptidase 4	Homo sapiens (human)
focal adhesion	Dipeptidyl peptidase 4	Homo sapiens (human)
cell surface	Dipeptidyl peptidase 4	Homo sapiens (human)
membrane	Dipeptidyl peptidase 4	Homo sapiens (human)
apical plasma membrane	Dipeptidyl peptidase 4	Homo sapiens (human)
lamellipodium	Dipeptidyl peptidase 4	Homo sapiens (human)
endocytic vesicle	Dipeptidyl peptidase 4	Homo sapiens (human)
lamellipodium membrane	Dipeptidyl peptidase 4	Homo sapiens (human)
membrane raft	Dipeptidyl peptidase 4	Homo sapiens (human)
intercellular canaliculus	Dipeptidyl peptidase 4	Homo sapiens (human)
extracellular exosome	Dipeptidyl peptidase 4	Homo sapiens (human)
plasma membrane	Dipeptidyl peptidase 4	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 2C19	Homo sapiens (human)
plasma membrane	Cytochrome P450 2C19	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2C19	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2C19	Homo sapiens (human)
cytoplasm	Cytochrome P450 2C19	Homo sapiens (human)
mitochondrial matrix	Carbonic anhydrase 5A, mitochondrial	Homo sapiens (human)
mitochondrion	Carbonic anhydrase 5A, mitochondrial	Homo sapiens (human)
cytoplasm	Carbonic anhydrase 5A, mitochondrial	Homo sapiens (human)
mitochondrion	Carbonic anhydrase 5A, mitochondrial	Homo sapiens (human)
cytosol	Carbonic anhydrase 7	Homo sapiens (human)
cytoplasm	Carbonic anhydrase 7	Homo sapiens (human)
nucleolus	Carbonic anhydrase 9	Homo sapiens (human)
plasma membrane	Carbonic anhydrase 9	Homo sapiens (human)
membrane	Carbonic anhydrase 9	Homo sapiens (human)
basolateral plasma membrane	Carbonic anhydrase 9	Homo sapiens (human)
microvillus membrane	Carbonic anhydrase 9	Homo sapiens (human)
plasma membrane	Carbonic anhydrase 9	Homo sapiens (human)
microtubule cytoskeleton	Tubulin beta-2B chain	Bos taurus (cattle)
side of membrane	Carbonic anhydrase 4	Bos taurus (cattle)
plasma membrane	Carbonic anhydrase 14	Homo sapiens (human)
membrane	Carbonic anhydrase 14	Homo sapiens (human)
basolateral plasma membrane	Carbonic anhydrase 14	Homo sapiens (human)
apical plasma membrane	Carbonic anhydrase 14	Homo sapiens (human)
plasma membrane	Carbonic anhydrase 14	Homo sapiens (human)
mitochondrion	Carbonic anhydrase 5B, mitochondrial	Homo sapiens (human)
mitochondrial matrix	Carbonic anhydrase 5B, mitochondrial	Homo sapiens (human)
mitochondrion	Carbonic anhydrase 5B, mitochondrial	Homo sapiens (human)
cytoplasm	Carbonic anhydrase 5B, mitochondrial	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (348)

Assay ID	Title	Year	Journal	Article
AID1797276	Esterase Assay from Article 10.1021/jm031079w: \\Carbonic anhydrase inhibitors. Design of selective, membrane-impermeant inhibitors targeting the human tumor-associated isozyme IX.\\	2004	Journal of medicinal chemistry, Apr-22, Volume: 47, Issue:9	Carbonic anhydrase inhibitors. Design of selective, membrane-impermeant inhibitors targeting the human tumor-associated isozyme IX.
AID1796855	CA Inhibition Assay from Article 10.1021/jm0494826: \\Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/membrane-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating hydrazino moieties.\\	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/membrane-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating hydrazino moieties.
AID1798982	CA Inhibition Assay from Article 10.1021/jm9003126: \\Carbonic anhydrase inhibitors. Cloning, characterization, and inhibition studies of a new beta-carbonic anhydrase from Mycobacterium tuberculosis.\\	2009	Journal of medicinal chemistry, May-14, Volume: 52, Issue:9	Carbonic anhydrase inhibitors. Cloning, characterization, and inhibition studies of a new beta-carbonic anhydrase from Mycobacterium tuberculosis.
AID1798985	CA Inhibition Assay from Article 10.1021/jm9000488: \\Molecular cloning, characterization, and inhibition studies of the Rv1284 beta-carbonic anhydrase from Mycobacterium tuberculosis with sulfonamides and a sulfamate.\\	2009	Journal of medicinal chemistry, Apr-23, Volume: 52, Issue:8	Molecular cloning, characterization, and inhibition studies of the Rv1284 beta-carbonic anhydrase from Mycobacterium tuberculosis with sulfonamides and a sulfamate.
AID1796595	CA Inhibition Assay from Article 10.1021/jm060531j: \\Carbonic anhydrase inhibitors: Hypoxia-activatable sulfonamides incorporating disulfide bonds that target the tumor-associated isoform IX.\\	2006	Journal of medicinal chemistry, Sep-07, Volume: 49, Issue:18	Carbonic anhydrase inhibitors: Hypoxia-activatable sulfonamides incorporating disulfide bonds that target the tumor-associated isoform IX.
AID1796552	CA Inhibition Assay from Article 10.1021/jm0512600: \\Carbonic anhydrase inhibitors: DNA cloning and inhibition studies of the alpha-carbonic anhydrase from Helicobacter pylori, a new target for developing sulfonamide and sulfamate gastric drugs.\\	2006	Journal of medicinal chemistry, Mar-23, Volume: 49, Issue:6	Carbonic anhydrase inhibitors: DNA cloning and inhibition studies of the alpha-carbonic anhydrase from Helicobacter pylori, a new target for developing sulfonamide and sulfamate gastric drugs.
AID1797360	CA Inhibition Assay from Article 10.1021/jm061320h: \\Carbonic anhydrase inhibitors: inhibition of isozymes I, II, and IX with triazole-linked O-glycosides of benzene sulfonamides.\\	2007	Journal of medicinal chemistry, Apr-05, Volume: 50, Issue:7	Carbonic anhydrase inhibitors: inhibition of isozymes I, II, and IX with triazole-linked O-glycosides of benzene sulfonamides.
AID1799734	Inhibition Assay from Article 10.1080/14756360802218441: \\Carbonic anhydrase inhibitors. Biphenylsulfonamides with inhibitory action towards the transmembrane, tumor-associated isozymes IX possess cytotoxic activity against human colon, lung and breast ca	2009	Journal of enzyme inhibition and medicinal chemistry, Apr, Volume: 24, Issue:2	Carbonic anhydrase inhibitors. Biphenylsulfonamides with inhibitory action towards the transmembrane, tumor-associated isozymes IX possess cytotoxic activity against human colon, lung and breast cancer cell lines.
AID1799511	Enzymatic Assay from Article 10.1016/j.chembiol.2006.05.008: \\MASPIT: three-hybrid trap for quantitative proteome fingerprinting of small molecule-protein interactions in mammalian cells.\\	2006	Chemistry & biology, Jul, Volume: 13, Issue:7	MASPIT: three-hybrid trap for quantitative proteome fingerprinting of small molecule-protein interactions in mammalian cells.
AID1798769	CA Inhibition Assay from Article 10.1021/jm801267c: \\Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV.\\	2009	Journal of medicinal chemistry, Feb-12, Volume: 52, Issue:3	Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV.
AID1796582	CA Inhibition Assay from Article 10.1021/jm050483n: \\Carbonic anhydrase inhibitors. The mitochondrial isozyme VB as a new target for sulfonamide and sulfamate inhibitors.\\	2005	Journal of medicinal chemistry, Dec-01, Volume: 48, Issue:24	Carbonic anhydrase inhibitors. The mitochondrial isozyme VB as a new target for sulfonamide and sulfamate inhibitors.
AID1796771	CA Inhibition Assay from Article 10.1021/jm050333c: \\Carbonic anhydrase inhibitors: stacking with Phe131 determines active site binding region of inhibitors as exemplified by the X-ray crystal structure of a membrane-impermeant antitumor sulfonamide compl	2005	Journal of medicinal chemistry, Sep-08, Volume: 48, Issue:18	Carbonic anhydrase inhibitors: stacking with Phe131 determines active site binding region of inhibitors as exemplified by the X-ray crystal structure of a membrane-impermeant antitumor sulfonamide complexed with isozyme II.
AID1799266	CA Inhibition Assay from Article 10.1016/j.bmc.2009.05.002: \\Carbonic anhydrase inhibitors. Inhibition and homology modeling studies of the fungal beta-carbonic anhydrase from Candida albicans with sulfonamides.\\	2009	Bioorganic & medicinal chemistry, Jul-01, Volume: 17, Issue:13	Carbonic anhydrase inhibitors. Inhibition and homology modeling studies of the fungal beta-carbonic anhydrase from Candida albicans with sulfonamides.
AID1347411	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID726232	Inhibition of Trypanosoma cruzi CL Brener recombinant alpha-carbonic anhydrase expressed in insect Sf9 cell Baculovirus system by stopped flow CO2 hydration assay	2013	Journal of medicinal chemistry, Feb-28, Volume: 56, Issue:4	Cloning, characterization, and sulfonamide and thiol inhibition studies of an α-carbonic anhydrase from Trypanosoma cruzi, the causative agent of Chagas disease.
AID299243	Inhibition of human carbonic anhydrase 2 by stopped-flow CO2 hydrase assay	2007	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 17, Issue:13	Carbonic anhydrase inhibitors: the beta-carbonic anhydrase from Helicobacter pylori is a new target for sulfonamide and sulfamate inhibitors.
AID254247	Inhibition of cloned human carbonic anhydrase II	2005	Journal of medicinal chemistry, Sep-08, Volume: 48, Issue:18	Carbonic anhydrase inhibitors: stacking with Phe131 determines active site binding region of inhibitors as exemplified by the X-ray crystal structure of a membrane-impermeant antitumor sulfonamide complexed with isozyme II.
AID281083	Inhibition of human recombinant isozyme CA2 by CO2 hydration method	2007	Journal of medicinal chemistry, Apr-05, Volume: 50, Issue:7	Carbonic anhydrase inhibitors: inhibition of isozymes I, II, and IX with triazole-linked O-glycosides of benzene sulfonamides.
AID1142833	Inhibition of human carbonic anhydrase-1 by stopped-flow CO2 hydration assay	2014	Bioorganic & medicinal chemistry, Jun-01, Volume: 22, Issue:11	Sulfonamide inhibition studies of two β-carbonic anhydrases from the bacterial pathogen Legionella pneumophila.
AID1194026	Inhibition of recombinant Methanosarcina thermophila gamma-carbonic anhydrase by stopped flow CO2 hydrase assay	2015	Bioorganic & medicinal chemistry, Apr-15, Volume: 23, Issue:8	Sulfonamide inhibition studies of the γ-carbonic anhydrase from the Antarctic cyanobacterium Nostoc commune.
AID1062684	Inhibition of human CA12 after 15 mins by stopped-flow CO2 hydration assay	2014	European journal of medicinal chemistry, Jan, Volume: 71	Carbonic anhydrase inhibitors. Synthesis, and molecular structure of novel series N-substituted N'-(2-arylmethylthio-4-chloro-5-methylbenzenesulfonyl)guanidines and their inhibition of human cytosolic isozymes I and II and the transmembrane tumor-associat
AID1278412	Inhibition of Pseudoalteromonas haloplanktis gamma carbonic anhydrase preincubated for 15 mins by stopped flow CO2 hydration assay	2016	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4	Sulfonamide inhibition studies of the γ-carbonic anhydrase from the Antarctic bacterium Colwellia psychrerythraea.
AID1278410	Inhibition of Porphyromonas gingivalis gamma carbonic anhydrase preincubated for 15 mins by stopped flow CO2 hydration assay	2016	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4	Sulfonamide inhibition studies of the γ-carbonic anhydrase from the Antarctic bacterium Colwellia psychrerythraea.
AID287699	Inhibition of human recombinant carbonic anhydrase 2 by CO2 hydration method	2007	Bioorganic & medicinal chemistry, Mar-15, Volume: 15, Issue:6	Carbonic anhydrase and matrix metalloproteinase inhibitors. Inhibition of human tumor-associated isozymes IX and cytosolic isozyme I and II with sulfonylated hydroxamates.
AID743514	Inhibition of human recombinant carbonic anhydrase 2 preincubated for 15 mins by CO2 hydration stopped-flow assay	2013	Bioorganic & medicinal chemistry, Mar-15, Volume: 21, Issue:6	The alpha-carbonic anhydrase from the thermophilic bacterium Sulfurihydrogenibium yellowstonense YO3AOP1 is highly susceptible to inhibition by sulfonamides.
AID263637	Inhibition of human recombinant CA2	2006	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 16, Issue:8	Carbonic anhydrase inhibitors: cloning and sulfonamide inhibition studies of a carboxyterminal truncated alpha-carbonic anhydrase from Helicobacter pylori.
AID1678002	Induction of RBM39 degradation in human VCaP cells assessed as AR splicing modulation by measuring reduction in AR-V7 splice variant mRNA transcript level at 1 uM incubated for 24 hrs in presence of AR antagonist MDV by RT-qPCR analysis relative to DMSO c	2020	Bioorganic & medicinal chemistry, 10-15, Volume: 28, Issue:20	The splicing modulator sulfonamide indisulam reduces AR-V7 in prostate cancer cells.
AID1204091	Inhibition of recombinant human transmembrane, tumor-associated form of carbonic anhydrase-12 preincubated for 15 mins by stopped flow CO2 hydration assay	2015	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 25, Issue:11	Synthesis of Schiff base derivatives of 4-(2-aminoethyl)-benzenesulfonamide with inhibitory activity against carbonic anhydrase isoforms I, II, IX and XII.
AID254240	Inhibitory activity against human cloned Carbonic anhydrase I by the CO2 hydration method	2005	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 15, Issue:21	Carbonic anhydrase inhibitors: inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with benzo[b]thiophene 1,1-dioxide sulfonamides.
AID48088	Inhibitory activity against human carbonic anhydrase II	2004	Bioorganic & medicinal chemistry letters, Feb-23, Volume: 14, Issue:4	Carbonic anhydrase inhibitors: the first selective, membrane-impermeant inhibitors targeting the tumor-associated isozyme IX.
AID255389	Selectivity is measured as ratio of Ki value of Carbonic anhydrase II to that of Carbonic anhydrase IX	2005	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 15, Issue:21	Carbonic anhydrase inhibitors: inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with benzo[b]thiophene 1,1-dioxide sulfonamides.
AID1061069	Inhibition of human recombinant carbonic anhydrase 2 preincubated for 15 mins by stopped flow CO2 hydration assay	2014	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1	Sulfonamide inhibition studies of the δ-carbonic anhydrase from the diatom Thalassiosira weissflogii.
AID238259	Ratio against Carbonic anhydrase II to Carbonic anhydrase IX	2005	Bioorganic & medicinal chemistry letters, May-02, Volume: 15, Issue:9	Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating thioureido-sulfanilyl scaffolds.
AID238753	Inhibitory activity against Carbonic anhydrase I	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/membrane-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating hydrazino moieties.
AID577530	Inhibition of Brucella suis carbonic anhydrase II by spectrophotometry at pH 8.3	2011	Bioorganic & medicinal chemistry, Feb-01, Volume: 19, Issue:3	A new β-carbonic anhydrase from Brucella suis, its cloning, characterization, and inhibition with sulfonamides and sulfamates, leading to impaired pathogen growth.
AID1067225	Selectivity ratio of Ki for human transmembrane carbonic anhydrase 2 to Ki for human cytosolic carbonic anhydrase 12	2014	Bioorganic & medicinal chemistry, Mar-01, Volume: 22, Issue:5	Carbonic anhydrase inhibitors: synthesis and inhibition of the human carbonic anhydrase isoforms I, II, IX and XII with benzene sulfonamides incorporating 4- and 3-nitrophthalimide moieties.
AID367821	Inhibition of human recombinant CA2 by stopped-flow CO2 hydrase assay	2009	Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3	Carbonic anhydrase inhibitors: inhibition of the beta-class enzyme from the yeast Saccharomyces cerevisiae with sulfonamides and sulfamates.
AID770582	Inhibition of human membrane bound carbonic anhydrase 12 preincubated for 15 mins at room temperature followed by 72 hrs at 4 degC by stopped flow CO2 hydration assay	2013	Bioorganic & medicinal chemistry, Oct-01, Volume: 21, Issue:19	Carbonic anhydrase inhibitors: synthesis and inhibition of the human carbonic anhydrase isoforms I, II, VII, IX and XII with benzene sulfonamides incorporating 4,5,6,7-tetrabromophthalimide moiety.
AID1278409	Inhibition of human carbonic anhydrase 2 preincubated for 15 mins by CO2 hydrase stopped flow assay	2016	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4	Sulfonamide inhibition studies of the γ-carbonic anhydrase from the Antarctic bacterium Colwellia psychrerythraea.
AID367822	Inhibition of Saccharomyces cerevisiae recombinant CA expressed in Escherichia coli by stopped-flow CO2 hydrase assay	2009	Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3	Carbonic anhydrase inhibitors: inhibition of the beta-class enzyme from the yeast Saccharomyces cerevisiae with sulfonamides and sulfamates.
AID281085	Selectivity ratio of human CA9 over human CA1	2007	Journal of medicinal chemistry, Apr-05, Volume: 50, Issue:7	Carbonic anhydrase inhibitors: inhibition of isozymes I, II, and IX with triazole-linked O-glycosides of benzene sulfonamides.
AID1061067	Inhibition of Porphyromonas gingivalis recombinant gamma-carbonic anhydrase preincubated for 15 mins by stopped flow CO2 hydration assay	2014	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1	Sulfonamide inhibition studies of the δ-carbonic anhydrase from the diatom Thalassiosira weissflogii.
AID614107	Inhibition of human cloned carbonic anhydrase 9 catalytic domain preincubated for 15 mins by stopped flow CO2 hydration assay	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	Carbonic anhydrase inhibitors. Synthesis, molecular structures, and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associated) and XIV with novel 3-pyridinesulfonamide derivatives.
AID1154447	Inhibition of human cloned transmembrane tumor-associated catalytic domain of carbonic anhydrase 9 preincubated for 15 mins by stopped flow CO2 hydration assay	2014	European journal of medicinal chemistry, Jul-23, Volume: 82	Carbonic anhydrase inhibitors. Synthesis of a novel series of 5-substituted 2,4-dichlorobenzenesulfonamides and their inhibition of human cytosolic isozymes I and II and the transmembrane tumor-associated isozymes IX and XII.
AID408469	Inhibition of human recombinant CA1 by stopped flow CO2 hydration assay	2008	Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11	Carbonic anhydrase inhibitors: bioreductive nitro-containing sulfonamides with selectivity for targeting the tumor associated isoforms IX and XII.
AID47748	Inhibitory activity of compound against human carbonic anhydrase II	2004	Bioorganic & medicinal chemistry letters, Jan-19, Volume: 14, Issue:2	Carbonic anhydrase inhibitors: X-ray crystallographic structure of the adduct of human isozyme II with the antipsychotic drug sulpiride.
AID1262267	Inhibition of Chionodraco hamatus alphaCA incubated for 15 mins prior to testing by stopped flow CO2 hydrase assay	2015	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 25, Issue:23	Anion and sulfonamide inhibition studies of an α-carbonic anhydrase from the Antarctic hemoglobinless fish Chionodraco hamatus.
AID644381	Inhibition of human recombinant carbonic anhydrase 2 after 15 mins by stopped flow CO2 hydration assay	2012	Bioorganic & medicinal chemistry, Feb-15, Volume: 20, Issue:4	Cloning, characterization and sulfonamide inhibition studies of an α-carbonic anhydrase from the living fossil sponge Astrosclera willeyana.
AID614105	Inhibition of human cloned carbonic anhydrase 1 preincubated for 15 mins by stopped flow CO2 hydration assay	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	Carbonic anhydrase inhibitors. Synthesis, molecular structures, and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associated) and XIV with novel 3-pyridinesulfonamide derivatives.
AID299249	Inhibition of Helicobacter pylori alpha carbonic anhydrase by stopped-flow CO2 hydrase assay	2007	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 17, Issue:13	Carbonic anhydrase inhibitors: the beta-carbonic anhydrase from Helicobacter pylori is a new target for sulfonamide and sulfamate inhibitors.
AID764717	Inhibition of human cytosolic carbonic anhydrase 7 preincubated for 15 mins by stopped flow CO2 hydration assay	2013	Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17	Carbonic anhydrase inhibitors: Synthesis and inhibition of the cytosolic mammalian carbonic anhydrase isoforms I, II and VII with benzene sulfonamides incorporating 4,5,6,7-tetrachlorophthalimide moiety.
AID238409	Inhibition constant against human carbonic anhydrase I	2005	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 15, Issue:12	Carbonic anhydrase inhibitors. Inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, IX, and XII with Schiff's bases incorporating chromone and aromatic sulfonamide moieties, and their zinc complexes.
AID349606	Inhibition of human recombinant carbonic anhydrase 2 by stopped flow CO2 hydration assay	2009	Journal of medicinal chemistry, May-14, Volume: 52, Issue:9	Carbonic anhydrase inhibitors. Cloning, characterization, and inhibition studies of a new beta-carbonic anhydrase from Mycobacterium tuberculosis.
AID238084	Inhibition constant against human (cloned) isozyme (hCA II) by CO2 hydration method	2005	Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15	Carbonic anhydrase inhibitors. Design of fluorescent sulfonamides as probes of tumor-associated carbonic anhydrase IX that inhibit isozyme IX-mediated acidification of hypoxic tumors.
AID486934	Inhibition of human cloned carbonic anhydrase 9 catalytic domain preincubated for 15 mins by stopped flow CO2 hydration assay	2010	European journal of medicinal chemistry, Jun, Volume: 45, Issue:6	Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associated) and XIV with 4-substituted 3-pyridinesulfonamides.
AID486934	Inhibition of human cloned carbonic anhydrase 9 catalytic domain preincubated for 15 mins by stopped flow CO2 hydration assay	2010	European journal of medicinal chemistry, Sep, Volume: 45, Issue:9	Carbonic anhydrase inhibitors. Regioselective synthesis of novel 1-substituted 1,4-dihydro-4-oxo-3-pyridinesulfonamides and their inhibition of the human cytosolic isozymes I and II and transmembrane cancer-associated isozymes IX and XII.
AID238083	Inhibition constant against human cloned isozyme (hCA IX) by CO2 hydration method	2005	Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15	Carbonic anhydrase inhibitors. Design of fluorescent sulfonamides as probes of tumor-associated carbonic anhydrase IX that inhibit isozyme IX-mediated acidification of hypoxic tumors.
AID484214	Inhibition of human carbonic anhydrase 2	2010	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 20, Issue:12	New hydroxypyrimidinone-containing sulfonamides as carbonic anhydrase inhibitors also acting as MMP inhibitors.
AID263639	Selectivity for Helicobacter pylori recombinant CA over human recombinant CA2	2006	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 16, Issue:8	Carbonic anhydrase inhibitors: cloning and sulfonamide inhibition studies of a carboxyterminal truncated alpha-carbonic anhydrase from Helicobacter pylori.
AID1677992	Effect on MDV-induced recovery of DHT-suppressed full length AR mRNA expression in human VCaP cells at 10 uM preincubated for 24 hrs with DHT followed by wash-out and then incubated with compound for 24 hrs in presence of AR antagonist MDV by RT-qPCR anal	2020	Bioorganic & medicinal chemistry, 10-15, Volume: 28, Issue:20	The splicing modulator sulfonamide indisulam reduces AR-V7 in prostate cancer cells.
AID486936	Inhibition of human full length carbonic anhydrase 14 catalytic domain preincubated for 15 mins by stopped flow CO2 hydration assay	2010	European journal of medicinal chemistry, Jun, Volume: 45, Issue:6	Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associated) and XIV with 4-substituted 3-pyridinesulfonamides.
AID486936	Inhibition of human full length carbonic anhydrase 14 catalytic domain preincubated for 15 mins by stopped flow CO2 hydration assay	2010	European journal of medicinal chemistry, Sep, Volume: 45, Issue:9	Carbonic anhydrase inhibitors. Regioselective synthesis of novel 1-substituted 1,4-dihydro-4-oxo-3-pyridinesulfonamides and their inhibition of the human cytosolic isozymes I and II and transmembrane cancer-associated isozymes IX and XII.
AID1453413	Inhibition of human carbonic anhydrase-2 assessed as reduction in CO2 hydration preincubated for 15 mins followed by CO2 addition measured for 10 to 100 secs by stopped-flow assay
AID261579	Inhibition of human recombinant carbonic anhydrase 1 by stopped-flow CO2 hydrase assay	2006	Journal of medicinal chemistry, Mar-23, Volume: 49, Issue:6	Carbonic anhydrase inhibitors: DNA cloning and inhibition studies of the alpha-carbonic anhydrase from Helicobacter pylori, a new target for developing sulfonamide and sulfamate gastric drugs.
AID275806	Inhibition of full length human recombinant CA VI	2007	Journal of medicinal chemistry, Jan-25, Volume: 50, Issue:2	Carbonic anhydrase inhibitors. DNA cloning, characterization, and inhibition studies of the human secretory isoform VI, a new target for sulfonamide and sulfamate inhibitors.
AID414961	Inhibition of Mycobacterium tuberculosis H37Rv recombinant beta-carbonic anhydrase 1 expressed in Escherichia coli BL21 by stopped flow CO2 hydration method	2009	Journal of medicinal chemistry, Apr-23, Volume: 52, Issue:8	Molecular cloning, characterization, and inhibition studies of the Rv1284 beta-carbonic anhydrase from Mycobacterium tuberculosis with sulfonamides and a sulfamate.
AID1154445	Inhibition of human cloned cytosolic carbonic anhydrase 1 preincubated for 15 mins by stopped flow CO2 hydration assay	2014	European journal of medicinal chemistry, Jul-23, Volume: 82	Carbonic anhydrase inhibitors. Synthesis of a novel series of 5-substituted 2,4-dichlorobenzenesulfonamides and their inhibition of human cytosolic isozymes I and II and the transmembrane tumor-associated isozymes IX and XII.
AID1758423	Inhibition of human CA9 preincubated for 15 mins by phenol red dye based stopped flow CO2 hydration assay	2021	European journal of medicinal chemistry, May-05, Volume: 217	Comprehensive study on potent and selective carbonic anhydrase inhibitors: Synthesis, bioactivities and molecular modelling studies of 4-(3-(2-arylidenehydrazine-1-carbonyl)-5-(thiophen-2-yl)-1H-pyrazole-1-yl) benzenesulfonamides.
AID1593068	Inhibition of human CA 12 catalytic domain	2019	European journal of medicinal chemistry, Apr-15, Volume: 168	Pyridazinone-substituted benzenesulfonamides display potent inhibition of membrane-bound human carbonic anhydrase IX and promising antiproliferative activity against cancer cell lines.
AID1067228	Inhibition of human transmembrane carbonic anhydrase 9 by stopped-flow CO2 hydration assay	2014	Bioorganic & medicinal chemistry, Mar-01, Volume: 22, Issue:5	Carbonic anhydrase inhibitors: synthesis and inhibition of the human carbonic anhydrase isoforms I, II, IX and XII with benzene sulfonamides incorporating 4- and 3-nitrophthalimide moieties.
AID281086	Selectivity ratio of human CA9 over human CA2	2007	Journal of medicinal chemistry, Apr-05, Volume: 50, Issue:7	Carbonic anhydrase inhibitors: inhibition of isozymes I, II, and IX with triazole-linked O-glycosides of benzene sulfonamides.
AID1287520	Inhibition of recombinant Enterobacter sp. B13 beta carbonic anhydrase incubated for 15 mins by stopped-flow CO2 hydration assay	2016	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 26, Issue:7	Sulfonamide inhibition studies of the β-carbonic anhydrase from the newly discovered bacterium Enterobacter sp. B13.
AID48292	Inhibition constant evaluated for the inhibition of bovine CA IV (Carbonic anhydrase IV)	2004	Journal of medicinal chemistry, Apr-22, Volume: 47, Issue:9	Carbonic anhydrase inhibitors. Design of selective, membrane-impermeant inhibitors targeting the human tumor-associated isozyme IX.
AID1434429	Inhibition of Burkholderia pseudomallei Gamma-carbonic anhydrase assessed as reduction in CO2 hydration preincubated for 15 mins followed by CO2 addition measured for 10 to 100 sec by Line-Weaver Burk plot analysis
AID1275910	Inhibition of Vibrio cholerae beta-carbonic anhydrase using CO2 as substrate preincubated for 15 mins by stopped-flow CO2 hydration assay	2016	Bioorganic & medicinal chemistry, Mar-01, Volume: 24, Issue:5	Sulfonamide inhibition studies of the β-carbonic anhydrase from the pathogenic bacterium Vibrio cholerae.
AID238787	Inhibitory activity against human carbonic anhydrase II expressed in Escherichia coli BL21	2004	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 14, Issue:21	Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating 1,2,4-triazine moieties.
AID1677987	Antitumor activity against human VCaP cells xenografted in NSG mouse assessed as tumor volume at 10 mg/kg, po co-administered with 25 mg/kg AR antagonist MDV via gavage with 5 days on and 2 days off dosing schedule for 6 weeks and measured bi-weekly for 6	2020	Bioorganic & medicinal chemistry, 10-15, Volume: 28, Issue:20	The splicing modulator sulfonamide indisulam reduces AR-V7 in prostate cancer cells.
AID486932	Inhibition of human cloned carbonic anhydrase 1 preincubated for 15 mins by stopped flow CO2 hydration assay	2010	European journal of medicinal chemistry, Jun, Volume: 45, Issue:6	Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associated) and XIV with 4-substituted 3-pyridinesulfonamides.
AID486932	Inhibition of human cloned carbonic anhydrase 1 preincubated for 15 mins by stopped flow CO2 hydration assay	2010	European journal of medicinal chemistry, Sep, Volume: 45, Issue:9	Carbonic anhydrase inhibitors. Regioselective synthesis of novel 1-substituted 1,4-dihydro-4-oxo-3-pyridinesulfonamides and their inhibition of the human cytosolic isozymes I and II and transmembrane cancer-associated isozymes IX and XII.
AID552128	Inhibition of human recombinant CA2 by stopped-flow CO2 hydration assay	2011	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2	Carbonic anhydrase inhibitors. Inhibition studies with anions and sulfonamides of a new cytosolic enzyme from the scleractinian coral Stylophora pistillata.
AID743513	Inhibition of Helicobacter pylori recombinant alpha carbonic anhydrase preincubated for 15 mins by CO2 hydration stopped-flow assay	2013	Bioorganic & medicinal chemistry, Mar-15, Volume: 21, Issue:6	The alpha-carbonic anhydrase from the thermophilic bacterium Sulfurihydrogenibium yellowstonense YO3AOP1 is highly susceptible to inhibition by sulfonamides.
AID238769	Inhibitory activity against Carbonic anhydrase IX	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/membrane-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating hydrazino moieties.
AID770581	Selectivity ratio of Ki for human carbonic anhydrase 2 to Ki for human carbonic anhydrase 9	2013	Bioorganic & medicinal chemistry, Oct-01, Volume: 21, Issue:19	Carbonic anhydrase inhibitors: synthesis and inhibition of the human carbonic anhydrase isoforms I, II, VII, IX and XII with benzene sulfonamides incorporating 4,5,6,7-tetrabromophthalimide moiety.
AID52986	In vitro antiproliferative activity against colon 38 murine adenocarcinoma	1999	Journal of medicinal chemistry, Sep-23, Volume: 42, Issue:19	Discovery of novel antitumor sulfonamides targeting G1 phase of the cell cycle.
AID48287	Inhibitory activity against carbonic anhydrase IV from bovine lung microsomes	2004	Bioorganic & medicinal chemistry letters, Feb-23, Volume: 14, Issue:4	Carbonic anhydrase inhibitors: the first selective, membrane-impermeant inhibitors targeting the tumor-associated isozyme IX.
AID612732	Inhibition of Salmonella Typhimurium recombinant carbonic anhydrase 2 at pH 8.3 by stopped flow CO2 hydration assay	2011	Bioorganic & medicinal chemistry, Aug-15, Volume: 19, Issue:16	Inhibition studies of the β-carbonic anhydrases from the bacterial pathogen Salmonella enterica serovar Typhimurium with sulfonamides and sulfamates.
AID1204095	Selectivity ratio Ki for recombinant human cytosolic form of carbonic anhydrase-2 to Ki for recombinant human transmembrane, tumor-associated form of carbonic anhydrase-12	2015	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 25, Issue:11	Synthesis of Schiff base derivatives of 4-(2-aminoethyl)-benzenesulfonamide with inhibitory activity against carbonic anhydrase isoforms I, II, IX and XII.
AID1677985	Reduction in AR-V7 level in tumor lysates of NSG mouse xenografted with human VCaP cells at 10 mg/kg, po administered via gavage with 5 days on and 2 days off dosing schedule for 6 weeks by immunoblot analysis	2020	Bioorganic & medicinal chemistry, 10-15, Volume: 28, Issue:20	The splicing modulator sulfonamide indisulam reduces AR-V7 in prostate cancer cells.
AID287700	Inhibition of human recombinant carbonic anhydrase 9 by CO2 hydration method	2007	Bioorganic & medicinal chemistry, Mar-15, Volume: 15, Issue:6	Carbonic anhydrase and matrix metalloproteinase inhibitors. Inhibition of human tumor-associated isozymes IX and cytosolic isozyme I and II with sulfonylated hydroxamates.
AID484213	Inhibition of human carbonic anhydrase 1	2010	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 20, Issue:12	New hydroxypyrimidinone-containing sulfonamides as carbonic anhydrase inhibitors also acting as MMP inhibitors.
AID263636	Inhibition of human recombinant CA1	2006	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 16, Issue:8	Carbonic anhydrase inhibitors: cloning and sulfonamide inhibition studies of a carboxyterminal truncated alpha-carbonic anhydrase from Helicobacter pylori.
AID1061169	Inhibition of recombinant Methanosarcina thermophila gamma-CA CAM by stopped flow CO2 hydration assay	2014	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1	Sulfonamide inhibition studies of the γ-carbonic anhydrase from the oral pathogen Porphyromonas gingivalis.
AID1062685	Inhibition of human CA9 after 15 mins by stopped-flow CO2 hydration assay	2014	European journal of medicinal chemistry, Jan, Volume: 71	Carbonic anhydrase inhibitors. Synthesis, and molecular structure of novel series N-substituted N'-(2-arylmethylthio-4-chloro-5-methylbenzenesulfonyl)guanidines and their inhibition of human cytosolic isozymes I and II and the transmembrane tumor-associat
AID512002	Inhibition of human cloned CA2 after 15 mins by stopped-flow CO2 hydration assay	2010	European journal of medicinal chemistry, Jun, Volume: 45, Issue:6	Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associated) and XIV with 4-substituted 3-pyridinesulfonamides.
AID512002	Inhibition of human cloned CA2 after 15 mins by stopped-flow CO2 hydration assay	2010	European journal of medicinal chemistry, Sep, Volume: 45, Issue:9	Carbonic anhydrase inhibitors. Regioselective synthesis of novel 1-substituted 1,4-dihydro-4-oxo-3-pyridinesulfonamides and their inhibition of the human cytosolic isozymes I and II and transmembrane cancer-associated isozymes IX and XII.
AID1194024	Inhibition of human recombinant carbonic anhydrase 1 by stopped flow CO2 hydrase assay	2015	Bioorganic & medicinal chemistry, Apr-15, Volume: 23, Issue:8	Sulfonamide inhibition studies of the γ-carbonic anhydrase from the Antarctic cyanobacterium Nostoc commune.
AID1434430	Inhibition of Vibrio cholerae Gamma-carbonic anhydrase assessed as reduction in CO2 hydration preincubated for 15 mins followed by CO2 addition measured for 10 to 100 sec by Line-Weaver Burk plot analysis
AID436565	Inhibition of cloned Stylophora pistillata alpha-CA expressed in human HEK293 cells by stopped-flow CO2 assay	2009	Bioorganic & medicinal chemistry, Jul-15, Volume: 17, Issue:14	Carbonic anhydrase inhibitors. Inhibition studies of a coral secretory isoform by sulfonamides.
AID1268963	Inhibition of recombinant human carbonic anhydrase-2 by stopped flow CO2 hydrase assay	2016	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2	Sulfonamide inhibition studies of the α-carbonic anhydrase from the gammaproteobacterium Thiomicrospira crunogena XCL-2, TcruCA.
AID238223	Inhibitory constant against human Carbonic anhydrase II	2005	Bioorganic & medicinal chemistry letters, May-02, Volume: 15, Issue:9	Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating thioureido-sulfanilyl scaffolds.
AID1195369	Inhibition of human carbonic anhydrase 1 pre-incubated for 15 mins by stopped-flow CO2 hydration assay	2015	Bioorganic & medicinal chemistry, May-15, Volume: 23, Issue:10	The β-carbonic anhydrase from the malaria mosquito Anopheles gambiae is highly inhibited by sulfonamides.
AID577526	Inhibition of human carbonic anhydrase I by spectrophotometry at pH 7.5	2011	Bioorganic & medicinal chemistry, Feb-01, Volume: 19, Issue:3	A new β-carbonic anhydrase from Brucella suis, its cloning, characterization, and inhibition with sulfonamides and sulfamates, leading to impaired pathogen growth.
AID349608	Inhibition of full length Mycobacterium tuberculosis H37Rv recombinant carbonic anhydrase 3 expressed in Escherichia coli BL21 by stopped flow CO2 hydration assay	2009	Journal of medicinal chemistry, May-14, Volume: 52, Issue:9	Carbonic anhydrase inhibitors. Cloning, characterization, and inhibition studies of a new beta-carbonic anhydrase from Mycobacterium tuberculosis.
AID612731	Inhibition of Salmonella Typhimurium recombinant carbonic anhydrase 1 at pH 8.3 by stopped flow CO2 hydration assay	2011	Bioorganic & medicinal chemistry, Aug-15, Volume: 19, Issue:16	Inhibition studies of the β-carbonic anhydrases from the bacterial pathogen Salmonella enterica serovar Typhimurium with sulfonamides and sulfamates.
AID271039	Inhibition of human cloned CA9 catalytic domain by CO2 hydration assay	2006	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 16, Issue:18	Carbonic anhydrase inhibitors. Inhibition of the cytosolic human isozymes I and II, and the transmembrane, tumor-associated isozymes IX and XII with substituted aromatic sulfonamides activatable in hypoxic tumors.
AID1262264	Inhibition of human CA2 incubated for 15 mins prior to testing by stopped flow CO2 hydrase assay	2015	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 25, Issue:23	Anion and sulfonamide inhibition studies of an α-carbonic anhydrase from the Antarctic hemoglobinless fish Chionodraco hamatus.
AID317578	Inhibition of human CA9	2008	Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6	Inhibition of carbonic anhydrases with glycosyltriazole benzene sulfonamides.
AID271172	Inhibition of human recombinant carbonic anhydrase 1 by stopped-flow CO2 hydrase assay	2006	Journal of medicinal chemistry, Sep-07, Volume: 49, Issue:18	Carbonic anhydrase inhibitors: Hypoxia-activatable sulfonamides incorporating disulfide bonds that target the tumor-associated isoform IX.
AID238772	Binding affinity towards human cloned carbonic anhydrase II	2004	Bioorganic & medicinal chemistry letters, Dec-06, Volume: 14, Issue:23	Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides derived from 4-isothiocyanato-benzolamide.
AID644380	Inhibition of human recombinant carbonic anhydrase 1 after 15 mins by stopped flow CO2 hydration assay	2012	Bioorganic & medicinal chemistry, Feb-15, Volume: 20, Issue:4	Cloning, characterization and sulfonamide inhibition studies of an α-carbonic anhydrase from the living fossil sponge Astrosclera willeyana.
AID331499	Inhibition of human recombinant carbonic anhydrase 2 by CO2 hydration stopped-flow assay	2008	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 18, Issue:12	Carbonic anhydrase inhibitors: design of spin-labeled sulfonamides incorporating TEMPO moieties as probes for cytosolic or transmembrane isozymes.
AID427123	Inhibition of Cryptococcus neoformans recombinant Can2 by stopped-flow CO2 hydration assay	2009	Bioorganic & medicinal chemistry, Jul-01, Volume: 17, Issue:13	Carbonic anhydrase inhibitors. Inhibition and homology modeling studies of the fungal beta-carbonic anhydrase from Candida albicans with sulfonamides.
AID408472	Inhibition of human cloned CA12 catalytic domain by stopped flow CO2 hydration assay	2008	Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11	Carbonic anhydrase inhibitors: bioreductive nitro-containing sulfonamides with selectivity for targeting the tumor associated isoforms IX and XII.
AID261580	Inhibition of human recombinant carbonic anhydrase 2 by stopped-flow CO2 hydrase assay	2006	Journal of medicinal chemistry, Mar-23, Volume: 49, Issue:6	Carbonic anhydrase inhibitors: DNA cloning and inhibition studies of the alpha-carbonic anhydrase from Helicobacter pylori, a new target for developing sulfonamide and sulfamate gastric drugs.
AID287698	Inhibition of human recombinant carbonic anhydrase 1 by CO2 hydration method	2007	Bioorganic & medicinal chemistry, Mar-15, Volume: 15, Issue:6	Carbonic anhydrase and matrix metalloproteinase inhibitors. Inhibition of human tumor-associated isozymes IX and cytosolic isozyme I and II with sulfonylated hydroxamates.
AID484216	Selectivity ratio of Ki for human carbonic anhydrase 9 to human carbonic anhydrase 2	2010	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 20, Issue:12	New hydroxypyrimidinone-containing sulfonamides as carbonic anhydrase inhibitors also acting as MMP inhibitors.
AID1628036	Inhibition of full length human cytosolic carbonic anhydrase 1 preincubated for 15 mins by stop flow CO2 hydrase assay	2016	Bioorganic & medicinal chemistry letters, 09-01, Volume: 26, Issue:17	Cloning, expression, purification and sulfonamide inhibition profile of the complete domain of the η-carbonic anhydrase from Plasmodium falciparum.
AID48301	Inhibitory activity against human carbonic anhydrase IX	2004	Bioorganic & medicinal chemistry letters, May-03, Volume: 14, Issue:9	Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozyme IX with fluorine-containing sulfonamides. The first subnanomolar CA IX inhibitor discovered.
AID238467	Inhibition constant against human carbonic anhydrase XII	2005	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 15, Issue:12	Carbonic anhydrase inhibitors. Inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, IX, and XII with Schiff's bases incorporating chromone and aromatic sulfonamide moieties, and their zinc complexes.
AID1678003	Induction of RBM39 degradation in human VCaP cells assessed as reduction in AR-V7 protein expression preincubated for 24 hrs with DHT followed by wash-out and incubated with compound for 24 hrs in presence of AR antagonist MDV by western blot analysis	2020	Bioorganic & medicinal chemistry, 10-15, Volume: 28, Issue:20	The splicing modulator sulfonamide indisulam reduces AR-V7 in prostate cancer cells.
AID1183267	Inhibition of human cloned CA9 catalytic domain pre-incubated with enzyme for 15 mins by phenol red based CO2 hydration stopped-flow assay	2014	European journal of medicinal chemistry, Sep-12, Volume: 84	Synthesis of a new series of N⁴-substituted 4-(2-aminoethyl)benzenesulfonamides and their inhibitory effect on human carbonic anhydrase cytosolic isozymes I and II and transmembrane tumor-associated isozymes IX and XII.
AID1593067	Inhibition of human CA 9 catalytic domain	2019	European journal of medicinal chemistry, Apr-15, Volume: 168	Pyridazinone-substituted benzenesulfonamides display potent inhibition of membrane-bound human carbonic anhydrase IX and promising antiproliferative activity against cancer cell lines.
AID150686	Antiproliferative activity against P388 murine leukemia in vitro	1999	Journal of medicinal chemistry, Sep-23, Volume: 42, Issue:19	Discovery of novel antitumor sulfonamides targeting G1 phase of the cell cycle.
AID612726	Inhibition of human recombinant carbonic anhydrase 2 at pH 7.5 by stopped flow CO2 hydration assay	2011	Bioorganic & medicinal chemistry, Aug-15, Volume: 19, Issue:16	Inhibition studies of the β-carbonic anhydrases from the bacterial pathogen Salmonella enterica serovar Typhimurium with sulfonamides and sulfamates.
AID725956	Inhibition of human recombinant carbonic anhydrase 2 by stopped flow CO2 hydration assay	2013	Journal of medicinal chemistry, Feb-28, Volume: 56, Issue:4	Cloning, characterization, and sulfonamide and thiol inhibition studies of an α-carbonic anhydrase from Trypanosoma cruzi, the causative agent of Chagas disease.
AID1275911	Inhibition of Vibrio cholerae alpha-carbonic anhydrase using CO2 as substrate preincubated for 15 mins by stopped-flow CO2 hydration assay	2016	Bioorganic & medicinal chemistry, Mar-01, Volume: 24, Issue:5	Sulfonamide inhibition studies of the β-carbonic anhydrase from the pathogenic bacterium Vibrio cholerae.
AID1593066	Inhibition of full length human CA 2	2019	European journal of medicinal chemistry, Apr-15, Volume: 168	Pyridazinone-substituted benzenesulfonamides display potent inhibition of membrane-bound human carbonic anhydrase IX and promising antiproliferative activity against cancer cell lines.
AID244127	Ratio of Ki for human carbonic anhydrases II and IX	2004	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 14, Issue:21	Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating 1,2,4-triazine moieties.
AID275809	Inhibition of catalytic domain of human recombinant CA IX	2007	Journal of medicinal chemistry, Jan-25, Volume: 50, Issue:2	Carbonic anhydrase inhibitors. DNA cloning, characterization, and inhibition studies of the human secretory isoform VI, a new target for sulfonamide and sulfamate inhibitors.
AID238620	Inhibitory activity against cytosolic human carbonic anhydrase I	2005	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 15, Issue:3	Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with bis-sulfamates.
AID331498	Inhibition of human recombinant carbonic anhydrase 1 by CO2 hydration stopped-flow assay	2008	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 18, Issue:12	Carbonic anhydrase inhibitors: design of spin-labeled sulfonamides incorporating TEMPO moieties as probes for cytosolic or transmembrane isozymes.
AID386500	Inhibition of human cloned CA1 by stopped-flow CO2 hydration method	2008	Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7	Carbonic anhydrase inhibitors: inhibition of human cytosolic isozymes I and II and tumor-associated isozymes IX and XII with S-substituted 4-chloro-2-mercapto-5-methyl-benzenesulfonamides.
AID1183265	Inhibition of human cloned CA1 pre-incubated with enzyme for 15 mins by phenol red based CO2 hydration stopped-flow assay	2014	European journal of medicinal chemistry, Sep-12, Volume: 84	Synthesis of a new series of N⁴-substituted 4-(2-aminoethyl)benzenesulfonamides and their inhibitory effect on human carbonic anhydrase cytosolic isozymes I and II and transmembrane tumor-associated isozymes IX and XII.
AID254248	Inhibition of catalytic domain of human recombinant carbonic anhydrase IX	2005	Journal of medicinal chemistry, Sep-08, Volume: 48, Issue:18	Carbonic anhydrase inhibitors: stacking with Phe131 determines active site binding region of inhibitors as exemplified by the X-ray crystal structure of a membrane-impermeant antitumor sulfonamide complexed with isozyme II.
AID512001	Inhibition of human cloned CA1 after 15 mins by stopped-flow CO2 hydration assay	2010	European journal of medicinal chemistry, Jun, Volume: 45, Issue:6	Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associated) and XIV with 4-substituted 3-pyridinesulfonamides.
AID512001	Inhibition of human cloned CA1 after 15 mins by stopped-flow CO2 hydration assay	2010	European journal of medicinal chemistry, Sep, Volume: 45, Issue:9	Carbonic anhydrase inhibitors. Regioselective synthesis of novel 1-substituted 1,4-dihydro-4-oxo-3-pyridinesulfonamides and their inhibition of the human cytosolic isozymes I and II and transmembrane cancer-associated isozymes IX and XII.
AID243098	Ratio of inhibitory activity of human cytosolic carbonic anhydrase II to tumor associated carbonic anhydrase IX	2005	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 15, Issue:3	Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with bis-sulfamates.
AID1062687	Inhibition of human CA1 cytosolic isoform after 15 mins by stopped-flow CO2 hydration assay	2014	European journal of medicinal chemistry, Jan, Volume: 71	Carbonic anhydrase inhibitors. Synthesis, and molecular structure of novel series N-substituted N'-(2-arylmethylthio-4-chloro-5-methylbenzenesulfonyl)guanidines and their inhibition of human cytosolic isozymes I and II and the transmembrane tumor-associat
AID1677996	Induction of RBM39 degradation in human VCaP cells assessed as AR mRNA splicing modulation by measuring reduction in AR-V7 splice variant mRNA transcript level at 10 uM incubated for 24 hrs by RT-qPCR analysis relative to DMSO control	2020	Bioorganic & medicinal chemistry, 10-15, Volume: 28, Issue:20	The splicing modulator sulfonamide indisulam reduces AR-V7 in prostate cancer cells.
AID281082	Inhibition of human recombinant isozyme CA1 by CO2 hydration method	2007	Journal of medicinal chemistry, Apr-05, Volume: 50, Issue:7	Carbonic anhydrase inhibitors: inhibition of isozymes I, II, and IX with triazole-linked O-glycosides of benzene sulfonamides.
AID486935	Inhibition of human cloned carbonic anhydrase 12 catalytic domain preincubated for 15 mins by stopped flow CO2 hydration assay	2010	European journal of medicinal chemistry, Jun, Volume: 45, Issue:6	Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associated) and XIV with 4-substituted 3-pyridinesulfonamides.
AID486935	Inhibition of human cloned carbonic anhydrase 12 catalytic domain preincubated for 15 mins by stopped flow CO2 hydration assay	2010	European journal of medicinal chemistry, Sep, Volume: 45, Issue:9	Carbonic anhydrase inhibitors. Regioselective synthesis of novel 1-substituted 1,4-dihydro-4-oxo-3-pyridinesulfonamides and their inhibition of the human cytosolic isozymes I and II and transmembrane cancer-associated isozymes IX and XII.
AID1677998	Reduction in RBM39 level in tumor lysates of NSG mouse xenografted with human VCaP cells at 10 mg/kg, po co-administered with 25 mg/kg AR antagonist MDV via gavage with 5 days on and 2 days off dosing schedule for 6 weeks by immunoblot analysis	2020	Bioorganic & medicinal chemistry, 10-15, Volume: 28, Issue:20	The splicing modulator sulfonamide indisulam reduces AR-V7 in prostate cancer cells.
AID331501	Selectivity ratio of Ki for human recombinant carbonic anhydrase 2 to Ki for human cloned carbonic anhydrase 9	2008	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 18, Issue:12	Carbonic anhydrase inhibitors: design of spin-labeled sulfonamides incorporating TEMPO moieties as probes for cytosolic or transmembrane isozymes.
AID293814	Selectivity for human recombinant CA9 over human recombinant CA2	2007	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 17, Issue:6	Carbonic anhydrase inhibitors: inhibition of cytosolic/tumor-associated isoforms I, II, and IX with iminodiacetic carboxylates/hydroxamates also incorporating benzenesulfonamide moieties.
AID238085	Inhibition constant against human (cloned) isozyme (hCA I) by the CO2 hydration method	2005	Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15	Carbonic anhydrase inhibitors. Design of fluorescent sulfonamides as probes of tumor-associated carbonic anhydrase IX that inhibit isozyme IX-mediated acidification of hypoxic tumors.
AID50375	Inhibitory activity against human carbonic anhydrase I	2004	Bioorganic & medicinal chemistry letters, May-03, Volume: 14, Issue:9	Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozyme IX with fluorine-containing sulfonamides. The first subnanomolar CA IX inhibitor discovered.
AID1061068	Inhibition of Leishmania donovani chagasi recombinant beta-carbonic anhydrase preincubated for 15 mins by stopped flow CO2 hydration assay	2014	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1	Sulfonamide inhibition studies of the δ-carbonic anhydrase from the diatom Thalassiosira weissflogii.
AID764719	Inhibition of human cytosolic carbonic anhydrase 1 preincubated for 15 mins by stopped flow CO2 hydration assay	2013	Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17	Carbonic anhydrase inhibitors: Synthesis and inhibition of the cytosolic mammalian carbonic anhydrase isoforms I, II and VII with benzene sulfonamides incorporating 4,5,6,7-tetrachlorophthalimide moiety.
AID1677995	Induction of RBM39 degradation in human VCaP cells assessed as AR splicing modulation by measuring reduction in AR-V7 splice variant mRNA transcript level at 10 uM incubated for 24 hrs in presence of AR antagonist MDV by RT-qPCR analysis relative to DMSO	2020	Bioorganic & medicinal chemistry, 10-15, Volume: 28, Issue:20	The splicing modulator sulfonamide indisulam reduces AR-V7 in prostate cancer cells.
AID349607	Inhibition of Mycobacterium tuberculosis recombinant carbonic anhydrase 1 encoded by Rv1284 by stopped flow CO2 hydration assay	2009	Journal of medicinal chemistry, May-14, Volume: 52, Issue:9	Carbonic anhydrase inhibitors. Cloning, characterization, and inhibition studies of a new beta-carbonic anhydrase from Mycobacterium tuberculosis.
AID1188134	Inhibition of human recombinant Carbonic anhydrase 1 compound preincubated for 15 mins by stopped flow CO2 hydrase assay method	2014	Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17	Sulfonamide inhibition study of the carbonic anhydrases from the bacterial pathogen Porphyromonas gingivalis: the β-class (PgiCAb) versus the γ-class (PgiCA) enzymes.
AID1195370	Inhibition of human carbonic anhydrase 2 pre-incubated for 15 mins by stopped-flow CO2 hydration assay	2015	Bioorganic & medicinal chemistry, May-15, Volume: 23, Issue:10	The β-carbonic anhydrase from the malaria mosquito Anopheles gambiae is highly inhibited by sulfonamides.
AID669116	Inhibition of Cryptococcus neoformans Can2 preincubated for 15 mins measured for 10 to 100 sec by stopped-flow method	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Molecular cloning, characterization, and inhibition studies of a β-carbonic anhydrase from Malassezia globosa, a potential antidandruff target.
AID512003	Inhibition of human cloned catalytic domain of CA9 after 15 mins by stopped-flow CO2 hydration assay	2010	European journal of medicinal chemistry, Jun, Volume: 45, Issue:6	Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associated) and XIV with 4-substituted 3-pyridinesulfonamides.
AID512003	Inhibition of human cloned catalytic domain of CA9 after 15 mins by stopped-flow CO2 hydration assay	2010	European journal of medicinal chemistry, Sep, Volume: 45, Issue:9	Carbonic anhydrase inhibitors. Regioselective synthesis of novel 1-substituted 1,4-dihydro-4-oxo-3-pyridinesulfonamides and their inhibition of the human cytosolic isozymes I and II and transmembrane cancer-associated isozymes IX and XII.
AID48295	Inhibition constant evaluated for the inhibition of human CA IX (Carbonic anhydrase IX)	2004	Journal of medicinal chemistry, Apr-22, Volume: 47, Issue:9	Carbonic anhydrase inhibitors. Design of selective, membrane-impermeant inhibitors targeting the human tumor-associated isozyme IX.
AID1628038	Inhibition of recombinant Plasmodium falciparum eta-carbonic anhydrase (181 to 538 residues) expressed in Escherichia coli artic express (DE3) preincubated for 15 mins by stop flow CO2 hydrase assay	2016	Bioorganic & medicinal chemistry letters, 09-01, Volume: 26, Issue:17	Cloning, expression, purification and sulfonamide inhibition profile of the complete domain of the η-carbonic anhydrase from Plasmodium falciparum.
AID711662	Selectivity ratio of Ki for human CA2 to Ki for human CA9	2012	European journal of medicinal chemistry, Oct, Volume: 56	Carbonic anhydrase inhibitors. Regioselective synthesis of novel series 1-substituted 1,4-dihydro-4-oxo-3-pyridinesulfonamides and their inhibition of the human cytosolic isozymes I and II and transmembrane cancer-associated isozymes IX and XII.
AID301578	Inhibition of human recombinant CA 3 assessed as CO2 hydration by stopped flow kinetic assay	2007	Bioorganic & medicinal chemistry, Dec-01, Volume: 15, Issue:23	Carbonic anhydrase inhibitors: cloning, characterization, and inhibition studies of the cytosolic isozyme III with sulfonamides.
AID552127	Inhibition of human recombinant CA1 by stopped-flow CO2 hydration assay	2011	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2	Carbonic anhydrase inhibitors. Inhibition studies with anions and sulfonamides of a new cytosolic enzyme from the scleractinian coral Stylophora pistillata.
AID254241	Inhibitory activity against human cloned Carbonic anhydrase II by the CO2 hydration method	2005	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 15, Issue:21	Carbonic anhydrase inhibitors: inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with benzo[b]thiophene 1,1-dioxide sulfonamides.
AID743515	Inhibition of human recombinant carbonic anhydrase 1 preincubated for 15 mins by CO2 hydration stopped-flow assay	2013	Bioorganic & medicinal chemistry, Mar-15, Volume: 21, Issue:6	The alpha-carbonic anhydrase from the thermophilic bacterium Sulfurihydrogenibium yellowstonense YO3AOP1 is highly susceptible to inhibition by sulfonamides.
AID1142838	Inhibition of Helicobacter pylori carbonic anhydrase by stopped-flow CO2 hydration assay	2014	Bioorganic & medicinal chemistry, Jun-01, Volume: 22, Issue:11	Sulfonamide inhibition studies of two β-carbonic anhydrases from the bacterial pathogen Legionella pneumophila.
AID1154446	Inhibition of human cloned cytosolic carbonic anhydrase 2 preincubated for 15 mins by stopped flow CO2 hydration assay	2014	European journal of medicinal chemistry, Jul-23, Volume: 82	Carbonic anhydrase inhibitors. Synthesis of a novel series of 5-substituted 2,4-dichlorobenzenesulfonamides and their inhibition of human cytosolic isozymes I and II and the transmembrane tumor-associated isozymes IX and XII.
AID1188138	Inhibition of Porphyromonas gingivalis Gamma-carbonic anhydrase compound preincubated for 15 mins by stopped flow CO2 hydrase assay method	2014	Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17	Sulfonamide inhibition study of the carbonic anhydrases from the bacterial pathogen Porphyromonas gingivalis: the β-class (PgiCAb) versus the γ-class (PgiCA) enzymes.
AID238220	Inhibitory constant against human Carbonic anhydrase II	2005	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 15, Issue:12	Carbonic anhydrase inhibitors: novel sulfonamides incorporating 1,3,5-triazine moieties as inhibitors of the cytosolic and tumour-associated carbonic anhydrase isozymes I, II and IX.
AID1268962	Inhibition of recombinant human carbonic anhydrase-1 by stopped flow CO2 hydrase assay	2016	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2	Sulfonamide inhibition studies of the α-carbonic anhydrase from the gammaproteobacterium Thiomicrospira crunogena XCL-2, TcruCA.
AID770585	Inhibition of human cytosolic carbonic anhydrase 2 preincubated for 15 mins at room temperature followed by 72 hrs at 4 degC by stopped flow CO2 hydration assay	2013	Bioorganic & medicinal chemistry, Oct-01, Volume: 21, Issue:19	Carbonic anhydrase inhibitors: synthesis and inhibition of the human carbonic anhydrase isoforms I, II, VII, IX and XII with benzene sulfonamides incorporating 4,5,6,7-tetrabromophthalimide moiety.
AID1194028	Inhibition of recombinant Nostoc commune gamma-carbonic anhydrase preincubated for 15 mins by stopped flow CO2 hydrase assay	2015	Bioorganic & medicinal chemistry, Apr-15, Volume: 23, Issue:8	Sulfonamide inhibition studies of the γ-carbonic anhydrase from the Antarctic cyanobacterium Nostoc commune.
AID1183268	Inhibition of human cloned CA12 catalytic domain pre-incubated with enzyme for 15 mins by phenol red based CO2 hydration stopped-flow assay	2014	European journal of medicinal chemistry, Sep-12, Volume: 84	Synthesis of a new series of N⁴-substituted 4-(2-aminoethyl)benzenesulfonamides and their inhibitory effect on human carbonic anhydrase cytosolic isozymes I and II and transmembrane tumor-associated isozymes IX and XII.
AID414955	Inhibition of human recombinant carbonic anhydrase 1 by stopped flow CO2 hydration method	2009	Journal of medicinal chemistry, Apr-23, Volume: 52, Issue:8	Molecular cloning, characterization, and inhibition studies of the Rv1284 beta-carbonic anhydrase from Mycobacterium tuberculosis with sulfonamides and a sulfamate.
AID1278411	Inhibition of Nostoc commune gamma carbonic anhydrase preincubated for 15 mins by stopped flow CO2 hydration assay	2016	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4	Sulfonamide inhibition studies of the γ-carbonic anhydrase from the Antarctic bacterium Colwellia psychrerythraea.
AID436563	Inhibition of human recombinant CA1 by stopped-flow CO2 assay	2009	Bioorganic & medicinal chemistry, Jul-15, Volume: 17, Issue:14	Carbonic anhydrase inhibitors. Inhibition studies of a coral secretory isoform by sulfonamides.
AID234910	Relative resistance value as the ratio of IC50 for the resistant cell line to that of parental cell line.	2002	Journal of medicinal chemistry, Oct-24, Volume: 45, Issue:22	Array-based structure and gene expression relationship study of antitumor sulfonamides including N-[2-[(4-hydroxyphenyl)amino]-3-pyridinyl]-4-methoxybenzenesulfonamide and N-(3-chloro-7-indolyl)-1,4-benzenedisulfonamide.
AID261582	Selectivity ratio for human carbonic anhydrase 2 over Helicobacter pylori carbonic anhydrase	2006	Journal of medicinal chemistry, Mar-23, Volume: 49, Issue:6	Carbonic anhydrase inhibitors: DNA cloning and inhibition studies of the alpha-carbonic anhydrase from Helicobacter pylori, a new target for developing sulfonamide and sulfamate gastric drugs.
AID293812	Inhibition of human recombinant CA2 by stopped flow CO2 hydrase assay	2007	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 17, Issue:6	Carbonic anhydrase inhibitors: inhibition of cytosolic/tumor-associated isoforms I, II, and IX with iminodiacetic carboxylates/hydroxamates also incorporating benzenesulfonamide moieties.
AID1061066	Inhibition of Thalassiosira weissflogii delta carbonic anhydrase preincubated for 15 mins by stopped flow CO2 hydration assay	2014	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1	Sulfonamide inhibition studies of the δ-carbonic anhydrase from the diatom Thalassiosira weissflogii.
AID214028	Inhibitory activity against tubulin polymerization.	2002	Journal of medicinal chemistry, Oct-24, Volume: 45, Issue:22	Array-based structure and gene expression relationship study of antitumor sulfonamides including N-[2-[(4-hydroxyphenyl)amino]-3-pyridinyl]-4-methoxybenzenesulfonamide and N-(3-chloro-7-indolyl)-1,4-benzenedisulfonamide.
AID1240214	Inhibition of Nostoc commune gamma carbonic anhydrase by CO2 hydration assay	2015	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 25, Issue:17	Sulfonamide inhibition studies of the γ-carbonic anhydrase from the Antarctic bacterium Pseudoalteromonas haloplanktis.
AID238211	Inhibitory constant against human Carbonic anhydrase I	2005	Bioorganic & medicinal chemistry letters, May-02, Volume: 15, Issue:9	Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating thioureido-sulfanilyl scaffolds.
AID711212	Inhibition of recombinant Vibrio cholerae carbonic anhydrase expressed in Escherichia coli (DE3) preincubated for 15 mins by stopped-flow CO2 hydrase assay	2012	Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23	DNA cloning, characterization, and inhibition studies of an α-carbonic anhydrase from the pathogenic bacterium Vibrio cholerae.
AID1275913	Inhibition of human Carbonic anhydrase1 using CO2 as substrate preincubated for 15 mins by stopped-flow CO2 hydration assay	2016	Bioorganic & medicinal chemistry, Mar-01, Volume: 24, Issue:5	Sulfonamide inhibition studies of the β-carbonic anhydrase from the pathogenic bacterium Vibrio cholerae.
AID293811	Inhibition of human recombinant CA1 by stopped flow CO2 hydrase assay	2007	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 17, Issue:6	Carbonic anhydrase inhibitors: inhibition of cytosolic/tumor-associated isoforms I, II, and IX with iminodiacetic carboxylates/hydroxamates also incorporating benzenesulfonamide moieties.
AID271174	Inhibition of human recombinant carbonic anhydrase 9 by stopped-flow CO2 hydrase assay	2006	Journal of medicinal chemistry, Sep-07, Volume: 49, Issue:18	Carbonic anhydrase inhibitors: Hypoxia-activatable sulfonamides incorporating disulfide bonds that target the tumor-associated isoform IX.
AID1678005	Induction of RBM39 degradation in human VCaP cells assessed as reduction in RBM39 protein expression at 10 uM preincubated for 24 hrs with DHT followed by wash-out and incubated with compound for 24 hrs in presence of AR antagonist MDV by western blot ana	2020	Bioorganic & medicinal chemistry, 10-15, Volume: 28, Issue:20	The splicing modulator sulfonamide indisulam reduces AR-V7 in prostate cancer cells.
AID50352	Inhibition constant evaluated for the inhibition of human CA I (Carbonic anhydrase I)	2004	Journal of medicinal chemistry, Apr-22, Volume: 47, Issue:9	Carbonic anhydrase inhibitors. Design of selective, membrane-impermeant inhibitors targeting the human tumor-associated isozyme IX.
AID271175	Selectivity for human recombinant carbonic anhydrase 9 over carbonic anhydrase 2	2006	Journal of medicinal chemistry, Sep-07, Volume: 49, Issue:18	Carbonic anhydrase inhibitors: Hypoxia-activatable sulfonamides incorporating disulfide bonds that target the tumor-associated isoform IX.
AID1204093	Selectivity ratio Ki for recombinant human cytosolic form of carbonic anhydrase-2 to Ki for recombinant human transmembrane, tumor-associated form of carbonic anhydrase-9	2015	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 25, Issue:11	Synthesis of Schiff base derivatives of 4-(2-aminoethyl)-benzenesulfonamide with inhibitory activity against carbonic anhydrase isoforms I, II, IX and XII.
AID1188136	Inhibition of Helicobacter pylori Beta-carbonic anhydrase compound preincubated for 15 mins by stopped flow CO2 hydrase assay method	2014	Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17	Sulfonamide inhibition study of the carbonic anhydrases from the bacterial pathogen Porphyromonas gingivalis: the β-class (PgiCAb) versus the γ-class (PgiCA) enzymes.
AID1188135	Inhibition of human recombinant Carbonic anhydrase 2 compound preincubated for 15 mins by stopped flow CO2 hydrase assay method	2014	Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17	Sulfonamide inhibition study of the carbonic anhydrases from the bacterial pathogen Porphyromonas gingivalis: the β-class (PgiCAb) versus the γ-class (PgiCA) enzymes.
AID271173	Inhibition of human recombinant carbonic anhydrase 2 by stopped-flow CO2 hydrase assay	2006	Journal of medicinal chemistry, Sep-07, Volume: 49, Issue:18	Carbonic anhydrase inhibitors: Hypoxia-activatable sulfonamides incorporating disulfide bonds that target the tumor-associated isoform IX.
AID1142834	Inhibition of human carbonic anhydrase-2 by stopped-flow CO2 hydration assay	2014	Bioorganic & medicinal chemistry, Jun-01, Volume: 22, Issue:11	Sulfonamide inhibition studies of two β-carbonic anhydrases from the bacterial pathogen Legionella pneumophila.
AID369274	Inhibition of human recombinant carbonic anhydrase 9 catalytic domain by stopped flow CO2 hydrase assay	2009	Journal of medicinal chemistry, Feb-12, Volume: 52, Issue:3	Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV.
AID299250	Inhibition of Helicobacter pylori beta carbonic anhydrase by stopped-flow CO2 hydrase assay	2007	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 17, Issue:13	Carbonic anhydrase inhibitors: the beta-carbonic anhydrase from Helicobacter pylori is a new target for sulfonamide and sulfamate inhibitors.
AID271711	Inhibition of human cloned CA2 by CO2 hydration method	2006	Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22	A novel class of carbonic anhydrase inhibitors: glycoconjugate benzene sulfonamides prepared by "click-tailing".
AID281084	Inhibition of catalytic domain of human recombinant isozyme CA9 by CO2 hydration method	2007	Journal of medicinal chemistry, Apr-05, Volume: 50, Issue:7	Carbonic anhydrase inhibitors: inhibition of isozymes I, II, and IX with triazole-linked O-glycosides of benzene sulfonamides.
AID238635	Inhibitory activity against cytosolic human carbonic anhydrase II	2005	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 15, Issue:3	Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with bis-sulfamates.
AID239048	Inhibitory activity against membrane bound tumor associated human carbonic anhydrase IX	2005	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 15, Issue:3	Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with bis-sulfamates.
AID614108	Inhibition of human cloned carbonic anhydrase 12 catalytic domain preincubated for 15 mins by stopped flow CO2 hydration assay	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	Carbonic anhydrase inhibitors. Synthesis, molecular structures, and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associated) and XIV with novel 3-pyridinesulfonamide derivatives.
AID1287517	Inhibition of human carbonic anhydrase 1 incubated for 15 mins by stopped-flow CO2 hydration assay	2016	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 26, Issue:7	Sulfonamide inhibition studies of the β-carbonic anhydrase from the newly discovered bacterium Enterobacter sp. B13.
AID414956	Inhibition of human recombinant carbonic anhydrase 2 by stopped flow CO2 hydration method	2009	Journal of medicinal chemistry, Apr-23, Volume: 52, Issue:8	Molecular cloning, characterization, and inhibition studies of the Rv1284 beta-carbonic anhydrase from Mycobacterium tuberculosis with sulfonamides and a sulfamate.
AID1240215	Inhibition of Pseudoalteromonas haloplanktis gamma carbonic anhydrase by CO2 hydration assay	2015	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 25, Issue:17	Sulfonamide inhibition studies of the γ-carbonic anhydrase from the Antarctic bacterium Pseudoalteromonas haloplanktis.
AID1275565	Selectivity ratio, ratio of Ki for human carbonic anhydrase-1 to Ki for human carbonic anhydrase-2	2016	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4	Pyridazinone substituted benzenesulfonamides as potent carbonic anhydrase inhibitors.
AID371703	Inhibition of Mycobacterium tuberculosis recombinant carbonic anhydrase Rv3273 by by stopped flow CO2 hydration assay	2009	Journal of medicinal chemistry, Jul-09, Volume: 52, Issue:13	Discovery of low nanomolar and subnanomolar inhibitors of the mycobacterial beta-carbonic anhydrases Rv1284 and Rv3273.
AID275807	Inhibition of human recombinant cytosolic isozyme CA I by stopped-flow CO2 hydrase method	2007	Journal of medicinal chemistry, Jan-25, Volume: 50, Issue:2	Carbonic anhydrase inhibitors. DNA cloning, characterization, and inhibition studies of the human secretory isoform VI, a new target for sulfonamide and sulfamate inhibitors.
AID386501	Inhibition of human cloned CA9 catalytic domain by stopped-flow CO2 hydration method	2008	Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7	Carbonic anhydrase inhibitors: inhibition of human cytosolic isozymes I and II and tumor-associated isozymes IX and XII with S-substituted 4-chloro-2-mercapto-5-methyl-benzenesulfonamides.
AID552130	Inhibition of Stylophora pistillata carbonic anhydrase by stopped-flow CO2 hydration assay	2011	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2	Carbonic anhydrase inhibitors. Inhibition studies with anions and sulfonamides of a new cytosolic enzyme from the scleractinian coral Stylophora pistillata.
AID552131	Inhibition of Stylophora pistillata carbonic anhydrase 2 by stopped-flow CO2 hydration assay	2011	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2	Carbonic anhydrase inhibitors. Inhibition studies with anions and sulfonamides of a new cytosolic enzyme from the scleractinian coral Stylophora pistillata.
AID427122	Inhibition of Candida albicans recombinant Nce103 by stopped-flow CO2 hydration assay	2009	Bioorganic & medicinal chemistry, Jul-01, Volume: 17, Issue:13	Carbonic anhydrase inhibitors. Inhibition and homology modeling studies of the fungal beta-carbonic anhydrase from Candida albicans with sulfonamides.
AID408471	Inhibition of human cloned CA9 catalytic domain by stopped flow CO2 hydration assay	2008	Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11	Carbonic anhydrase inhibitors: bioreductive nitro-containing sulfonamides with selectivity for targeting the tumor associated isoforms IX and XII.
AID293813	Inhibition of human recombinant CA9 by stopped flow CO2 hydrase assay	2007	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 17, Issue:6	Carbonic anhydrase inhibitors: inhibition of cytosolic/tumor-associated isoforms I, II, and IX with iminodiacetic carboxylates/hydroxamates also incorporating benzenesulfonamide moieties.
AID512004	Inhibition of human cloned catalytic domain of CA12 after 15 mins by stopped-flow CO2 hydration assay	2010	European journal of medicinal chemistry, Jun, Volume: 45, Issue:6	Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associated) and XIV with 4-substituted 3-pyridinesulfonamides.
AID512004	Inhibition of human cloned catalytic domain of CA12 after 15 mins by stopped-flow CO2 hydration assay	2010	European journal of medicinal chemistry, Sep, Volume: 45, Issue:9	Carbonic anhydrase inhibitors. Regioselective synthesis of novel 1-substituted 1,4-dihydro-4-oxo-3-pyridinesulfonamides and their inhibition of the human cytosolic isozymes I and II and transmembrane cancer-associated isozymes IX and XII.
AID386502	Inhibition of human cloned CA12 catalytic domain by stopped-flow CO2 hydration method	2008	Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7	Carbonic anhydrase inhibitors: inhibition of human cytosolic isozymes I and II and tumor-associated isozymes IX and XII with S-substituted 4-chloro-2-mercapto-5-methyl-benzenesulfonamides.
AID261581	Inhibition of Helicobacter pylori recombinant carbonic anhydrase by stopped-flow CO2 hydrase assay	2006	Journal of medicinal chemistry, Mar-23, Volume: 49, Issue:6	Carbonic anhydrase inhibitors: DNA cloning and inhibition studies of the alpha-carbonic anhydrase from Helicobacter pylori, a new target for developing sulfonamide and sulfamate gastric drugs.
AID612725	Inhibition of human recombinant carbonic anhydrase 1 at pH 7.5 by stopped flow CO2 hydration assay	2011	Bioorganic & medicinal chemistry, Aug-15, Volume: 19, Issue:16	Inhibition studies of the β-carbonic anhydrases from the bacterial pathogen Salmonella enterica serovar Typhimurium with sulfonamides and sulfamates.
AID1677999	Reduction in total AR isoforms in tumor lysates of NSG mouse xenografted with human VCaP cells at 10 mg/kg, po co-administered with 25 mg/kg AR antagonist MDV via gavage with 5 days on and 2 days off dosing schedule for 6 weeks by immunoblot analysis	2020	Bioorganic & medicinal chemistry, 10-15, Volume: 28, Issue:20	The splicing modulator sulfonamide indisulam reduces AR-V7 in prostate cancer cells.
AID369272	Inhibition of human recombinant carbonic anhydrase 2 by stopped flow CO2 hydrase assay	2009	Journal of medicinal chemistry, Feb-12, Volume: 52, Issue:3	Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV.
AID1275564	Inhibition of human carbonic anhydrase-2 using p-nitrophenyl acetate as substrate by esterase assay	2016	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4	Pyridazinone substituted benzenesulfonamides as potent carbonic anhydrase inhibitors.
AID1061170	Inhibition of Porphyromonas gingivalis gamma-carbonic anhydrase expressed in Escherichia coli preincubated for 15 mins by stopped flow CO2 hydration assay	2014	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1	Sulfonamide inhibition studies of the γ-carbonic anhydrase from the oral pathogen Porphyromonas gingivalis.
AID271713	Selectivity for human CA9 over CA1	2006	Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22	A novel class of carbonic anhydrase inhibitors: glycoconjugate benzene sulfonamides prepared by "click-tailing".
AID669117	Inhibition of Candida albicans CaNce103 preincubated for 15 mins measured for 10 to 100 sec by stopped-flow method	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Molecular cloning, characterization, and inhibition studies of a β-carbonic anhydrase from Malassezia globosa, a potential antidandruff target.
AID1678001	Induction of RBM39 degradation in human VCaP cells assessed as AR splicing modulation by measuring reduction in AR-V7 splice variant mRNA transcript level at 3 uM incubated for 24 hrs in presence of AR antagonist MDV by RT-qPCR analysis relative to DMSO c	2020	Bioorganic & medicinal chemistry, 10-15, Volume: 28, Issue:20	The splicing modulator sulfonamide indisulam reduces AR-V7 in prostate cancer cells.
AID371706	Inhibition of human recombinant CA2 by stopped flow CO2 hydration assay	2009	Journal of medicinal chemistry, Jul-09, Volume: 52, Issue:13	Discovery of low nanomolar and subnanomolar inhibitors of the mycobacterial beta-carbonic anhydrases Rv1284 and Rv3273.
AID1268965	Inhibition of recombinant Thiomicrospira crunogena XCL-2 carbonic anhydrase by stopped flow CO2 hydrase assay	2016	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2	Sulfonamide inhibition studies of the α-carbonic anhydrase from the gammaproteobacterium Thiomicrospira crunogena XCL-2, TcruCA.
AID1434428	Inhibition of human carbonic anhydrase 2 assessed as reduction in CO2 hydration preincubated for 15 mins followed by CO2 addition measured for 10 to 100 sec by Line-Weaver Burk plot analysis
AID437750	Inhibition of full length Mycobacterium tuberculosis H37Rv recombinant carbonic anhydrase 2 encoded by RV3588c by stopped flow CO2 hydration assay	2009	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 19, Issue:23	Carbonic anhydrase inhibitors. Characterization and inhibition studies of the most active beta-carbonic anhydrase from Mycobacterium tuberculosis, Rv3588c.
AID238770	Inhibitory activity against human carbonic anhydrase I expressed in Escherichia coli BL21	2004	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 14, Issue:21	Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating 1,2,4-triazine moieties.
AID271038	Inhibition of human cloned CA2 by CO2 hydration assay	2006	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 16, Issue:18	Carbonic anhydrase inhibitors. Inhibition of the cytosolic human isozymes I and II, and the transmembrane, tumor-associated isozymes IX and XII with substituted aromatic sulfonamides activatable in hypoxic tumors.
AID1142836	Inhibition of Legionella pneumophilia subsp. Pneumophila strain Philadelphia-1 carbonic anhydrase-1 assessed as CO2 hydrase activity by stopped-flow assay	2014	Bioorganic & medicinal chemistry, Jun-01, Volume: 22, Issue:11	Sulfonamide inhibition studies of two β-carbonic anhydrases from the bacterial pathogen Legionella pneumophila.
AID271712	Inhibition of human cloned CA9 catalytic domain by CO2 hydration method	2006	Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22	A novel class of carbonic anhydrase inhibitors: glycoconjugate benzene sulfonamides prepared by "click-tailing".
AID254246	Inhibitory activity against catalytic domain of human cloned Carbonic anhydrase IX by the CO2 hydration method	2005	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 15, Issue:21	Carbonic anhydrase inhibitors: inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with benzo[b]thiophene 1,1-dioxide sulfonamides.
AID50377	Inhibitory activity against human carbonic anhydrase I	2004	Bioorganic & medicinal chemistry letters, Feb-23, Volume: 14, Issue:4	Carbonic anhydrase inhibitors: the first selective, membrane-impermeant inhibitors targeting the tumor-associated isozyme IX.
AID459696	Inhibition of Brucella suis CA1 expressed in Escherichia coli BL21(DE3) by stopped-flow CO2-hydration assay	2010	Journal of medicinal chemistry, Mar-11, Volume: 53, Issue:5	Cloning, characterization, and inhibition studies of a beta-carbonic anhydrase from Brucella suis.
AID725955	Inhibition of human recombinant carbonic anhydrase 1 by stopped flow CO2 hydration assay	2013	Journal of medicinal chemistry, Feb-28, Volume: 56, Issue:4	Cloning, characterization, and sulfonamide and thiol inhibition studies of an α-carbonic anhydrase from Trypanosoma cruzi, the causative agent of Chagas disease.
AID486933	Inhibition of human cloned carbonic anhydrase 2 preincubated for 15 mins by stopped flow CO2 hydration assay	2010	European journal of medicinal chemistry, Jun, Volume: 45, Issue:6	Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associated) and XIV with 4-substituted 3-pyridinesulfonamides.
AID486933	Inhibition of human cloned carbonic anhydrase 2 preincubated for 15 mins by stopped flow CO2 hydration assay	2010	European journal of medicinal chemistry, Sep, Volume: 45, Issue:9	Carbonic anhydrase inhibitors. Regioselective synthesis of novel 1-substituted 1,4-dihydro-4-oxo-3-pyridinesulfonamides and their inhibition of the human cytosolic isozymes I and II and transmembrane cancer-associated isozymes IX and XII.
AID1677986	Reduction in total AR isoforms in tumor lysates of NSG mouse xenografted with human VCaP cells at 10 mg/kg, po administered via gavage with 5 days on and 2 days off dosing schedule for 6 weeks by immunoblot analysis	2020	Bioorganic & medicinal chemistry, 10-15, Volume: 28, Issue:20	The splicing modulator sulfonamide indisulam reduces AR-V7 in prostate cancer cells.
AID275808	Inhibition of human recombinant cytosolic isozyme CA II by stopped-flow CO2 hydrase method	2007	Journal of medicinal chemistry, Jan-25, Volume: 50, Issue:2	Carbonic anhydrase inhibitors. DNA cloning, characterization, and inhibition studies of the human secretory isoform VI, a new target for sulfonamide and sulfamate inhibitors.
AID1240216	Inhibition of Methanosarcina thermophila recombinant gamma carbonic anhydrase by stopped flow CO2 hydrase assay method	2015	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 25, Issue:17	Sulfonamide inhibition studies of the γ-carbonic anhydrase from the Antarctic bacterium Pseudoalteromonas haloplanktis.
AID1067226	Selectivity ratio of Ki for human transmembrane carbonic anhydrase 2 to Ki for human cytosolic carbonic anhydrase 9	2014	Bioorganic & medicinal chemistry, Mar-01, Volume: 22, Issue:5	Carbonic anhydrase inhibitors: synthesis and inhibition of the human carbonic anhydrase isoforms I, II, IX and XII with benzene sulfonamides incorporating 4- and 3-nitrophthalimide moieties.
AID1194027	Inhibition of recombinant Porphyromonas gingivalis gamma-carbonic anhydrase by stopped flow CO2 hydrase assay	2015	Bioorganic & medicinal chemistry, Apr-15, Volume: 23, Issue:8	Sulfonamide inhibition studies of the γ-carbonic anhydrase from the Antarctic cyanobacterium Nostoc commune.
AID263638	Inhibition of Helicobacter pylori recombinant CA	2006	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 16, Issue:8	Carbonic anhydrase inhibitors: cloning and sulfonamide inhibition studies of a carboxyterminal truncated alpha-carbonic anhydrase from Helicobacter pylori.
AID48302	Inhibitory activity against human carbonic anhydrase IX	2004	Bioorganic & medicinal chemistry letters, Feb-23, Volume: 14, Issue:4	Carbonic anhydrase inhibitors: the first selective, membrane-impermeant inhibitors targeting the tumor-associated isozyme IX.
AID238438	Inhibition constant against human carbonic anhydrase IX	2005	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 15, Issue:12	Carbonic anhydrase inhibitors. Inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, IX, and XII with Schiff's bases incorporating chromone and aromatic sulfonamide moieties, and their zinc complexes.
AID238774	Binding affinity towards human cloned carbonic anhydrase IX	2004	Bioorganic & medicinal chemistry letters, Dec-06, Volume: 14, Issue:23	Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides derived from 4-isothiocyanato-benzolamide.
AID1453412	Inhibition of human carbonic anhydrase-1 assessed as reduction in CO2 hydration preincubated for 15 mins followed by CO2 addition measured for 10 to 100 secs by stopped-flow assay
AID770584	Inhibition of human cytosolic carbonic anhydrase 7 preincubated for 15 mins at room temperature followed by 72 hrs at 4 degC by stopped flow CO2 hydration assay	2013	Bioorganic & medicinal chemistry, Oct-01, Volume: 21, Issue:19	Carbonic anhydrase inhibitors: synthesis and inhibition of the human carbonic anhydrase isoforms I, II, VII, IX and XII with benzene sulfonamides incorporating 4,5,6,7-tetrabromophthalimide moiety.
AID271714	Selectivity for human CA9 over CA2	2006	Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22	A novel class of carbonic anhydrase inhibitors: glycoconjugate benzene sulfonamides prepared by "click-tailing".
AID614109	Inhibition of human cloned full length carbonic anhydrase 14 preincubated for 15 mins by stopped flow CO2 hydration assay	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	Carbonic anhydrase inhibitors. Synthesis, molecular structures, and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associated) and XIV with novel 3-pyridinesulfonamide derivatives.
AID778725	Inhibition of recombinant Leishmania donovani chagasi beta-carbonic anhydrase expressed in baculovirus infected insect Sf9 cells incubated for 15 mins prior to testing by stopped flow CO2 hydrase assay	2013	Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18	Cloning, characterization, and inhibition studies of a β-carbonic anhydrase from Leishmania donovani chagasi, the protozoan parasite responsible for leishmaniasis.
AID614106	Inhibition of human cloned carbonic anhydrase 2 preincubated for 15 mins by stopped flow CO2 hydration assay	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	Carbonic anhydrase inhibitors. Synthesis, molecular structures, and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associated) and XIV with novel 3-pyridinesulfonamide derivatives.
AID47940	Inhibitory activity against human carbonic anhydrase II	2004	Bioorganic & medicinal chemistry letters, May-03, Volume: 14, Issue:9	Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozyme IX with fluorine-containing sulfonamides. The first subnanomolar CA IX inhibitor discovered.
AID1434427	Inhibition of recombinant human carbonic anhydrase 1 assessed as reduction in CO2 hydration preincubated for 15 mins followed by CO2 addition measured for 10 to 100 sec by Line-Weaver Burk plot analysis
AID256963	Inhibitory activity against human recombinant cytosolic CA2	2005	Journal of medicinal chemistry, Dec-01, Volume: 48, Issue:24	Carbonic anhydrase inhibitors. The mitochondrial isozyme VB as a new target for sulfonamide and sulfamate inhibitors.
AID48112	Inhibitory activity of compound against bovine carbonic anhydrase IV	2004	Bioorganic & medicinal chemistry letters, Jan-19, Volume: 14, Issue:2	Carbonic anhydrase inhibitors: X-ray crystallographic structure of the adduct of human isozyme II with the antipsychotic drug sulpiride.
AID1067227	Inhibition of human transmembrane carbonic anhydrase 12 by stopped-flow CO2 hydration assay	2014	Bioorganic & medicinal chemistry, Mar-01, Volume: 22, Issue:5	Carbonic anhydrase inhibitors: synthesis and inhibition of the human carbonic anhydrase isoforms I, II, IX and XII with benzene sulfonamides incorporating 4- and 3-nitrophthalimide moieties.
AID1262263	Inhibition of human CA1 incubated for 15 mins prior to testing by stopped flow CO2 hydrase assay	2015	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 25, Issue:23	Anion and sulfonamide inhibition studies of an α-carbonic anhydrase from the Antarctic hemoglobinless fish Chionodraco hamatus.
AID81720	Effective concentration to inhibit cell proliferation by 50% relative to untreated control cell after 72 hr of continuous exposure in HCT116-C9 cell line	2002	Journal of medicinal chemistry, Oct-24, Volume: 45, Issue:22	Array-based structure and gene expression relationship study of antitumor sulfonamides including N-[2-[(4-hydroxyphenyl)amino]-3-pyridinyl]-4-methoxybenzenesulfonamide and N-(3-chloro-7-indolyl)-1,4-benzenedisulfonamide.
AID436564	Inhibition of human recombinant CA2 by stopped-flow CO2 assay	2009	Bioorganic & medicinal chemistry, Jul-15, Volume: 17, Issue:14	Carbonic anhydrase inhibitors. Inhibition studies of a coral secretory isoform by sulfonamides.
AID669119	Inhibition of GST-tagged Malassezia globosa ATCC 96807/CBS 7966 MG-CA expressed in Escherichia coli BL21(DE3) cells preincubated for 15 mins measured for 10 to 100 sec by stopped-flow method	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Molecular cloning, characterization, and inhibition studies of a β-carbonic anhydrase from Malassezia globosa, a potential antidandruff target.
AID371705	Inhibition of human recombinant CA1 by stopped flow CO2 hydration assay	2009	Journal of medicinal chemistry, Jul-09, Volume: 52, Issue:13	Discovery of low nanomolar and subnanomolar inhibitors of the mycobacterial beta-carbonic anhydrases Rv1284 and Rv3273.
AID427125	Inhibition of human recombinant carbonic anhydrase 1 by stopped-flow CO2 hydrase method	2009	Bioorganic & medicinal chemistry, Jul-01, Volume: 17, Issue:13	Carbonic anhydrase inhibitors. Inhibition and homology modeling studies of the fungal beta-carbonic anhydrase from Candida albicans with sulfonamides.
AID256964	Inhibitory activity against human recombinant mitochondrial isozyme CA VA	2005	Journal of medicinal chemistry, Dec-01, Volume: 48, Issue:24	Carbonic anhydrase inhibitors. The mitochondrial isozyme VB as a new target for sulfonamide and sulfamate inhibitors.
AID743512	Inhibition of Sulfurihydrogenibium yellowstonense YO3AOP1 recombinant carbonic anhydrase preincubated for 15 mins by CO2 hydration stopped-flow assay	2013	Bioorganic & medicinal chemistry, Mar-15, Volume: 21, Issue:6	The alpha-carbonic anhydrase from the thermophilic bacterium Sulfurihydrogenibium yellowstonense YO3AOP1 is highly susceptible to inhibition by sulfonamides.
AID238768	Inhibitory activity against Carbonic anhydrase II	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/membrane-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating hydrazino moieties.
AID50344	Inhibitory activity of compound against human carbonic anhydrase I	2004	Bioorganic & medicinal chemistry letters, Jan-19, Volume: 14, Issue:2	Carbonic anhydrase inhibitors: X-ray crystallographic structure of the adduct of human isozyme II with the antipsychotic drug sulpiride.
AID1628037	Inhibition of human cytosolic carbonic anhydrase 2 preincubated for 15 mins by stop flow CO2 hydrase assay	2016	Bioorganic & medicinal chemistry letters, 09-01, Volume: 26, Issue:17	Cloning, expression, purification and sulfonamide inhibition profile of the complete domain of the η-carbonic anhydrase from Plasmodium falciparum.
AID1154448	Inhibition of human cloned transmembrane tumor-associated catalytic domain of carbonic anhydrase 12 preincubated for 15 mins by stopped flow CO2 hydration assay	2014	European journal of medicinal chemistry, Jul-23, Volume: 82	Carbonic anhydrase inhibitors. Synthesis of a novel series of 5-substituted 2,4-dichlorobenzenesulfonamides and their inhibition of human cytosolic isozymes I and II and the transmembrane tumor-associated isozymes IX and XII.
AID1183266	Inhibition of human cloned CA2 pre-incubated with enzyme for 15 mins by phenol red based CO2 hydration stopped-flow assay	2014	European journal of medicinal chemistry, Sep-12, Volume: 84	Synthesis of a new series of N⁴-substituted 4-(2-aminoethyl)benzenesulfonamides and their inhibitory effect on human carbonic anhydrase cytosolic isozymes I and II and transmembrane tumor-associated isozymes IX and XII.
AID1278413	Inhibition of recombinant Colwellia psychrerythraea gamma carbonic anhydrase preincubated for 15 mins by stopped flow CO2 hydration assay	2016	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4	Sulfonamide inhibition studies of the γ-carbonic anhydrase from the Antarctic bacterium Colwellia psychrerythraea.
AID1268964	Inhibition of recombinant Sulfurihydrogenibium yellowstonense YO3AOP1 carbonic anhydrase by stopped flow CO2 hydrase assay	2016	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2	Sulfonamide inhibition studies of the α-carbonic anhydrase from the gammaproteobacterium Thiomicrospira crunogena XCL-2, TcruCA.
AID1678004	Induction of RBM39 degradation in human VCaP cells assessed as reduction in RBM39 protein expression preincubated for 24 hrs with DHT followed by wash-out and incubated with compound for 24 hrs in presence of AR antagonist MDV by western blot analysis	2020	Bioorganic & medicinal chemistry, 10-15, Volume: 28, Issue:20	The splicing modulator sulfonamide indisulam reduces AR-V7 in prostate cancer cells.
AID349605	Inhibition of human recombinant carbonic anhydrase 1 by stopped flow CO2 hydration assay	2009	Journal of medicinal chemistry, May-14, Volume: 52, Issue:9	Carbonic anhydrase inhibitors. Cloning, characterization, and inhibition studies of a new beta-carbonic anhydrase from Mycobacterium tuberculosis.
AID408470	Inhibition of human recombinant CA2 by stopped flow CO2 hydration assay	2008	Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11	Carbonic anhydrase inhibitors: bioreductive nitro-containing sulfonamides with selectivity for targeting the tumor associated isoforms IX and XII.
AID1291363	Inhibition of recombinant Vibrio cholerae gamma-carbonic anhydrase preincubated for 15 mins by stopped-flow CO2 hydration assay	2016	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 26, Issue:8	Comparison of the sulfonamide inhibition profiles of the α-, β- and γ-carbonic anhydrases from the pathogenic bacterium Vibrio cholerae.
AID238208	Inhibitory constant against human Carbonic anhydrase I	2005	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 15, Issue:12	Carbonic anhydrase inhibitors: novel sulfonamides incorporating 1,3,5-triazine moieties as inhibitors of the cytosolic and tumour-associated carbonic anhydrase isozymes I, II and IX.
AID271037	Inhibition of human cloned CA1 by CO2 hydration assay	2006	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 16, Issue:18	Carbonic anhydrase inhibitors. Inhibition of the cytosolic human isozymes I and II, and the transmembrane, tumor-associated isozymes IX and XII with substituted aromatic sulfonamides activatable in hypoxic tumors.
AID1287518	Inhibition of human carbonic anhydrase 2 incubated for 15 mins by stopped-flow CO2 hydration assay	2016	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 26, Issue:7	Sulfonamide inhibition studies of the β-carbonic anhydrase from the newly discovered bacterium Enterobacter sp. B13.
AID744415	Inhibition of recombinant full length Candida glabrata NCE103 expressed in Escherichia coli BL21 preincubated for 15 mins by stopped-flow CO2 hydrase assay	2013	Bioorganic & medicinal chemistry letters, May-01, Volume: 23, Issue:9	Carbonic anhydrase inhibitors: inhibition of the β-class enzyme from the pathogenic yeast Candida glabrata with sulfonamides, sulfamates and sulfamides.
AID152704	Effective concentration to inhibit cell proliferation by 50% relative to untreated control cell after 72 hr of continuous exposure in P388 cell line	2002	Journal of medicinal chemistry, Oct-24, Volume: 45, Issue:22	Array-based structure and gene expression relationship study of antitumor sulfonamides including N-[2-[(4-hydroxyphenyl)amino]-3-pyridinyl]-4-methoxybenzenesulfonamide and N-(3-chloro-7-indolyl)-1,4-benzenedisulfonamide.
AID1067230	Inhibition of human cytosolic carbonic anhydrase 1 by stopped-flow CO2 hydration assay	2014	Bioorganic & medicinal chemistry, Mar-01, Volume: 22, Issue:5	Carbonic anhydrase inhibitors: synthesis and inhibition of the human carbonic anhydrase isoforms I, II, IX and XII with benzene sulfonamides incorporating 4- and 3-nitrophthalimide moieties.
AID1677984	Reduction in AR-V7 level in tumor lysates of NSG mouse xenografted with human VCaP cells at 10 mg/kg, po co-administered with 25 mg/kg AR antagonist MDV via gavage with 5 days on and 2 days off dosing schedule for 6 weeks by immunoblot analysis	2020	Bioorganic & medicinal chemistry, 10-15, Volume: 28, Issue:20	The splicing modulator sulfonamide indisulam reduces AR-V7 in prostate cancer cells.
AID386499	Inhibition of human cloned CA2 by stopped-flow CO2 hydration method	2008	Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7	Carbonic anhydrase inhibitors: inhibition of human cytosolic isozymes I and II and tumor-associated isozymes IX and XII with S-substituted 4-chloro-2-mercapto-5-methyl-benzenesulfonamides.
AID47900	Inhibition constant evaluated for the inhibition of human CA II (Carbonic anhydrase II)	2004	Journal of medicinal chemistry, Apr-22, Volume: 47, Issue:9	Carbonic anhydrase inhibitors. Design of selective, membrane-impermeant inhibitors targeting the human tumor-associated isozyme IX.
AID1204092	Selectivity ratio Ki for recombinant human cytosolic form of carbonic anhydrase-1 to Ki for recombinant human transmembrane, tumor-associated form of carbonic anhydrase-9	2015	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 25, Issue:11	Synthesis of Schiff base derivatives of 4-(2-aminoethyl)-benzenesulfonamide with inhibitory activity against carbonic anhydrase isoforms I, II, IX and XII.
AID369275	Inhibition of mouse recombinant carbonic anhydrase 15 by stopped flow CO2 hydrase assay	2009	Journal of medicinal chemistry, Feb-12, Volume: 52, Issue:3	Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV.
AID1204094	Selectivity ratio Ki for recombinant human cytosolic form of carbonic anhydrase-1 to Ki for recombinant human transmembrane, tumor-associated form of carbonic anhydrase-12	2015	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 25, Issue:11	Synthesis of Schiff base derivatives of 4-(2-aminoethyl)-benzenesulfonamide with inhibitory activity against carbonic anhydrase isoforms I, II, IX and XII.
AID256965	Inhibitory activity against human recombinant mitochondrial isozyme CA VB	2005	Journal of medicinal chemistry, Dec-01, Volume: 48, Issue:24	Carbonic anhydrase inhibitors. The mitochondrial isozyme VB as a new target for sulfonamide and sulfamate inhibitors.
AID371704	Inhibition of Mycobacterium tuberculosis recombinant carbonic anhydrase Rv1284 by by stopped flow CO2 hydration assay	2009	Journal of medicinal chemistry, Jul-09, Volume: 52, Issue:13	Discovery of low nanomolar and subnanomolar inhibitors of the mycobacterial beta-carbonic anhydrases Rv1284 and Rv3273.
AID233702	Selectivity ratio, inhibition (Ki) of human carbonic anhydrase IX compared to human carbonic anhydrase II	2004	Bioorganic & medicinal chemistry letters, May-03, Volume: 14, Issue:9	Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozyme IX with fluorine-containing sulfonamides. The first subnanomolar CA IX inhibitor discovered.
AID1240217	Inhibition of human recombinant carbonic anhydrase-2 by stopped flow CO2 hydrase assay method	2015	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 25, Issue:17	Sulfonamide inhibition studies of the γ-carbonic anhydrase from the Antarctic bacterium Pseudoalteromonas haloplanktis.
AID1287519	Inhibition of Vibrio cholerae beta carbonic anhydrase incubated for 15 mins by stopped-flow CO2 hydration assay	2016	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 26, Issue:7	Sulfonamide inhibition studies of the β-carbonic anhydrase from the newly discovered bacterium Enterobacter sp. B13.
AID577531	Inhibition of Brucella suis carbonic anhydrase I by spectrophotometry at pH 8.3	2011	Bioorganic & medicinal chemistry, Feb-01, Volume: 19, Issue:3	A new β-carbonic anhydrase from Brucella suis, its cloning, characterization, and inhibition with sulfonamides and sulfamates, leading to impaired pathogen growth.
AID577527	Inhibition of human carbonic anhydrase II by spectrophotometry at pH 7.5	2011	Bioorganic & medicinal chemistry, Feb-01, Volume: 19, Issue:3	A new β-carbonic anhydrase from Brucella suis, its cloning, characterization, and inhibition with sulfonamides and sulfamates, leading to impaired pathogen growth.
AID238224	Inhibitory constant against human Carbonic anhydrase IX	2005	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 15, Issue:12	Carbonic anhydrase inhibitors: novel sulfonamides incorporating 1,3,5-triazine moieties as inhibitors of the cytosolic and tumour-associated carbonic anhydrase isozymes I, II and IX.
AID1453410	Inhibition of Francisella tularensis beta-carbonic anhydrase assessed as reduction in CO2 hydration preincubated for 15 mins followed by CO2 addition measured for 10 to 100 secs by stopped-flow assay
AID1194025	Inhibition of human recombinant carbonic anhydrase 2 by stopped flow CO2 hydrase assay	2015	Bioorganic & medicinal chemistry, Apr-15, Volume: 23, Issue:8	Sulfonamide inhibition studies of the γ-carbonic anhydrase from the Antarctic cyanobacterium Nostoc commune.
AID369271	Inhibition of human recombinant carbonic anhydrase 1 by stopped flow CO2 hydrase assay	2009	Journal of medicinal chemistry, Feb-12, Volume: 52, Issue:3	Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV.
AID1190065	Inhibition of Plasmodium falciparum Eta-carbonic anhydrase pre-incubated for 15 mins before CO2 substrate addition by stopped-flow CO2 hydration assay	2015	Bioorganic & medicinal chemistry, Feb-01, Volume: 23, Issue:3	Sulfonamide inhibition studies of the η-class carbonic anhydrase from the malaria pathogen Plasmodium falciparum.
AID238227	Inhibitory constant against human Carbonic anhydrase IX	2005	Bioorganic & medicinal chemistry letters, May-02, Volume: 15, Issue:9	Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating thioureido-sulfanilyl scaffolds.
AID427124	Inhibition of Helicobacter pylori beta-carbonic anhydrase by stopped-flow CO2 hydration assay	2009	Bioorganic & medicinal chemistry, Jul-01, Volume: 17, Issue:13	Carbonic anhydrase inhibitors. Inhibition and homology modeling studies of the fungal beta-carbonic anhydrase from Candida albicans with sulfonamides.
AID764718	Inhibition of human cytosolic carbonic anhydrase 2 preincubated for 15 mins by stopped flow CO2 hydration assay	2013	Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17	Carbonic anhydrase inhibitors: Synthesis and inhibition of the cytosolic mammalian carbonic anhydrase isoforms I, II and VII with benzene sulfonamides incorporating 4,5,6,7-tetrachlorophthalimide moiety.
AID1190063	Inhibition of human recombinant carbonic anhydrase 1 by stopped-flow CO2 hydration assay	2015	Bioorganic & medicinal chemistry, Feb-01, Volume: 23, Issue:3	Sulfonamide inhibition studies of the η-class carbonic anhydrase from the malaria pathogen Plasmodium falciparum.
AID1190064	Inhibition of human recombinant carbonic anhydrase 2 by stopped-flow CO2 hydration assay	2015	Bioorganic & medicinal chemistry, Feb-01, Volume: 23, Issue:3	Sulfonamide inhibition studies of the η-class carbonic anhydrase from the malaria pathogen Plasmodium falciparum.
AID81721	Effective concentration to inhibit cell proliferation by 50% relative to untreated control cell after 72 hr of continuous exposure in HCT116-C9 -C1cell line	2002	Journal of medicinal chemistry, Oct-24, Volume: 45, Issue:22	Array-based structure and gene expression relationship study of antitumor sulfonamides including N-[2-[(4-hydroxyphenyl)amino]-3-pyridinyl]-4-methoxybenzenesulfonamide and N-(3-chloro-7-indolyl)-1,4-benzenedisulfonamide.
AID1677989	Antiproliferative activity against human VCaP cells assessed as reduction in cell viability at 1 to 10 uM after 14 days in presence of AR antagonist MDV by Celltiter-Glo luminescence assay	2020	Bioorganic & medicinal chemistry, 10-15, Volume: 28, Issue:20	The splicing modulator sulfonamide indisulam reduces AR-V7 in prostate cancer cells.
AID369273	Inhibition of human full length recombinant carbonic anhydrase 6 by stopped flow CO2 hydrase assay	2009	Journal of medicinal chemistry, Feb-12, Volume: 52, Issue:3	Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV.
AID484215	Inhibition of human carbonic anhydrase 9	2010	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 20, Issue:12	New hydroxypyrimidinone-containing sulfonamides as carbonic anhydrase inhibitors also acting as MMP inhibitors.
AID271040	Inhibition of human cloned CA12 catalytic domain by CO2 hydration assay	2006	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 16, Issue:18	Carbonic anhydrase inhibitors. Inhibition of the cytosolic human isozymes I and II, and the transmembrane, tumor-associated isozymes IX and XII with substituted aromatic sulfonamides activatable in hypoxic tumors.
AID1262266	Inhibition of weddell seal alphaCA incubated for 15 mins prior to testing by stopped flow CO2 hydrase assay	2015	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 25, Issue:23	Anion and sulfonamide inhibition studies of an α-carbonic anhydrase from the Antarctic hemoglobinless fish Chionodraco hamatus.
AID1062686	Inhibition of human CA2 cytosolic isoform after 15 mins by stopped-flow CO2 hydration assay	2014	European journal of medicinal chemistry, Jan, Volume: 71	Carbonic anhydrase inhibitors. Synthesis, and molecular structure of novel series N-substituted N'-(2-arylmethylthio-4-chloro-5-methylbenzenesulfonyl)guanidines and their inhibition of human cytosolic isozymes I and II and the transmembrane tumor-associat
AID1275563	Inhibition of human carbonic anhydrase-1 using p-nitrophenyl acetate as substrate by esterase assay	2016	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4	Pyridazinone substituted benzenesulfonamides as potent carbonic anhydrase inhibitors.
AID244240	Binding affinity ratio towards human cloned carbonic anhydrase II to that of human cloned carbonic anhydrase IX	2004	Bioorganic & medicinal chemistry letters, Dec-06, Volume: 14, Issue:23	Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides derived from 4-isothiocyanato-benzolamide.
AID1677991	Antagonist activity at AR in human VCaP cells assessed as upregulation of DHT-suppressed AR-V7 mRNA transcript level at 10 uM preincubated for 24 hrs with DHT followed by wash-out and then incubated with compound for 24 hrs by RT-qPCR analysis	2020	Bioorganic & medicinal chemistry, 10-15, Volume: 28, Issue:20	The splicing modulator sulfonamide indisulam reduces AR-V7 in prostate cancer cells.
AID244399	Selectivity ratio of Inhibitory constant against human carbonic anhydrase II to carbonic anhydrase IX	2005	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 15, Issue:12	Carbonic anhydrase inhibitors: novel sulfonamides incorporating 1,3,5-triazine moieties as inhibitors of the cytosolic and tumour-associated carbonic anhydrase isozymes I, II and IX.
AID1195371	Inhibition of Anopheles gambiae carbonic anhydrase pre-incubated for 15 mins by stopped-flow CO2 hydration assay	2015	Bioorganic & medicinal chemistry, May-15, Volume: 23, Issue:10	The β-carbonic anhydrase from the malaria mosquito Anopheles gambiae is highly inhibited by sulfonamides.
AID1677988	Antitumor activity against human VCaP cells xenografted in NSG mouse assessed as tumor volume at 10 mg/kg, po administered via gavage with 5 days on and 2 days off dosing schedule for 6 weeks and measured bi-weekly for 6 weeks	2020	Bioorganic & medicinal chemistry, 10-15, Volume: 28, Issue:20	The splicing modulator sulfonamide indisulam reduces AR-V7 in prostate cancer cells.
AID1453411	Inhibition of Burkholderia pseudomallei beta-carbonic anhydrase assessed as reduction in CO2 hydration preincubated for 15 mins followed by CO2 addition measured for 10 to 100 secs by stopped-flow assay
AID1275912	Inhibition of human Carbonic anhydrase2 using CO2 as substrate preincubated for 15 mins by stopped-flow CO2 hydration assay	2016	Bioorganic & medicinal chemistry, Mar-01, Volume: 24, Issue:5	Sulfonamide inhibition studies of the β-carbonic anhydrase from the pathogenic bacterium Vibrio cholerae.
AID1142837	Inhibition of Legionella pneumophilia subsp. Pneumophila strain Philadelphia-1 carbonic anhydrase-2 assessed as CO2 hydrase activity by stopped-flow assay	2014	Bioorganic & medicinal chemistry, Jun-01, Volume: 22, Issue:11	Sulfonamide inhibition studies of two β-carbonic anhydrases from the bacterial pathogen Legionella pneumophila.
AID644379	Inhibition of GST-tagged astrosclera willeyana Astrosclerin-3 expressed in Escherichia coli after 15 mins preincubation by stopped flow CO2 hydration assay	2012	Bioorganic & medicinal chemistry, Feb-15, Volume: 20, Issue:4	Cloning, characterization and sulfonamide inhibition studies of an α-carbonic anhydrase from the living fossil sponge Astrosclera willeyana.
AID238437	Inhibition constant against human carbonic anhydrase II	2005	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 15, Issue:12	Carbonic anhydrase inhibitors. Inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, IX, and XII with Schiff's bases incorporating chromone and aromatic sulfonamide moieties, and their zinc complexes.
AID331500	Inhibition of human cloned carbonic anhydrase 9 by CO2 hydration stopped-flow assay	2008	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 18, Issue:12	Carbonic anhydrase inhibitors: design of spin-labeled sulfonamides incorporating TEMPO moieties as probes for cytosolic or transmembrane isozymes.
AID770583	Inhibition of human membrane bound carbonic anhydrase 9 preincubated for 15 mins at room temperature followed by 72 hrs at 4 degC by stopped flow CO2 hydration assay	2013	Bioorganic & medicinal chemistry, Oct-01, Volume: 21, Issue:19	Carbonic anhydrase inhibitors: synthesis and inhibition of the human carbonic anhydrase isoforms I, II, VII, IX and XII with benzene sulfonamides incorporating 4,5,6,7-tetrabromophthalimide moiety.
AID367820	Inhibition of human recombinant CA1 by stopped-flow CO2 hydrase assay	2009	Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3	Carbonic anhydrase inhibitors: inhibition of the beta-class enzyme from the yeast Saccharomyces cerevisiae with sulfonamides and sulfamates.
AID271710	Inhibition of human cloned CA1 by CO2 hydration method	2006	Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22	A novel class of carbonic anhydrase inhibitors: glycoconjugate benzene sulfonamides prepared by "click-tailing".
AID552129	Inhibition of human recombinant CA6 by stopped-flow CO2 hydration assay	2011	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2	Carbonic anhydrase inhibitors. Inhibition studies with anions and sulfonamides of a new cytosolic enzyme from the scleractinian coral Stylophora pistillata.
AID770586	Inhibition of human cytosolic carbonic anhydrase 1 preincubated for 15 mins at room temperature followed by 72 hrs at 4 degC by stopped flow CO2 hydration assay	2013	Bioorganic & medicinal chemistry, Oct-01, Volume: 21, Issue:19	Carbonic anhydrase inhibitors: synthesis and inhibition of the human carbonic anhydrase isoforms I, II, VII, IX and XII with benzene sulfonamides incorporating 4,5,6,7-tetrabromophthalimide moiety.
AID299242	Inhibition of human carbonic anhydrase 1 by stopped-flow CO2 hydrase assay	2007	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 17, Issue:13	Carbonic anhydrase inhibitors: the beta-carbonic anhydrase from Helicobacter pylori is a new target for sulfonamide and sulfamate inhibitors.
AID238760	Binding affinity towards human cloned carbonic anhydrase I	2004	Bioorganic & medicinal chemistry letters, Dec-06, Volume: 14, Issue:23	Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides derived from 4-isothiocyanato-benzolamide.
AID1204106	Inhibition of recombinant Streptococcus mutans UA159 beta-carbonic anhydrase expressed in Escherichia coli Arctic cells preincubated for 15 mins by stopped flow CO2 hydrase assay	2015	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 25, Issue:11	Sulfonamide inhibition study of the β-class carbonic anhydrase from the caries producing pathogen Streptococcus mutans.
AID1678000	Recovery of DHT-suppressed full length AR mRNA expression in human VCaP cells at 10 uM preincubated for 24 hrs with DHT followed by wash-out and then incubated with compound for 24 hrs by RT-qPCR analysis	2020	Bioorganic & medicinal chemistry, 10-15, Volume: 28, Issue:20	The splicing modulator sulfonamide indisulam reduces AR-V7 in prostate cancer cells.
AID437749	Inhibition of human recombinant CA2 by stopped-flow hydration assay	2009	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 19, Issue:23	Carbonic anhydrase inhibitors. Characterization and inhibition studies of the most active beta-carbonic anhydrase from Mycobacterium tuberculosis, Rv3588c.
AID1067229	Inhibition of human cytosolic carbonic anhydrase 2 by stopped-flow CO2 hydration assay	2014	Bioorganic & medicinal chemistry, Mar-01, Volume: 22, Issue:5	Carbonic anhydrase inhibitors: synthesis and inhibition of the human carbonic anhydrase isoforms I, II, IX and XII with benzene sulfonamides incorporating 4- and 3-nitrophthalimide moieties.
AID669115	Inhibition of human carbonic anhydrase 2 preincubated for 15 mins measured for 10 to 100 sec by stopped-flow method	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Molecular cloning, characterization, and inhibition studies of a β-carbonic anhydrase from Malassezia globosa, a potential antidandruff target.
AID1677990	Induction of RBM39 degradation in human VCaP cells assessed as AR splicing modulation by measuring reduction in AR-V7 splice variant mRNA transcript level incubated for 24 hrs in presence of AR antagonist MDV by RT-qPCR analysis	2020	Bioorganic & medicinal chemistry, 10-15, Volume: 28, Issue:20	The splicing modulator sulfonamide indisulam reduces AR-V7 in prostate cancer cells.
AID1677997	Reduction in RBM39 level in tumor lysates of NSG mouse xenografted with human VCaP cells at 10 mg/kg, po administered via gavage with 5 days on and 2 days off dosing schedule for 6 weeks by immunoblot analysis	2020	Bioorganic & medicinal chemistry, 10-15, Volume: 28, Issue:20	The splicing modulator sulfonamide indisulam reduces AR-V7 in prostate cancer cells.
AID96007	Antiproliferative activity against KB human nasopharynx carcinoma in vitro	1999	Journal of medicinal chemistry, Sep-23, Volume: 42, Issue:19	Discovery of novel antitumor sulfonamides targeting G1 phase of the cell cycle.
AID1677993	Induction of RBM39 degradation in human VCaP cells assessed as down regulation of MDV-induced recovery of DHT-suppressed AR-V7 splice variant mRNA level at 10 uM preincubated for 24 hrs with DHT followed by wash-out and incubated with compound for 24 hrs	2020	Bioorganic & medicinal chemistry, 10-15, Volume: 28, Issue:20	The splicing modulator sulfonamide indisulam reduces AR-V7 in prostate cancer cells.
AID1188137	Inhibition of Porphyromonas gingivalis Beta-carbonic anhydrase compound preincubated for 15 mins by stopped flow CO2 hydrase assay method	2014	Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17	Sulfonamide inhibition study of the carbonic anhydrases from the bacterial pathogen Porphyromonas gingivalis: the β-class (PgiCAb) versus the γ-class (PgiCA) enzymes.
AID238788	Inhibitory activity against human carbonic anhydrase IX expressed in Escherichia coli BL21	2004	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 14, Issue:21	Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating 1,2,4-triazine moieties.
AID1677994	Effect on full-length AR mRNA level in human VCaP cells at 10 uM after 24 hrs by RT-qPCR analysis	2020	Bioorganic & medicinal chemistry, 10-15, Volume: 28, Issue:20	The splicing modulator sulfonamide indisulam reduces AR-V7 in prostate cancer cells.
AID153385	Effective concentration to inhibit cell proliferation by 50% relative to untreated control cell after 72 hr of continuous exposure in P388/4.0 r-M cell line	2002	Journal of medicinal chemistry, Oct-24, Volume: 45, Issue:22	Array-based structure and gene expression relationship study of antitumor sulfonamides including N-[2-[(4-hydroxyphenyl)amino]-3-pyridinyl]-4-methoxybenzenesulfonamide and N-(3-chloro-7-indolyl)-1,4-benzenedisulfonamide.
AID1346202	Human carbonic anhydrase 7 (4.2.1.1 Carbonate dehydratases)	2013	Bioorganic & medicinal chemistry, Oct-01, Volume: 21, Issue:19	Carbonic anhydrase inhibitors: synthesis and inhibition of the human carbonic anhydrase isoforms I, II, VII, IX and XII with benzene sulfonamides incorporating 4,5,6,7-tetrabromophthalimide moiety.
AID1346210	Human carbonic anhydrase 12 (4.2.1.1 Carbonate dehydratases)	2013	Bioorganic & medicinal chemistry, Oct-01, Volume: 21, Issue:19	Carbonic anhydrase inhibitors: synthesis and inhibition of the human carbonic anhydrase isoforms I, II, VII, IX and XII with benzene sulfonamides incorporating 4,5,6,7-tetrabromophthalimide moiety.
AID1345928	Human carbonic anhydrase 1 (4.2.1.1 Carbonate dehydratases)	2013	Bioorganic & medicinal chemistry, Oct-01, Volume: 21, Issue:19	Carbonic anhydrase inhibitors: synthesis and inhibition of the human carbonic anhydrase isoforms I, II, VII, IX and XII with benzene sulfonamides incorporating 4,5,6,7-tetrabromophthalimide moiety.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	1 (0.67)	18.2507
2000's	78 (52.35)	29.6817
2010's	50 (33.56)	24.3611
2020's	20 (13.42)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	13 (8.72%)	5.53%
Reviews	5 (3.36%)	6.00%
Case Studies	1 (0.67%)	4.05%
Observational	0 (0.00%)	0.25%
Other	130 (87.25%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (10)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
[NCT00165854]	Phase 2	46 participants	Interventional	2003-03-31	Completed
Non-Randomized, Open, Uncontrolled, Dose Comparison Study of E7070 in Patients With Gastric Cancer [NCT00165594]	Phase 1/Phase 2	50 participants	Interventional	2005-02-28	Terminated(stopped due to Study was completed.)
[NCT00165867]	Phase 2	40 participants	Interventional	2005-04-30	Completed
Open Label Phase II Study Of E7070 In Patients With Metastatic Melanoma (Stage IV) [NCT00014625]	Phase 2	28 participants (Actual)	Interventional	2001-02-28	Completed
An Open-Label Phase II Study of E7070 in Metastatic Breast Cancer Patients Previously Treated With an Anthracycline, a Taxane, and Capecitabine [NCT00080197]	Phase 2	250 participants	Interventional	2004-02-29	Completed
An Open-label, Randomized, Phase II Study of the Efficacy and Safety of Indisulam (E7070) in Combination With Capecitabine Versus Capecitabine Monotherapy for the Treatment of Metastatic Breast Cancer Patients Following Prior Anthracycline and Taxane Ther [NCT00165880]	Phase 2	62 participants (Actual)	Interventional	2004-12-31	Terminated(stopped due to This study was stopped prematurely due to lack of efficacy.)
A Phase II Study of E7070 in Patients With Progressive Inoperable and/or Metastatic Renal Cell Carcinoma (RCC) [NCT00059735]	Phase 2	30 participants (Actual)	Interventional	2002-05-31	Completed
Phase I Study to Determine the Safety of E7070 in Patients With a Solid Tumor on a Single IV Infusion Repeated Every 3 Weeks [NCT00003976]	Phase 1	30 participants (Anticipated)	Interventional	1998-03-31	Completed
Phase I Dose-Finding Study of E7070 in Combination With Irinotecan [NCT00060567]	Phase 1	88 participants (Actual)	Interventional	2003-03-31	Completed
Phase I Study to Determine the Safety of E7070 in Patients With a Solid Tumor as a Single IV Infusion Weekly X 4, Repeated Every 6 Weeks [NCT00003981]	Phase 1	30 participants (Anticipated)	Interventional	1998-04-30	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
hydrobromic acid Hydrobromic Acid: Hydrobromic acid (HBr). A solution of hydrogen bromide gas in water.. hydrobromide : Salts formally resulting from the reaction of hydrobromic acid with an organic base.. hydrogen bromide : A diatomic molecule containing covalently bonded hydrogen and bromine atoms.	2.49	2	0	gas molecular entity; hydrogen halide; mononuclear parent hydride	mouse metabolite
hydrochloric acid Hydrochloric Acid: A strong corrosive acid that is commonly used as a laboratory reagent. It is formed by dissolving hydrogen chloride in water. GASTRIC ACID is the hydrochloric acid component of GASTRIC JUICE.. hydrogen chloride : A mononuclear parent hydride consisting of covalently bonded hydrogen and chlorine atoms.	2.49	2	0	chlorine molecular entity; gas molecular entity; hydrogen halide; mononuclear parent hydride	mouse metabolite
hydrogen sulfide Hydrogen Sulfide: A flammable, poisonous gas with a characteristic odor of rotten eggs. It is used in the manufacture of chemicals, in metallurgy, and as an analytical reagent. (From Merck Index, 11th ed). hydrogen sulfide : A sulfur hydride consisting of a single sulfur atom bonded to two hydrogen atoms. A highly poisonous, flammable gas with a characteristic odour of rotten eggs, it is often produced by bacterial decomposition of organic matter in the absence of oxygen.. thiol : An organosulfur compound in which a thiol group, -SH, is attached to a carbon atom of any aliphatic or aromatic moiety.	2.49	2	0	gas molecular entity; hydracid; mononuclear parent hydride; sulfur hydride	Escherichia coli metabolite; genotoxin; metabolite; signalling molecule; toxin; vasodilator agent
cyanic acid [no description available]	2.49	2	0	one-carbon compound; pseudohalogen oxoacid
carbonic acid Carbonic Acid: Carbonic acid (H2C03). The hypothetical acid of carbon dioxide and water. It exists only in the form of its salts (carbonates), acid salts (hydrogen carbonates), amines (carbamic acid), and acid chlorides (carbonyl chloride). (From Grant & Hackh's Chemical Dictionary, 5th ed)	2.49	2	0	carbon oxoacid; chalcocarbonic acid	mouse metabolite
hydrogen cyanide Hydrogen Cyanide: Hydrogen cyanide (HCN); A toxic liquid or colorless gas. It is found in the smoke of various tobacco products and released by combustion of nitrogen-containing organic materials.. hydrogen cyanide : A one-carbon compound consisting of a methine group triple bonded to a nitrogen atom	2.49	2	0	hydracid; one-carbon compound	Escherichia coli metabolite; human metabolite; poison
thiocyanic acid thiocyanic acid : A hydracid that is cyanic acid in which the oxygen is replaced by a sulfur atom.	2.49	2	0	hydracid; one-carbon compound; organosulfur compound	Escherichia coli metabolite
nitrates Nitrates: Inorganic or organic salts and esters of nitric acid. These compounds contain the NO3- radical.	2.11	1	0	monovalent inorganic anion; nitrogen oxoanion; reactive nitrogen species
nitric acid Nitric Acid: Nitric acid (HNO3). A colorless liquid that is used in the manufacture of inorganic and organic nitrates and nitro compounds for fertilizers, dye intermediates, explosives, and many different organic chemicals. Continued exposure to vapor may cause chronic bronchitis; chemical pneumonitis may occur. (From Merck Index, 11th ed). nitric acid : A nitrogen oxoacid of formula HNO3 in which the nitrogen atom is bonded to a hydroxy group and by equivalent bonds to the remaining two oxygen atoms.	2.06	1	0	nitrogen oxoacid	protic solvent; reagent
sulfurous acid [no description available]	2.49	2	0	sulfur oxoacid
sulfuric acid sulfuric acid : A sulfur oxoacid that consists of two oxo and two hydroxy groups joined covalently to a central sulfur atom.	2.49	2	0	sulfur oxoacid	catalyst
uracil 2,4-dihydroxypyrimidine: a urinary biomarker for bipolar disorder	2	1	0	pyrimidine nucleobase; pyrimidone	allergen; Daphnia magna metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; prodrug; Saccharomyces cerevisiae metabolite
acetazolamide Acetazolamide: One of the CARBONIC ANHYDRASE INHIBITORS that is sometimes effective against absence seizures. It is sometimes useful also as an adjunct in the treatment of tonic-clonic, myoclonic, and atonic seizures, particularly in women whose seizures occur or are exacerbated at specific times in the menstrual cycle. However, its usefulness is transient often because of rapid development of tolerance. Its antiepileptic effect may be due to its inhibitory effect on brain carbonic anhydrase, which leads to an increased transneuronal chloride gradient, increased chloride current, and increased inhibition. (From Smith and Reynard, Textbook of Pharmacology, 1991, p337)	5.76	80	0	monocarboxylic acid amide; sulfonamide; thiadiazoles	anticonvulsant; diuretic; EC 4.2.1.1 (carbonic anhydrase) inhibitor
celecoxib [no description available]	5.1	40	0	organofluorine compound; pyrazoles; sulfonamide; toluenes	cyclooxygenase 2 inhibitor; geroprotector; non-narcotic analgesic; non-steroidal anti-inflammatory drug
diazepam Diazepam: A benzodiazepine with anticonvulsant, anxiolytic, sedative, muscle relaxant, and amnesic properties and a long duration of action. Its actions are mediated by enhancement of GAMMA-AMINOBUTYRIC ACID activity.. diazepam : A 1,4-benzodiazepinone that is 1,3-dihydro-2H-1,4-benzodiazepin-2-one substituted by a chloro group at position 7, a methyl group at position 1 and a phenyl group at position 5.	3.41	1	0	1,4-benzodiazepinone; organochlorine compound	anticonvulsant; anxiolytic drug; environmental contaminant; sedative; xenobiotic
dichlorphenamide Dichlorphenamide: A carbonic anhydrase inhibitor that is used in the treatment of glaucoma.. diclofenamide : A sulfonamide that is benzene-1,3-disulfonamide in which the hydrogens at positions 4 and 5 are substituted by chlorine. An oral carbonic anhydrase inhibitor, it partially suppresses the secretion (inflow) of aqueous humor in the eye and so reduces intraocular pressure. It is used for the treatment of glaucoma.	5.64	71	0	dichlorobenzene; sulfonamide	antiglaucoma drug; EC 4.2.1.1 (carbonic anhydrase) inhibitor; ophthalmology drug
ethoxzolamide Ethoxzolamide: A carbonic anhydrase inhibitor used as diuretic and in glaucoma. It may cause hypokalemia.. ethoxzolamide : A sulfonamide that is 1,3-benzothiazole-2-sulfonamide which is substituted by an ethoxy group at position 6. A carbonic anhydrase inhibitor, it has been used in the treatment of glaucoma, and as a diuretic.	5.67	73	0	aromatic ether; benzothiazoles; sulfonamide	antiglaucoma drug; diuretic; EC 4.2.1.1 (carbonic anhydrase) inhibitor
fluorouracil Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.. 5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.	4.16	3	1	nucleobase analogue; organofluorine compound	antimetabolite; antineoplastic agent; environmental contaminant; immunosuppressive agent; radiosensitizing agent; xenobiotic
hydrochlorothiazide Hydrochlorothiazide: A thiazide diuretic often considered the prototypical member of this class. It reduces the reabsorption of electrolytes from the renal tubules. This results in increased excretion of water and electrolytes, including sodium, potassium, chloride, and magnesium. It is used in the treatment of several disorders including edema, hypertension, diabetes insipidus, and hypoparathyroidism.. hydrochlorothiazide : A benzothiadiazine that is 3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide substituted by a chloro group at position 6 and a sulfonamide at 7. It is diuretic used for the treatment of hypertension and congestive heart failure.	4.54	22	0	benzothiadiazine; organochlorine compound; sulfonamide	antihypertensive agent; diuretic; environmental contaminant; xenobiotic
hydroxyurea [no description available]	2.03	1	0	one-carbon compound; ureas	antimetabolite; antimitotic; antineoplastic agent; DNA synthesis inhibitor; EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor; genotoxin; immunomodulator; radical scavenger; teratogenic agent
ketoconazole 1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine : A dioxolane that is 1,3-dioxolane which is substituted at positions 2, 2, and 4 by imidazol-1-ylmethyl, 2,4-dichlorophenyl, and [para-(4-acetylpiperazin-1-yl)phenoxy]methyl groups, respectively.	2.07	1	0	dichlorobenzene; dioxolane; ether; imidazoles; N-acylpiperazine; N-arylpiperazine
mafenide Mafenide: A sulfonamide that inhibits the enzyme CARBONIC ANHYDRASE and is used as a topical anti-bacterial agent, especially in burn therapy.	5.11	41	0	aromatic amine
methazolamide Methazolamide: A carbonic anhydrase inhibitor that is used as a diuretic and in the treatment of glaucoma.	5.72	77	0	sulfonamide; thiadiazoles
saccharin Saccharin: Flavoring agent and non-nutritive sweetener.. saccharin : A 1,2-benzisothiazole having a keto-group at the 3-position and two oxo substituents at the 1-position. It is used as an artificial sweetening agent.	4.75	28	0	1,2-benzisothiazole; N-sulfonylcarboxamide	environmental contaminant; sweetening agent; xenobiotic
imatinib [no description available]	2.03	1	0	aromatic amine; benzamides; N-methylpiperazine; pyridines; pyrimidines	antineoplastic agent; apoptosis inducer; tyrosine kinase inhibitor
sulfanilamide [no description available]	5.11	41	0	substituted aniline; sulfonamide antibiotic; sulfonamide	antibacterial agent; drug allergen; EC 4.2.1.1 (carbonic anhydrase) inhibitor
sulpiride Sulpiride: A dopamine D2-receptor antagonist. It has been used therapeutically as an antidepressant, antipsychotic, and as a digestive aid. (From Merck Index, 11th ed). sulpiride : A member of the class of benzamides obtained from formal condensation between the carboxy group of 2-methoxy-5-sulfamoylbenzoic acid and the primary amino group of (1-ethylpyrrolidin-2-yl)methylamine.	5.24	47	0	benzamides; N-alkylpyrrolidine; sulfonamide	antidepressant; antiemetic; antipsychotic agent; dopaminergic antagonist
sulthiame sulthiame: was heading 1964-94 (see under THIAZINES 1964-90); use THIAZINES to search SULTHIAME 1966-94	4.82	30	0	organic molecular entity
zonisamide Zonisamide: A benzisoxazole and sulfonamide derivative that acts as a CALCIUM CHANNEL blocker. It is used primarily as an adjunctive antiepileptic agent for the treatment of PARTIAL SEIZURES, with or without secondary generalization.. zonisamide : A 1,2-benzoxazole compound having a sulfamoylmethyl substituent at the 3-position.	5.16	43	0	1,2-benzoxazoles; sulfonamide	anticonvulsant; antioxidant; central nervous system drug; protective agent; T-type calcium channel blocker
lysine Lysine: An essential amino acid. It is often added to animal feed.. lysine : A diamino acid that is caproic (hexanoic) acid bearing two amino substituents at positions 2 and 6.. L-lysine : An L-alpha-amino acid; the L-isomer of lysine.	2.21	1	0	aspartate family amino acid; L-alpha-amino acid zwitterion; L-alpha-amino acid; lysine; organic molecular entity; proteinogenic amino acid	algal metabolite; anticonvulsant; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; plant metabolite; Saccharomyces cerevisiae metabolite
sulfamic acid sulfamic acid: standard in alkalimetry; RN given refers to parent cpd; structure. sulfamic acid : The simplest of the sulfamic acids consisting of a single sulfur atom covalently bound by single bonds to hydroxy and amino groups and by double bonds to two oxygen atoms.	2.06	1	0	sulfamic acids
leucine Leucine: An essential branched-chain amino acid important for hemoglobin formation.. leucine : A branched-chain amino acid that consists of glycine in which one of the hydrogens attached to the alpha-carbon is substituted by an isobutyl group.	2	1	0	amino acid zwitterion; L-alpha-amino acid; leucine; proteinogenic amino acid; pyruvate family amino acid	algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; plant metabolite; Saccharomyces cerevisiae metabolite
4-toluenesulfonamide 4-toluenesulfonamide: RN given refers to parent cpd. toluene-4-sulfonamide : A sulfonamide that is benzenesulfonamide bearing a methyl group at position 4.	5.04	38	0	sulfonamide
benzenearsonic acid benzenearsonic acid: RN given refers to parent cpd; structure	2.06	1	0	arsonic acids; organoarsonic acid
benzenesulfonamide [no description available]	2.07	1	0	sulfonamide
pyrroles 1H-pyrrole : A tautomer of pyrrole that has the double bonds at positions 2 and 4.. pyrrole : A five-membered monocyclic heteroarene comprising one NH and four CH units which forms the parent compound of the pyrrole group of compounds. Its five-membered ring structure has three tautomers. A 'closed class'.. azole : Any monocyclic heteroarene consisting of a five-membered ring containing nitrogen. Azoles can also contain one or more other non-carbon atoms, such as nitrogen, sulfur or oxygen.	2.31	1	0	pyrrole; secondary amine
neoprontosil neoprontosil: RN given refers to parent cpd	2.03	1	0
carzenide [no description available]	5.06	39	0	sulfonamide
oxazoles Oxazoles: Five-membered heterocyclic ring structures containing an oxygen in the 1-position and a nitrogen in the 3-position, in distinction from ISOXAZOLES where they are at the 1,2 positions.. 1,3-oxazole : A five-membered monocyclic heteroarene that is an analogue of cyclopentadiene with O in place of CH2 at position 1 and N in place of CH at position 3.. oxazole : An azole based on a five-membered heterocyclic aromatic skeleton containing one N and one O atom.	3.12	1	0	1,3-oxazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
thiazoles [no description available]	3.52	2	0	1,3-thiazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
deoxycytidine [no description available]	3.83	2	1	pyrimidine 2'-deoxyribonucleoside	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
hydrofluoric acid Hydrofluoric Acid: Hydrofluoric acid. A solution of hydrogen fluoride in water. It is a colorless fuming liquid which can cause painful burns.. hydrogen fluoride : A diatomic molecule containing covalently bonded hydrogen and fluorine atoms.. organofluorine compound : An organofluorine compound is a compound containing at least one carbon-fluorine bond.	2.49	2	0	hydrogen halide; mononuclear parent hydride	NMR chemical shift reference compound
benzolamide Benzolamide: Selective renal carbonic anhydrase inhibitor. It may also be of use in certain cases of respiratory failure.	5.13	42	0
perchloric acid [no description available]	2.11	1	0	chlorine oxoacid
camptothecin NSC 100880: carboxylate (opened lactone) form of camptothecin; RN refers to (S)-isomer; structure given in first source	3.86	2	1	delta-lactone; pyranoindolizinoquinoline; quinoline alkaloid; tertiary alcohol	antineoplastic agent; EC 5.99.1.2 (DNA topoisomerase) inhibitor; genotoxin; plant metabolite
nitrous acid Nitrous Acid: Nitrous acid (HNO2). A weak acid that exists only in solution. It can form water-soluble nitrites and stable esters. (From Merck Index, 11th ed)	2.49	2	0	nitrogen oxoacid
hydrazoic acid [no description available]	2.06	1	0	nitrogen hydride
hydroiodic acid hydrogen iodide : A diatomic molecule containing covalently bonded hydrogen and iodine atoms.	2.49	2	0	gas molecular entity; hydrogen halide; mononuclear parent hydride	mouse metabolite
daunorubicin Daunorubicin: A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of LEUKEMIA and other NEOPLASMS.. anthracycline : Anthracyclines are polyketides that have a tetrahydronaphthacenedione ring structure attached by a glycosidic linkage to the amino sugar daunosamine.. daunorubicin : A natural product found in Actinomadura roseola.	3.14	1	0	aminoglycoside antibiotic; anthracycline; p-quinones; tetracenequinones	antineoplastic agent; bacterial metabolite
benzonidazole benzonidazole: used in treatment of Chagas' disease. benznidazole : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of (2-nitroimidazol-1-yl)acetic acid with the aromatic amino group of benzylamine. Used for treatment of Chagas disease.	2.08	1	0	C-nitro compound; imidazoles; monocarboxylic acid amide	antiprotozoal drug
azides Azides: Organic or inorganic compounds that contain the -N3 group.. azide : Any nitrogen molecular entity containing the group -N3.	2.11	1	0	pseudohalide anion	mitochondrial respiratory-chain inhibitor
2-aminosulfonyl-benzoic acid methyl ester 2-aminosulfonyl-benzoic acid methyl ester : A benzoate ester that is methyl benzoate substituted by a sulfamoyl group at position 2. It is a metabolite of the herbicide metsulfuron-methyl.	2.02	1	0	benzoate ester; methyl ester; sulfonamide	marine xenobiotic metabolite
irinotecan [no description available]	2.07	1	0	carbamate ester; delta-lactone; N-acylpiperidine; pyranoindolizinoquinoline; ring assembly; tertiary alcohol; tertiary amino compound	antineoplastic agent; apoptosis inducer; EC 5.99.1.2 (DNA topoisomerase) inhibitor; prodrug
capecitabine Capecitabine: A deoxycytidine derivative and fluorouracil PRODRUG that is used as an ANTINEOPLASTIC ANTIMETABOLITE in the treatment of COLON CANCER; BREAST CANCER and GASTRIC CANCER.. capecitabine : A carbamate ester that is cytidine in which the hydrogen at position 5 is replaced by fluorine and in which the amino group attached to position 4 is converted into its N-(penyloxy)carbonyl derivative. Capecitabine is a antineoplastic agent used in the treatment of cancers.	3.83	2	1	carbamate ester; cytidines; organofluorine compound	antimetabolite; antineoplastic agent; prodrug
thiazolyl blue thiazolyl blue: RN & II refers to bromide. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide : The bromide salt of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium.	2.01	1	0	organic bromide salt	colorimetric reagent; dye
benzeneboronic acid [no description available]	2.49	2	0	boronic acids
4-amino-6-chloro-1,3-benzenedisulfonamide 4-amino-6-chloro-1,3-benzenedisulfonamide: metabolite of hydrochlorothiazide	5.07	39	0	sulfonamide
disulphane [no description available]	4.35	18	0
brinzolamide brinzolamide: an antiglaucoma agent	5.38	54	0	sulfonamide; thienothiazine	antiglaucoma drug; EC 4.2.1.1 (carbonic anhydrase) inhibitor
2,4-disulfamyl-5-trifluoromethylaniline 2,4-disulfamyl-5-trifluoromethylaniline: precursor of hydroflumethiazide	5.04	38	0
4-bromobenzenesulfonamide 4-bromobenzenesulfonamide: a metabolite of ebrotidine	2.07	1	0
7-hydroxystaurosporine [no description available]	3.12	1	0
2-aminobenzenesulfonamide [no description available]	4.58	24	0	benzenes; sulfonamide
sulfamide sulfamide : The simplest of the sulfamic acids consisting of a single sulfur atom covalently bound by single bonds to two amino groups and by double bonds to two oxygen atoms.	2.49	2	0	sulfamides
5-amino-1,3,4-thiadiazole-2-sulfonamide 5-amino-1,3,4-thiadiazole-2-sulfonamide: structure in first source	5.07	39	0
aminozolamide aminozolamide: used in therapy of ocular hypertension	2.08	1	0
6-hydroxyethoxzolamide 6-hydroxyethoxzolamide: structure given in first source	2.08	1	0
hepsulfam hepsulfam: structure given in first source	2.02	1	0
valdecoxib [no description available]	5.07	39	0	isoxazoles; sulfonamide	antipyretic; antirheumatic drug; cyclooxygenase 2 inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug
methotrexate [no description available]	2.49	2	0	dicarboxylic acid; monocarboxylic acid amide; pteridines	abortifacient; antimetabolite; antineoplastic agent; antirheumatic drug; dermatologic drug; DNA synthesis inhibitor; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; immunosuppressive agent
estrone-3-o-sulfamate estrone-3-O-sulfamate: a steroid sulfatase inhibitor	2.42	2	0
cyc 202 seliciclib : 2,6-Diaminopurine carrying benzylamino, (2R)-1-hydroxybutan-2-yl and isopropyl substituents at C-6, C-2-N and N-9 respectively. It is an experimental drug candidate in the family of pharmacological cyclin-dependent kinase (CDK) inhibitors.	3.12	1	0	2,6-diaminopurines	antiviral drug; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
chlorzolamide chlorzolamide: structure	4.4	20	0
4-(2-aminoethyl)benzenesulfonamide [no description available]	5.13	42	0
n-(3-cyano-4-methyl-1h-indol-7-yl)-3-cyanobenzene-sulfonamide [no description available]	2.59	2	0
diflomotecan diflomotecan: a fluorinated E-ring modified camptothecin; structure in first source. diflomotecan : An organic heteropentacyclic compound that is (5R)-8-[(6,7-difluoroquinolin-3-yl)methyl]-5-ethyl-5-hydroxy-1,4,5,8-tetrahydrooxepino[3,4-c]pyridine-3,9-dione in which position 7 of the oxepinopyridine moiety is joined to position 3 of the difluoroquinoine ring by a single bond. An E-ring modified camptothecin analogue that has greater lactone stability in plasma compared with other topoisomerase I inhibitors.	3.45	1	1	epsilon-lactone; organic heteropentacyclic compound; organofluorine compound; organonitrogen heterocyclic compound; tertiary alcohol	antineoplastic agent; EC 5.99.1.2 (DNA topoisomerase) inhibitor
diba-1 DIBA-1: structure given in first source	2.44	2	0
carboplatin [no description available]	3.83	2	1
pd 173955 PD 173955: inhibits src family-selective tyrosine kinase; structure in first source	2.03	1	0	aryl sulfide; dichlorobenzene; methyl sulfide; pyridopyrimidine	tyrosine kinase inhibitor
(R)-(+)-sulpiride (R)-(+)-sulpiride : An optically active form of sulpiride having (R)-configuration. The active enantiomer of the racemic drug sulpiride.	2.02	1	0	sulpiride
1-(4-chlorophenyl)-3-(4-sulfamoylphenyl)urea [no description available]	2.08	1	0	sulfonamide
bms 387032 N-(5-(((5-(1,1-dimethylethyl)-2-oxazolyl)methyl)thio)-2-thiazolyl)-4-piperidinecarboxamide: a CDK2 inhibitor with antineoplastic activity; structure in first source. N-(5-{[(5-tert-butyl-1,3-oxazol-2-yl)methyl]sulfanyl}-1,3-thiazol-2-yl)piperidine-4-carboxamide : A secondary carboxamide resulting from the formal condensation of the carboxy group of piperidine-4-carboxylic acid with the amino group of 5-{[(5-tert-butyl-1,3-oxazol-2-yl)methyl]sulfanyl}-1,3-thiazol-2-amine. It is an ATP-competitive inhibitor of CDK2, CDK7 and CDK9 kinases and exhibits anti-cancer properties.	3.12	1	0	1,3-oxazoles; 1,3-thiazoles; organic sulfide; piperidinecarboxamide; secondary carboxamide	angiogenesis inhibitor; antineoplastic agent; apoptosis inducer; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
e 7010 E 7010: inhibits tubulin polymerization; structure given in first source	2.41	2	0	sulfonamide
2,6-dibromosulfanilamide 2,6-dibromosulfanilamide: structure in first source	3.15	5	0
benzene-1-3-disulfonamide [no description available]	4.25	16	0	sulfonamide
4-azidosulfanilamide [no description available]	2.03	1	0
dorzolamide dorzolamide: topically effective ocular hypotensive carbonic anhydrase inhibitor; RN refers to mono-HCl (4S-trans)-isomer. dorzolamide : 5,6-Dihydro-4H-thieno[2,3-b]thiopyran-2-sulfonamide 7,7-dioxide in which hydrogens at the 4 and 6 positions are substituted by ethylamino and methyl groups, respectively (4S, trans-configuration). A carbonic anhydrase inhibitor, it is used as the hydrochloride in ophthalmic solutions to lower increased intraocular pressure in the treatment of open-angle glaucoma and ocular hypertension.	5.34	52	0	sulfonamide; thiophenes	antiglaucoma drug; antihypertensive agent; EC 4.2.1.1 (carbonic anhydrase) inhibitor
topiramate Topiramate: A sulfamate-substituted fructose analog that was originally identified as a hypoglycemic agent. It is used for the treatment of EPILEPSY and MIGRAINE DISORDERS, and may also promote weight loss.. topiramate : A hexose derivative that is 2,3:4,5-di-O-isopropylidene-beta-D-fructopyranose in which the hydroxy group has been converted to the corresponding sulfamate ester. It blocks voltage-dependent sodium channels and is used as an antiepileptic and for the prevention of migraine.	5.2	45	0	cyclic ketal; ketohexose derivative; sulfamate ester	anticonvulsant; sodium channel blocker
alvocidib alvocidib: structure given in first source. alvocidib : A synthetic dihydroxyflavone that is 5,7-dihydroxyflavone which is substituted by a 3-hydroxy-1-methylpiperidin-4-yl group at position 8 and by a chlorine at the 2' position (the (-)-3S,4R stereoisomer). A cyclin-dependent kinase 9 (CDK9) inhibitor, it has been studied for the treatment of acute myeloid leukaemia, arthritis and atherosclerotic plaque formation.	3.12	1	0	dihydroxyflavone; hydroxypiperidine; monochlorobenzenes; tertiary amino compound	antineoplastic agent; antirheumatic drug; apoptosis inducer; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
palbociclib [no description available]	2.41	1	0	aminopyridine; aromatic ketone; cyclopentanes; piperidines; pyridopyrimidine; secondary amino compound; tertiary amino compound	antineoplastic agent; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
6-hydroxybenzothiazide-2-sulfonamide 6-hydroxybenzothiazide-2-sulfonamide: structure given in first source	4	13	0
staurosporine staurosporinium : Conjugate acid of staurosporine.	3.12	1	0	ammonium ion derivative
pazopanib pazopanib: a protein kinase inhibitor. pazopanib : A pyrimidine that is 5-(pyrimidin-2-yl}amino-2-methylbenzenesulfonamide substituted at position 4 by a (2,3-dimethylindazol-6-yl)(methyl)amino group. Used as its hydrochloride salt for treatment of kidney cancer.	2.31	1	0	aminopyrimidine; indazoles; sulfonamide	angiogenesis modulating agent; antineoplastic agent; tyrosine kinase inhibitor; vascular endothelial growth factor receptor antagonist
fedratinib fedratinib: a selective small-molecule inhibitor of JAK2	2.15	1	0	sulfonamide
piperidines Piperidines: A family of hexahydropyridines.	3.12	1	0
acenocoumarol Acenocoumarol: A coumarin that is used as an anticoagulant. Its actions and uses are similar to those of WARFARIN. (From Martindale, The Extra Pharmacopoeia, 30th ed, p233). acenocoumarol : A hydroxycoumarin that is warfarin in which the hydrogen at position 4 of the phenyl substituent is replaced by a nitro group.	2.02	1	0	C-nitro compound; hydroxycoumarin; methyl ketone	anticoagulant; EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor

Condition	Indicated	Relationship Strength	Studies	Trials
Leukemia P388 An experimental lymphocytic leukemia originally induced in DBA/2 mice by painting with methylcholanthrene.	0	2	1	0
Benign Neoplasms [description not available]	0	9.81	30	7
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	1	13.78	60	14
Cancer of Stomach [description not available]	0	3.02	4	0
Gastric Ulcer [description not available]	0	2.44	2	0
Gastritis Inflammation of the GASTRIC MUCOSA, a lesion observed in a number of unrelated disorders.	0	2.03	1	0
Stomach Neoplasms Tumors or cancer of the STOMACH.	1	5.02	4	0
Stomach Ulcer Ulceration of the GASTRIC MUCOSA due to contact with GASTRIC JUICE. It is often associated with HELICOBACTER PYLORI infection or consumption of nonsteroidal anti-inflammatory drugs (NSAIDS).	0	2.44	2	0
Anoxemia [description not available]	0	2.43	2	0
Hypoxia Sub-optimal OXYGEN levels in the ambient air of living organisms.	0	2.43	2	0
Kahler Disease [description not available]	0	2.03	1	0
Multiple Myeloma A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.	0	2.03	1	0
Breast Cancer [description not available]	0	2.45	2	0
Cancer of Colon [description not available]	0	2.51	2	0
Cancer of Lung [description not available]	0	4.33	4	1
Breast Neoplasms Tumors or cancer of the human BREAST.	1	4.45	2	0
Colonic Neoplasms Tumors or cancer of the COLON.	0	2.51	2	0
Lung Neoplasms Tumors or cancer of the LUNG.	0	4.33	4	1
Brucella Infection [description not available]	0	2.05	1	0
Brucellosis Infection caused by bacteria of the genus BRUCELLA mainly involving the MONONUCLEAR PHAGOCYTE SYSTEM. This condition is characterized by fever, weakness, malaise, and weight loss.	0	2.05	1	0
Infections, Salmonella [description not available]	0	2.06	1	0
Dermatomycoses Superficial infections of the skin or its appendages by any of various fungi.	0	2.07	1	0
Scalp Dermatoses Skin diseases involving the SCALP.	0	2.07	1	0
American Trypanosomiasis [description not available]	0	2.08	1	0
Chagas Disease Infection with the protozoan parasite TRYPANOSOMA CRUZI, a form of TRYPANOSOMIASIS endemic in Central and South America. It is named after the Brazilian physician Carlos Chagas, who discovered the parasite. Infection by the parasite (positive serologic result only) is distinguished from the clinical manifestations that develop years later, such as destruction of PARASYMPATHETIC GANGLIA; CHAGAS CARDIOMYOPATHY; and dysfunction of the ESOPHAGUS or COLON.	0	2.08	1	0
Leishmania Infection [description not available]	0	2.08	1	0
Leishmaniasis A disease caused by any of a number of species of protozoa in the genus LEISHMANIA. There are four major clinical types of this infection: cutaneous (Old and New World) (LEISHMANIASIS, CUTANEOUS), diffuse cutaneous (LEISHMANIASIS, DIFFUSE CUTANEOUS), mucocutaneous (LEISHMANIASIS, MUCOCUTANEOUS), and visceral (LEISHMANIASIS, VISCERAL).	0	2.08	1	0
Vibrio cholerae Infection [description not available]	0	2.13	1	0
Cholera An acute diarrheal disease endemic in India and Southeast Asia whose causative agent is VIBRIO CHOLERAE. This condition can lead to severe dehydration in a matter of hours unless quickly treated.	0	2.13	1	0
Cronobacter Infections [description not available]	0	2.13	1	0
Enterobacteriaceae Infections Infections with bacteria of the family ENTEROBACTERIACEAE.	0	2.13	1	0
Experimental Neoplasms [description not available]	0	2.46	2	0
Cancer of Prostate [description not available]	0	2.47	2	0
Prostatic Neoplasms Tumors or cancer of the PROSTATE.	0	2.47	2	0
Local Neoplasm Recurrence [description not available]	0	4.21	3	1
Neuroblastoma A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51)	0	2.41	1	0
Acute Myelogenous Leukemia [description not available]	0	2.82	2	0
Leukemia, Myeloid, Acute Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.	0	2.82	2	0
Cancer of Ovary [description not available]	0	2.6	1	0
Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.	0	2.6	1	0
Benign Neoplasms, Brain [description not available]	0	2.31	1	0
Astrocytoma, Grade IV [description not available]	0	2.31	1	0
Brain Neoplasms Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.	0	2.31	1	0
Glioblastoma A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.	0	2.31	1	0
Innate Inflammatory Response [description not available]	0	2.31	1	0
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	0	2.31	1	0
Carcinoma, Non-Small Cell Lung [description not available]	0	4.1	3	1
Thrombopenia [description not available]	0	5.58	6	3
Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.	0	4.1	3	1
Neutropenia A decrease in the number of NEUTROPHILS found in the blood.	0	6.31	8	5
Thrombocytopenia A subnormal level of BLOOD PLATELETS.	0	5.58	6	3
Blood Diseases [description not available]	0	4.66	3	2
Hematologic Diseases Disorders of the blood and blood forming tissues.	0	4.66	3	2
Colorectal Cancer [description not available]	0	2.07	1	0
Colorectal Neoplasms Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.	1	4.48	2	0
Dermatitis Medicamentosa [description not available]	0	3.39	1	1
Lassitude [description not available]	0	3.4	1	1
Hypokalemia Abnormally low potassium concentration in the blood. It may result from potassium loss by renal secretion or by the gastrointestinal route, as by vomiting or diarrhea. It may be manifested clinically by neuromuscular disorders ranging from weakness to paralysis, by electrocardiographic abnormalities (depression of the T wave and elevation of the U wave), by renal disease, and by gastrointestinal disorders. (Dorland, 27th ed)	0	3.4	1	1
Emesis [description not available]	0	3.4	1	1
Fatigue The state of weariness following a period of exertion, mental or physical, characterized by a decreased capacity for work and reduced efficiency to respond to stimuli.	0	3.4	1	1
Kidney Diseases Pathological processes of the KIDNEY or its component tissues.	0	3.4	1	1
Nausea An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.	0	3.4	1	1
Vomiting The forcible expulsion of the contents of the STOMACH through the MOUTH.	0	3.4	1	1
Carcinoma, Epidermoid [description not available]	0	3.4	1	1
Cancer of Head [description not available]	0	3.4	1	1
Metastase [description not available]	0	3.4	1	1
Anemia A reduction in the number of circulating ERYTHROCYTES or in the quantity of HEMOGLOBIN.	0	3.4	1	1
Carcinoma, Squamous Cell A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)	0	3.4	1	1
Head and Neck Neoplasms Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)	0	3.4	1	1
Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.	0	3.4	1	1
Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)	0	2.02	1	0
Disease Exacerbation [description not available]	0	4.32	1	1
Malignant Melanoma [description not available]	0	4.74	2	1
Cancer of Skin [description not available]	0	4.74	2	1
Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)	1	6.74	2	1
Skin Neoplasms Tumors or cancer of the SKIN.	0	4.74	2	1
Adverse Drug Event [description not available]	0	3.42	1	1
Carcinoma, Anaplastic [description not available]	0	3.42	1	1
Sarcoma, Epithelioid [description not available]	0	3.42	1	1
Carcinoma A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for cancer.	0	3.42	1	1
Sarcoma A connective tissue neoplasm formed by proliferation of mesodermal cells; it is usually highly malignant.	0	3.42	1	1
Drug-Related Side Effects and Adverse Reactions Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.	0	3.42	1	1
Lymph Node Metastasis [description not available]	0	2.03	1	0

n-(3-chloro-7-indolyl)-1,4-benzenedisulphonamide

Description

Cross-References

Synonyms (55)

Research Excerpts

Pharmacokinetics

Compound-Compound Interactions

Dosage Studied

Roles (2)

Drug Classes (3)

Protein Targets (43)

Inhibition Measurements

Other Measurements

Biological Processes (215)

Molecular Functions (91)

Ceullar Components (54)

Bioassays (348)

Research

Studies (149)

Market Indicators

Research Demand Index: 11.82

Study Types

Clinical Trials (10)

Trial Overview

n-(3-chloro-7-indolyl)-1,4-benzenedisulphonamide

Description

Cross-References

Synonyms (55)

Research Excerpts

Pharmacokinetics

Compound-Compound Interactions

Dosage Studied

Roles (2)

Drug Classes (3)

Protein Targets (43)

Inhibition Measurements

Other Measurements

Biological Processes (215)

Molecular Functions (91)

Ceullar Components (54)

Bioassays (348)

Research

Studies (149)

Market Indicators

Research Demand Index: 11.82

Study Types

Clinical Trials (10)

Trial Overview

Related Drugs (96)

Related Conditions (83)